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LIST OF ABBREVIATIONS 
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Vision impairment is estimated to affect 253 million people worldwide. Besides the obvious negative 
impact of this disability on the daily activities and social interactions of these people, it has been 
shown that vision impairment enhances the chance of unemployment and risk of suffering from 
depression and anxiety disorders. In view of these observations, worldwide effort is committed to 
gaining insight into the underlying causes of blinding pathologies and exploring options for their 
treatment. Vision impairment can be provoked by a wide variety of retinal diseases which can be 
inherited or acquired by origin. In both cases, several gene therapy strategies have been 
conceptualized that could represent viable treatment options. A primary requirement for potent 
retinal gene therapy is the effective delivery of therapeutic genes to the retina. This delivery could be 
facilitated by packaging the genes in nanoparticles (NPs) of which there is an endless variety thanks 
to the recent nanotechnology boom. Nevertheless, while proof-of-concept of many of these gene 
carriers has been well-established in in vitro cell cultures, the delivery of therapeutic genes to the 
retina in vivo remains troublesome due to the many drug delivery barriers present at the back of the 
eye. Surely, the interaction of NPs with these drug delivery barriers remains poorly characterized 
which hinders the progression of nanomedicine for retinal gene therapy. In the first part of the 
thesis, the principal aim is therefore to gain insight into the various drug delivery barriers in the eye 
and more importantly, to explore the potential links between NP physicochemistry and the NPs’ 
ability to cross these barriers. Since we are convinced that intravitreal (IVT) injection is a safe and 
straightforward method to deliver therapeutics close to the retina this thesis will mainly focus on the 
barriers encountered following this injection, i.e. the vitreous and inner limiting membrane (ILM).  
Chapter 1 provides a general introduction to the anatomy of the eye and the retina. Considering our 
interest in IVT injection and the close proximity of Müller cell endfeet to the ILM and vitreous, we will 
furthermore concentrate on the Müller cell as target cell type and look into its intriguing morphology 
and many functions. Next, we present an overview of the most well-documented inherited and most 
prevalent acquired retinal diseases and discuss the various forms of retinal gene therapy and gene 
carriers that can be applied to treat these diseases.  
In Chapter 2 the administration routes that can be applied to deliver therapeutic genes to the retina 
are explained together with the drug delivery barriers encountered. We describe in detail the 
composition of each ocular barrier and review the available literature on their barrier role toward all 
types of therapeutics, ranging from macromolecules to NPs. At the same time, we look into the 
influence of the size, charge and lipophilicity (i.e. physicochemistry) of the therapeutic(s) (carrier) on 
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their ability to overcome each barrier. Finally, the most valuable available in vitro and ex vivo 
methods to study the interaction of therapeutics and their carriers with these barriers are 
summarized. 
In Chapter 3 we aim to personally support researchers in the design of novel effective NPs by 
presenting a novel ex vivo model that allows to investigate the interaction of therapeutic carriers 
with the vitreoretinal interface, a highly important barrier encountered after IVT injection. We apply 
basic polystyrene beads as model particles to validate this model and look into the relative barrier 
role of the vitreous and ILM as drug delivery barriers.  
Based on our interest in applying Müller cells for the gene therapy strategy of ‘neuroprotection’, 
Chapter 4 describes a preliminary in vitro study where we evaluate the ability of Müller cells to take 
up a standard liposomal vector and process its pDNA or mRNA cargo into green fluorescent protein 
(GFP). Moreover, we explore the Müller cell’s performance in stressful circumstances by examining 
the liposome-induced transfection efficiency and cytotoxicity in hypoxic, hyperglycemic and 
oxidatively stressed cells – conditions linked to diabetic retinopathy and glaucoma. 
Besides retinal drug and gene delivery, a lot of organic as well as inorganic NP types are currently 
investigated for a myriad of biomedical applications. Unfortunately, the clinical translation of most of 
these NPs is severely hampered by concerns regarding their safety. Many common mechanisms of 
NP toxicity have indeed been discovered thus far of which autophagy alteration is a more recent 
discovery. Autophagy is an intracellular degradative process that is vital to preserve cellular 
homeostasis. In light of its importance within the cell, autophagy disruption has been linked to the 
pathogenesis of several diseases. While there is a high number of publications examining the 
interaction between NPs and the autophagy pathway, the diversity of NPs and methods applied 
prevents us to draw overall conclusions. In the second part of the thesis, the aim is therefore to look 
into the influence of NPs on the autophagy pathway, and more specifically, to attempt to decipher 
the impact of NP physicochemistry on their ability to affect autophagy. 
Chapter 5 provides a general introduction to nanomedicine, nanotoxicology and the autophagy 
pathway. More specifically, we summarize the most widely investigated organic and inorganic NPs 
for biomedical applications, the mechanisms by which NPs can affect the cell’s homeostasis as well as 
the autophagy pathway along with available methods to study it. Finally, we provide an overview of 
the mechanisms by which NPs can affect the autophagy pathway and discuss the most valuable 
studies examining NP-autophagy interactions while attempting to link NP physicochemistry to their 
effect on autophagy.  
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In Chapter 6 we present a nanotoxicological study on Quantum Dots (QDs), highly fluorescent NPs 
researched for imaging applications. We aim to look into the impact of surface chemistry on cellular 
toxicity by carefully comparing the effects of two QDs that only differ in their surface coating, i.e. 3-
mercaptopropionic acid and polyethylene glycol. To this end, we examined the aggregation profile, 
cellular uptake, cytotoxicity and associated ROS levels of QDs, and studied their effect on lysosomes 
and autophagosomes - the two most essential organelles of autophagy.  
Chapter 7 discusses the recent progress of nanotechnology and debates its future goals in context of 
toxicology and retinal gene therapy. At the same time, we position the work presented in this thesis 
within the broad scope of both fields. We highlight the predominant issues that currently limit nano 
to progress to the clinic along with conceptual guidelines that could help the field to advance (more) 
efficiently. Finally, having these guidelines in mind, we look into non-viral retinal gene delivery as a 
case study and attempt to envision how this research area should proceed. 
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ABSTRACT 
Our eyes are wonderful sense organs of unimaginable complexity that grant us vision. They allow us 
to appreciate the world’s beauty, to sense danger and to support our emotional communication 
through eye contact. Seeing the fundamental role vision plays in our existence, its loss has an 
immense impact on a person’s life. Sadly, at this moment vision impairment affects 253 million 
people worldwide.1 In light of this, a vast amount of research in the last decades has been dedicated 
to deciphering the biology and biochemistry of the retina along with identification of blinding gene 
mutations, disease pathogenesis and treatment strategies. In this thesis we have investigated several 
ocular drug delivery barriers with as ultimate goal to assist in the optimization of nanomedicines for 
treatment of retinal diseases. As an introduction to these studies, this chapter will provide a basic 
overview of the anatomy and function of the eye, the retina, and our target of interest, i.e. the 
Müller cell. We will briefly touch upon the most studied inherited and most prevalent acquired 
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1. ANATOMY OF THE EYE 
 
Figure 1.1 │ Schematic representation of the anatomy of the eye. 
The human eye has a spherical shape with an average diameter of 25 mm. The eye globe can be 
roughly divided in two segments: the anterior and the posterior segment (Figure 1.1).  
Anterior segment 
The anterior segment refers to the area in front of the lens and is made up of several structures that 
have as primary goal to guide light to the retina at the back of the eye. The pupil, which has a black 
appearance, represents the aperture that allows light to be projected onto the retina. The colored 
muscle tissue covering this pupil, i.e. the iris, functions as a diaphragm that controls the amount of 
light entering the eye. The outer surface of the anterior segment is the cornea, a transparent layer 
performing as a lens with great refractive power. The cornea therefore serves as the first essential 
element of the ocular optical system. The second light-focusing element of the anterior segment is 
the crystalline lens itself. Interestingly, while the focus of the cornea is fixed, the ciliary muscles 
surrounding the lens allow to tune light refraction by altering the lens’ curvature. This elegant system 
enables us to form a sharp image of objects despite varying distances.  
Posterior segment 
The posterior segment refers to the region behind the lens and includes the vitreous chamber, the 
retina, the choroid and the sclera. The vitreous chamber is the largest fluid-containing chamber in 
the eye and is filled with the transparent vitreous gel. The retina lies between the vitreous gel and 
the choroid and contains various cell types as discussed further in this chapter. Between the retina 
and the sclera lies the choroid, a highly vascularized layer supplying the outer retina with oxygen and 
nutrients. The blood supply of the inner retina is arranged by retinal blood vessels that stem from 
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one central retinal artery at the optic nerve head. This optic nerve can be found at the very back of 
the eye and is comprised of a bundle of ganglion cell axons wired toward the brain.2 Finally, the 
sclera, also referred to as “the white of the eye”, creates a supportive outer wall that contributes to 
the firm shape of the eye. It protects the inner structures against physical damage and against the 
potential invasion of pathogens. For a detailed description of the structure and function of the 
different parts of the posterior segment we refer the reader to Chapter 2. 
2. THE RETINA 
While many ocular structures are necessary for obtaining optimal vision, the most indispensable part 
is unquestionably the retina. Indeed, the retina forms the fundamental link between the eye and the 
brain which is vital for image processing. This demanding task requires a myriad of interactions 
between a variety of cell types. To this end, the retina exhibits an elegantly organized multilayer 
structure where no detail is coincidental yet carefully selected by evolution.  
The human retina is approximately 500 µm thick and is located between the vitreous and the 
choroid. At the anterior side, it is separated from the vitreous by the inner limiting membrane (ILM), 
an extracellular matrix that forms an important drug delivery barrier as discussed in Chapter 2 and 
studied in Chapter 3. As depicted in Figure 1.2., the retina is divided into two regions being the inner 
and outer retina which each comprise multiple cell layers.  
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Figure 1.2 │ Schematic drawing of the cellular organization of the retina. ILM: inner limiting membrane; NFL: 
nerve fiber layer;  GCL: ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: outer 
plexiform layer; ONL: outer nuclear layer; PRS: photoreceptor segments; RPE: retinal pigment epithelium. 1: 
ganglion cell; 2: astrocyte; 3: Müller cell; 4: amacrine cell; 5: horizontal cell; 6: bipolar cell; 7: photoreceptor 




After light has crossed the entire thickness of the retina it activates the rod and cone PRs by hitting 
the visual pigment in their disc membranes. The absorption of incoming photons by these pigments 
(e.g. rhodopsin) next triggers a biochemical cascade which ultimately generates an electrical signal 
that will be sent to the brain via various neuronal cell types: horizontal, amacrine, bipolar and retinal 
ganglion cells (RGCs). The distribution of rod and cone PRs is not uniform across the retina since 
several regions can be distinguished (indicated in Figure 1.3A). The region of the optic nerve does not 
display the light-sensing PRs resulting in the famous ‘blind spot’. In contrast, the macula or ‘yellow 
spot’ in the central region contains a high number of cone receptors responsible for daylight vision. 
Within this macular region, the fovea is characterized by the highest density of cone PRs responsible 
for detailed high resolution vision (Figure 1.3B).4 Curiously, many vertebrates lack this human-like 
fovea though they often do exhibit a similar cone-dense region referred to as the visual streak or 
area centralis.5 While the central region of the retina primarily harbors cone PRs, the periphery is 
highly rod-dominated. These rod PRs are activated by dim light and are therefore accountable for 
night vision. 
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Figure 1.3 │ A) The retina as seen through an ophthalmoscope. Image taken from 3. B) Optical coherence 
tomography showing the foveal pit. Image taken from 
6
.  
Next to PRs and neurons the retina also accommodates three types of glial cells i.e. microglia, 
astrocytes and Müller cells. The microglia, the immune cells of the retina, sense homeostasis with 
their many processes and so support in retinal surveillance.7 When activated, for example in 
response to injury or pathological stimuli, they undergo morphological changes and migrate to the 
region of injury.8 Arrived at the site of interest they phagocytose damaged neurons and secrete 
neuroprotective factors to help the retina to recover.7 Astrocytes mainly reside in the inner layers of 
the retina where they closely interact with retinal blood vessels and help to maintain the blood-
retinal barrier (BRB). In addition, like all glial cells, they support surrounding neurons by secretion of 
neuroprotective factors. The morphology and many functions of the Müller glia cell is discussed 
further in this chapter. 
The last cell type worth mentioning are the retinal pigment epithelium cells (RPE) which form a 
monolayer situated between the PRs and the choroid. They execute a multitude of functions 
including phagocytosis of the outer segments of PRs and support of the outer retina homeostasis 
through the provision of neuroprotective factors. In addition, the RPE represents a fundamental 
element of the visual cycle since it is responsible for the re-isomerization of all-trans retinal into 11-
cis retinal, an essential component of the rod pigment rhodopsin.9 The RPE furthermore forms the 
outer BRB by tightly regulating trans-epithelial transport (cfr. Chapter 2). 
3. THE MÜLLER CELL 
The Müller cell is named after its finder Heinrich Müller who in 1851 described these cells as radial 
fibers offering structural support to neighboring cells (Figure 1.4 A).10 While extensive research in the 
following century refined our view on Müller glial morphology and behavior, half of the currently 
known functions of the Müller cell have been discovered in the last 20 years.11 Müller cells are the 
principal glial cell type in the retina and are responsible for the support of retinal neurons. Their 
unique radial morphology matches this purpose since the Müller cell connects with each neuronal 
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cell type by spanning the entire thickness of the retina. Their endfeet are located in the inner retina 
and abut in the ILM. In the outer nuclear layer (ONL), they ensheath the PR somata and extend their 
microvilli into the subretinal space. Additionally, they interact with various cell types via their many 
side branches (Figure 1.4 B). 
 
Figure 1.4 │ Schematic drawing of Müller cell morphology. A) Heinrich Müller’s original drawings of Müller 
cells isolated from the retina’s of fish (I), frog (II) and pigeon (III) 
10




The Müller cell executes a great variety of essential functions which nearly all assist in the functional, 
metabolic or structural support of retinal neurons. Surely, Müller cells assist in the survival and 
function of PRs and neurons by secretion of neurotrophic factors, growth factors, cytokines and anti-
oxidants.13 They aid in the preservation of retinal homeostasis by controlling the transport of water, 
ions and waste. They furthermore influence synaptic activity through uptake of neurotransmitters, 
production of their precursors and release of gliotransmitters. They serve as a soft substrate for 
neuronal outgrowth and influence the inner blood-retinal barrier (iBRB) by close interaction with its 
endothelial cells.11 Müller cells also help to efficiently guide incoming light to the PRs by functioning 
as so-called ‘optical fibers’. Certainly, thanks to their fine-tuned morphology and subtle changes in 
refractive index along the different retinal layers, scattering of light is reduced and its focus on PRs is 
enhanced. In 2001, the intriguing discovery was made that Müller cells can exhibit stem cell 
properties.14 Upon retinal injury, Müller cells were proven capable to dedifferentiate, proliferate and 
generate neural stem cells.11 This finding changed our view on retinal regeneration completely and 
opened the door for a range of new therapies.15 In fact, the peculiar characteristics and functions of 
the Müller cell make this cell type an interesting target for many ocular therapies, as will be further 
debated in Chapter 3 and 4. Astonishingly, the examples of Müller glia functions explained here are 
merely a selection; Bringmann et al. presents a full overview in 11.  
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In response to pathogenic stimuli such as oxidative stress or injury, Müller cells can be triggered to 
morph into an active state called gliosis. This pro-active transformation involves changes on a 
morphological, biochemical and physiological level and is initiated in an attempt to protect the retina 
and/or aid in its recovery.16 During gliosis Müller cells exhibit at least the following three 
characteristics: increase in cell size, proliferation and upregulation of intermediate filaments such as 
glial fibrillary acidic protein.13 Unfortunately, Müller cell gliosis often works contra-productive and 
results in exacerbation of the retinal damage. Examples of gliosis adverse effects are glial scar 
formation, functional uncoupling from neurons and release of pro-inflammatory cytokines.13 
Strikingly, Müller cells respond to virtually all pathogenic stimuli but are also considered as the 
ultimate survivors of the retina because of their resistance to stress. 
4. RETINAL DISEASE 
Our vision is dependent on a complex interplay of cells and pathways. A defect in one of these 
elements, as present in retinal diseases, can therefore have detrimental effects on our vision. 
Unfortunately, retinal dystrophies are quite common. Their underlying causes are mostly 
multifactorial yet usually depend on genetic aberrations and/or environmental factors. In this section 
we will briefly point out the most clinically investigated inherited retinal disorders and the most 
prevalent acquired ones. 
Hereditary diseases 
The majority of disease-causing mutations are located in genes expressed in the RPE or the PRs. An 
example of a well-characterized inherited disease is retinitis pigmentosa (RP), which is an umbrella 
term for a heterogeneous group of retinal disorders each associated with PR loss. With more than 60 
causative genes identified and a prevalence of 1 in 3000 to 5000 individuals, it is the most commonly 
inherited retinal dystrophy.17,18 Its inheritance mode relies on the causative gene and includes 
autosomal dominant, autosomal recessive and X-linked.17 A common form of RP originates from 
mutations in the RHO gene encoding for the visual pigment rhodopsin.19 Since these RHO mutations 
have mainly consequences for rod PRs, patients usually first experience loss of peripheral and night 
vision. Yet, further progress of the disease is typically also characterized by cone cell death due to the 
initial loss of rod PRs.20  
Despite the rareness of Leber Congenital Amaurosis (LCA), a third of the clinical trials so far have 
been focusing on a specific type of LCA caused by loss-off-function mutations in the RPE65 gene.21 
Surely, the autosomal recessive heritance of this gene makes LCA-RPE65 an ideal candidate for gene 
replacement therapy. This RPE65 gene, expressed in the RPE, is partially responsible for the 
26 │ Chapter 1 
 
isomerization of all-trans retinal to 11-cis retinal. Since the latter component is essential for the 
function of the pigment rhodopsin, LCA is usually characterized by a very early onset.22  
Choroideremia is an X-linked recessive degenerative retinal disease with an estimated prevalence of 
1 in 50.000. Choroideremia-associated retinal degeneration is linked to mutations in the CHM gene 
which encodes for Rab-escort protein 1 (REP1), an essential protein for effective intracellular traffic 
in the retina. The disease usually initiates with loss of night vision to gradually progress towards 
overall blindness. The small gene size of CHM and loss-of-function nature of its mutations combined 
with the slow progression of the disease makes choroideremia an ideal target for gene therapy. 
Indeed, next to LCA, choroideremia is one of the most investigated disease targets in clinical trials.22a 
Finally, while most blinding mutations affect genes expressed in the outer retina, also the inner 
retina harbors cells worth targeting with gene therapy. An example of a retinal dystrophy originating 
in the inner retina is Leber’s Hereditary Optical Neuropathy (LHON). LHON’s pathogenesis derives 
from mutations in essential elements of the mitochondrial respiratory chain.  This mitochondrial 
defect next results in ganglion cell dysfunction which  clinically  leads to rapid loss of central vision 
with a typical onset age between 20 – 30 years.23 A specific challenge does lie in the fact that the 
mitochondria should be targeted instead of the nucleus.24 
Acquired diseases 
Next to inherited diseases correlated with specific genetic mutations, many retinal disorders are 
linked to aging and/or underlying diseases such as diabetes. In fact, these acquired disorders 
represent the largest fraction of blinding diseases. The cause of these diseases are usually 
multifactorial where also genetics play a role since family history is often regarded as a risk factor. 
Reaching above 30 million of visually impaired individuals worldwide, age-related macular 
degeneration (AMD) is surely regarded as one of the leading causes of vision impairment.25 AMD is a 
classic example of a multifactorial disease with as established influencing factors family history, 
smoking and nutrition.26 It primarily affects the elderly who suffer from progressive PR damage 
leading to loss of central vision, a condition that greatly hinders their daily activities and 
independence. Clinically, two distinct types can be distinguished: ‘dry’ AMD characterized by 
geographic atrophy, and ‘wet’ AMD identified by choroidal neovascularization. While dry AMD has 
no standardized treatment protocol, wet AMD is usually treated by intravitreal (IVT) injection of 
antibodies against vascular endothelial growth factor (VEGF).26  
The World Health Organization (WHO) estimates that diabetic retinopathy (DR) is responsible for 
15% of blindness in Europe & the USA. This is not surprising since the prevalence of diabetes is on the 
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rise and more than a third of diabetic patients suffer from DR.27 The molecular and biochemical 
mechanisms lying at the root of DR are highly complex and not yet fully understood, although it is 
hypothesized that the hyperglycemia and high levels of oxidative stress associated with diabetes 
trigger pathways that next elicit inflammation and upregulation of multiple growth and inflammatory 
factors which eventually contribute to the typical features of DR being neovascularization and BRB 
disruption.28 In its advanced stage DR can induce macular edema or progress into proliferative DR 
where vascular leakage and angiogenesis are the key concerns, respectively.  
Glaucoma is a general term for several neuropathies with as common hallmark the progressive loss 
of RGCs which leads to a gradual decline in vision. In contrast to AMD and DR, the pathogenesis of 
glaucoma generally originates in the anterior segment of the eye. A well-established risk factor for 
glaucoma development is indeed elevated intraocular pressure (IOP). However, is it clear IOP is not 
the only risk factor that should be monitored since a normal IOP does not guarantee a glaucoma-free 
life, nor do patients with high IOP necessarily develop glaucoma. In primary open-angle glaucoma, 
the most prevalent form, elevated IOP is usually caused by decreased drainage of fluid via the 
trabecular meshwork. Considering the loss of RGCs the retina of glaucomatous patients is 
characterized by alteration of the optic nerve and nerve fiber layer.29 
5. RETINAL GENE THERAPY 
Gene therapy strategies 
Hereditary as well as acquired retinal dystrophies can be treated by gene therapy. Depending on the 
disease and its progression different gene therapy strategies are valuable. In general, these strategies 
can be divided into two main categories i.e. gene-specific and non gene-specific approaches. 
Gene-specific approaches 
The gene replacement strategy (also referred to as gene augmentation) is the most widely 
investigated approach for treatment of retinal diseases and is based on the supplementation of a 
healthy version of the mutated gene. This strategy is mostly valuable for retinal dystrophies caused 
by loss-of-function mutations, since in these cases the function of the protein needs to be 
compensated without the need for abolishing the mutant protein. As mentioned before, the majority 
of these mutations occur in genes expressed in the outer retina like PRs or RPE cells. Thanks to the 
extensive research dedicated to this approach, most clinical trials up to now are based on gene 
replacement. In fact, this strategy reached a milestone only very recently since the first gene therapy 
treatment for RPE65-dependent LCA has been recommended for approval by the U.S. Food and Drug 
Administration (FDA).30  
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Dominant diseases that are caused by gain-of-function mutant alleles producing proteins with 
dominant negative or abnormal functions require a different strategy, i.e. gene silencing. In this case, 
the mutant mRNA is the main target which can be nullified by application of antisense nucleotides, 
ribozymes or an RNA interference approach based on shRNA or siRNA.30a If necessary, even a two-
step approach called ‘suppression and replacement’ could be applied where besides interfering with 
the mutant mRNA, a healthy copy of the gene is supplemented that is resistant to gene silencing.30b 
The most widely investigated disease targets for this approach are until now autosomal dominant 
forms of RP.30c 
Another gene-specific approach is gene editing such as the CRISPR/Cas system. In this technology, 
which is based on an anti-viral defense system of bacteria, a Cas9 nuclease complex is guided to a 
specific location of the genome by a synthetic ‘guide’ RNA where it generates double strand breaks. 
Depending on the treatment aim, these breaks can be repaired by joining the ends in a random 
fashion (Non-homologues End Joining), or by Homology Directed Repair where the gene is precisely 
replaced based on a donor template. Since this enables us to remove existing genes and replace 
them by new ones, this approach is especially relevant for gain-of-function mutations where it is 
necessary to eliminate the unwanted effects of the mutated protein. The rapid advancement of this 
technology has caused a revelation in the gene therapy field, also in the ocular context (cfr. Chapter 
7). 
Non gene-specific approaches 
Neuroprotection is a therapeutic strategy that focuses on the preservation of healthy neurons and 
the prevention of neuronal cell death regardless of the underlying genetic anomaly or pathogenic 
cause. This mutation-independent approach has therefore, in contrast to the gene replacement 
concept, the potential to treat a great variety of retinal diseases – inherited and acquired.31 
Neuroprotection is currently explored for diseases involving retinal ganglion cell and/or PR death of 
which the most commonly investigated diseases are glaucoma, RP and DR.32–39 In view of the short 
intravitreal half-life of proteins, an interesting tactic to ensure a prolonged neurotrophic effect is to 
deliver genes encoding for neuroprotective factors (e.g. growth factors, anti-apoptotic proteins) to 
the retina.32,37 After successful retinal uptake of the therapeutic genes, the transduced cells can then 
express the neurotrophic factors and secrete them in their surroundings to enhance neuron survival. 
This strategy will be further discussed in Chapter 4 where we look into Müller cells as targets for this 
approach. 
In optogenetics genes encoding for light-sensitive proteins are introduced into retinal neurons with 
the aim to let them take over the role of the lost PRs.40 The most widely investigated optogenetic 
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proteins are variants of channelrhodopsin, a light-gated ion channel that initiates cell depolarization 
when triggered. Potential cell types targeted by this strategy nearly all reside in the inner retinal 
layers and include amongst others ganglion cells and bipolar cells. Interestingly, since the 
optogenetic approach does not require viable PRs, this strategy could be used to treat patients in 
advanced stages of retinal degeneration.31,41  
Another gene therapy approach has been investigated specifically for wet AMD with the goal to find 
an effective long-term alternative to the frequent IVT injection of anti-VEGF antibodies. This 
approach, currently evaluated in clinical trials, is the viral delivery of genes encoding for a soluble 
VEGF receptor that could serve as a decoy for the excessive VEGF present in the retina.21  
Gene carriers 
For all gene therapy strategies presented above the smart design of an appropriate gene carrier is 
essential to guide the therapeutic gene through the many physiological and cellular barriers. Gene 
carriers can be classified in two types i.e. viral carriers and non-viral carriers. 
Viral vectors 
In context of retinal gene therapy, most clinical success has undoubtedly been achieved with viral 
vectors, of which the adeno-associated vector (AAV) has proven to be the most effective in 
transducing retinal cells.42 AAVs are small non-enveloped viruses (~25 nm) that have an icosahedral 
capsid which contain single-stranded DNA (Figure 1.6).  Their cellular tropism and induced expression 
kinetics depend highly on the AAV’s capsid serotype. Indeed, it has been reported that the naturally 
occurring serotype capsids mainly vary in the looped-out domains presented on the surface, 
therefore highly influencing their cellular interactions.43  To gain optimal transduction efficiency a lot 
of research has therefore been dedicated to the exploration of naturally occurring AAV capsids as 
well as capsid engineering. As a result of these studies many vectors have been developed that 
generate high levels of transgene expression after subretinal injection, with clinical trials mostly 
focusing on AAVs of serotype 2, 5 and 8.42  
 
Figure 1.6 │ Schematic drawing of an AAV vector.  
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However, considering the invasiveness of subretinal injection as explained in Chapter 2, there 
remains a lot of interest in an AAV able of efficiently transducing the retina following IVT 
administration. As a leading example, Dalkara et al. developed the AAV2-7m8 vector which 
successfully transduced mouse and macaque PRs after IVT injection. The vector variant was found by 
a strategy called in vivo directed evolution.44 Here, libraries of AAV variants are injected intravitreally 
into mice, after which the variants capable of reaching the outer retina are isolated by harvesting of 
PRs. After genomic extraction, the respective viral cap genes are then amplified by PCR for cloning 
and repackaging. Repeating this cycle eventually leads to the most powerful vector variant.45  
Non- viral vectors 
Despite the highly promising results generated with viral vectors, a few limitations should be taken 
into account. A relevant limitation of AAVs is for example their limited cargo capacity of 5 kb which is 
not sufficient for inherited diseases originating from mutations in larger genes (e.g. Stargardt 
disease). Furthermore, while the eye is considered as an immunoprivileged organ, AAV 
administration has been reported to induce innate as well as adaptive immune responses.46 This 
immune response was found to be dependent on the administration route since  IVT injection led to 
a more substantial humoral response than subretinal administration in non-human primates.46 Since 
these limitations might be circumvented by applying non-viral particles, many research groups, 
including ours, aim to explore the potential of these carriers for ocular (gene) therapy (cfr. Chapter 3 
and 4).  
Indeed, non-viral vectors might up to now lack the efficiency of their viral counterparts, their high 
cargo capacity, beneficial safety profile and straightforward surface modification definitely 
encourage further research. As discussed in Chapter 5, nanomedicine has known an immense boost 
over the last decade resulting in an ever increasing versatility of particle designs and compositions. 
Nanomedicine has also been gaining more attention in the ocular field, where studies mainly focus 
on soft NPs based on lipids (cfr. Chapter 4),47,48 proteins49,50 or polymers51,52. A full overview of the 
variety of particles developed for retinal drug delivery is given by Naash et al,53 though we have 
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Many ocular disorders leading to blindness could benefit from efficient delivery of therapeutics to 
the retina. However, despite extensive research into drug delivery vehicles and administration 
techniques, efficacy remains limited because of the many static and dynamic barriers present in the 
eye. Comprehension of the various barriers and especially how to overcome them can improve our 
ability to estimate the potential of existent drug delivery vectors and support the design of new ones. 
To this end, this chapter gives an overview of the most important ocular barriers for each 
administration route to the back of the eye. For each barrier, its biological composition and its role as 
an obstacle toward macromolecules, nanoparticles and viral vectors will be discussed; special 
attention will be paid to the influence of size, charge and lipophilicity of drug(s) (carrier) on their 
ability to overcome each barrier. Finally, the most significant available in vitro and ex vivo methods 
and models to test the potential of a therapeutic to cross each barrier are listed.   
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1. INTRODUCTION 
In Chapter 1 we discussed several therapeutic strategies to treat the wide variety of hereditary and 
acquired retinal diseases. However, the success of all these strategies is highly dependent on the 
delivery of the drugs and/or their carriers to the target site. To this end a great variety of advanced 
drug delivery systems are being investigated and developed, such as intravitreal implants and 
nanoparticles (NPs). However, although the eye is an easily accessible organ, its many physiological 
and anatomical barriers still considerably restrict effective delivery of therapeutics to the target site.  
A detailed characterization of the obstacles drug delivery carriers have to overcome is essential to 
define the barrier role of a specific ocular tissue. This in its turn allows for smart adjustments to the 
drug delivery carriers in line with the barriers’ properties. In vivo experiments are of great value to 
determine the overall efficiency of a drug delivery system with all barriers in place. In vitro and ex 
vivo studies, on the other hand, enable us to examine each barrier in the delivery process on its own, 
providing preliminary evidence of the ability of a delivery system to overcome this single barrier. 
Furthermore, ex vivo explant cultures allow us to experiment on ocular tissues of larger, more 
relevant species (e.g. pig, non-human primates or even human eyes) providing valuable information 
without proceeding to costly and labor-intensive in vivo work. The proper use of in vitro and ex vivo 
models can thus signify a great step forward in the design and optimization of therapeutics and their 
vehicles for ocular drug delivery.  
 
Figure 2.1 │ Overview of administration routes to target the posterior segment. 1: intravitreal injection; 2: 
subretinal injection; 3: systemic injection; 4: suprachoroidal injection; 5: transscleral administration; ILM: inner 
limiting membrane.  
As discussed in Chapter 1, many blinding diseases find their origin in the retina which requires drug 
delivery to the posterior segment. To reach this segment several administration routes are available, 
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as illustrated in Figure 2.1. Even though some administration routes are clinically preferred over 
others, each route comes with its own advantages and set of obstacles to conquer.1 In this chapter, 
we will discuss the biological structure of the barriers and biological obstacles encountered for each 
of these administration routes while linking drug (carrier) physicochemistry to successful barrier 
passage. Finally, we will give a summary of the most relevant in vitro and ex vivo methods that might 
be useful in research focusing on advanced drug delivery in the posterior segment of the eye.  
2. BARRIER COMPOSITION AND ROLE 
Barriers encountered after intravitreal injection 
During intravitreal (IVT) injection a drug formulation is injected into the vitreous humor of the eye 
(Figure 2.1). In the clinic, IVT injections happen on a daily basis for a plethora of drugs, with currently 
anti-VEGF (Vascular Edothelial Growth Factor) medication as the most routinely injected therapeutic 
against AMD. Delivering the therapeutics directly into the vitreous offers several benefits. Firstly, 
several anterior barriers are bypassed and the drug is delivered close to the target site. Secondly, the 
procedure is safe and relatively easy to perform.2,3 Given these advantages IVT injection is a widely 
investigated administration route for the delivery of an increasing variety of drug delivery systems, 
ranging from gene vectors to biodegradable implants.4 For retinal delivery of non-viral vectors to the 
inner retina, IVT injection is furthermore also our administration route of choice (cfr. Chapter 3). Still, 
established disadvantages of this technique compared to subretinal gene therapy are: a) the 
considerable dilution of the gene carriers in the vitreous volume, and b) the immune surveillance in 
the vitreous which can result in the formation of neutralizing antibodies against .e.g. AAV2 vectors.4a      
Overall, the intraocular location of the therapeutics is no guarantee for success, since the therapeutic 
efficiency is known to be highly dependent on the therapeutics’ ability to migrate from the injection 
site toward the retina.5 In this regard, there are two main obstacles that hamper successful therapy 
after IVT injection, namely the vitreous and the inner limiting membrane (ILM).  
Vitreous 
The vitreous body is a transparent gel-like structure with a volume of about 4 ml that occupies 
approximately 80% of the human eye. The function of the vitreous body is a recurring subject of 
discussion, but is mostly considered to regulate eye size during eye development.6 Due to its 
extremely high water content (98%-99%), the density of the vitreous body approximates that of 
water.5,7 The gel structure is composed of a 3-dimensional network of collagen fibers of collagen 
types II, IX, and V/XI, with collagen type II being the most abundant (60-75%). These collagen fibers 
provide the vitreous with flexibility and strength against mechanical tensions.7 The spaces in 
between these fibrils are filled with glycosaminoglycans (GAGs) of which hyaluronic acid (HA), a 
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highly hydrated negatively charged GAG, represents the bulk (Figure 2.2). The function of this linear 
polymer is to stabilize the collagen net and to ensure a swelling effect.8 The remaining fraction of 
GAGs is represented by chondroitin sulfate and heparin sulfate.9 Interestingly, the composition of the 
vitreous is not uniform throughout the whole vitreous body but different anatomical regions can be 
identified. Traditionally, the vitreous is regarded as consisting of two fractions.9a The largest volume 
is taken in by the central vitreous, which is characterized by a more liquid state owing to the low 
density of its collagen network. The cortical vitreous that delineates the retina contains higher 
concentrations of collagen as well as HA providing it with high mechanical strength.7 Interestingly, 
various investigators have indicated the presence of a complex area in front of the human macula 
which is fluid-like. This area, referred to as the ‘bursa premacularis’ is furthermore surrounded by 
multiple cisterns (fluid-filled cavities).9b While these structures have been identified in human eyes, it 
is up to now unclear to which extent the same or similar structures are present in the vitreous gel of 
other species. A well-described phenomenon that affects the structure of the vitreous humor is 
liquefaction. During this process, which is mostly induced by age, the vitreous degrades leading to a 
loss of its gel-like appearance and an increase of its free water content; both factors that can 
influence the barrier function of the vitreous.10  
 
Figure 2.2 │ Schematic drawing of the vitreoretinal (VR) interface and vitreous. The vitreoretinal interface is 
constituted from peripheral vitreous, the inner limiting membrane (ILM) and the endfeet of the Müller cells. 
The ILM has an extracellular matrix structure which forms the basement membrane of the Müller cells (M). The 
vitreous gel is formed by a network of collagen fibers of different types, mainly type II. The spaces in between 
these fibrils are filled with glycosaminoglycans, of which hyaluronic acid is the most abundant. G: ganglion cell. 
Vitreous figure is adapted from 
7
.  
In general, two types of barriers can be differentiated within the vitreous: the anatomical or static 
barrier represented by the vitreous structure itself, and the physiological or dynamic barrier 
represented by the flow processes and clearance pathways taking place in the vitreous. The fact that 
the vitreous represents an anatomical barrier toward drug diffusion has already been discovered 
early on, when Sakamoto et al. revealed that a vitrectomy significantly enhanced the transduction 
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efficiency of viral vectors from the vitreous.11 In the same line, also the penetration of non-viral 
vectors seems to be hindered by the vitreous gel structure.5 In this case, it is reported that the 
particle surface characteristics are of great importance. A general trend can be recognized: positively 
charged NPs are blocked in their diffusion by interaction with the negatively charged components of 
the vitreal network,12–17 while negatively charged particles, based on for example poly lactic-co-
glycolic acid (PLGA) or human serum albumin, distribute successfully across the vitreous humor.17–20 
Various surface coatings such as polyethyleneglycol (PEG) and HA have therefore been explored to 
shield the surfaces of cationic particles in order to improve the migration of the particles through the 
vitreous.14,21,22  
While NP charge evidently influences particle diffusion, the impact of particle size is less obvious. Xu 
et al. have estimated the average pore size of bovine vitreous to be ~550 ± 50nm and indeed 
witnessed that 1 µm sized particles were not able of maneuvering through the meshwork.16 In 
contrast, Martens et al. observed that negatively charged particles up to 1 µm were mobile in bovine 
vitreous based on a similar model.13 This suggested pore size of 550 nm is surely large enough for 
small molecules and antibodies to diffuse freely through the vitreal meshwork. In addition, since the 
NP size for ocular (gene) therapy usually varies from 10 to 500 nm, the mesh size should not 
represent an obstacle for particles as well. However, as will be discussed in the ILM section, it is 
important to keep in mind when aiming for retinal targets that there is also a size limit for 
penetration through the ILM that probably lies lower. 
Next to the anatomical barrier inherent to the vitreous structure, drug distribution is also influenced 
by physiological obstacles like clearance pathways and intraocular flow processes. The most 
important flow processes within the eye are the convective flows. These flows are driven by the 
pressure difference between the front and back side of the vitreous and are oriented in an anterior-
posterior direction.23,24 While these flows have barely any effect on the distribution of small drugs 
with high diffusivity, they can have a substantial effect on larger, less diffusible therapeutics, 
especially in larger species such as humans.23–25 The physicochemical characteristics of 
molecules/particles have a huge impact on the way they are cleared and thus influence their half-life 
in the eye. Smaller more lipophilic entities are usually cleared at the posterior side since these are 
easily able of crossing the blood-retina barrier, leading to short intravitreal half-lives of a couple of 
hours. Larger more hydrophilic therapeutics, on the other hand, are eliminated through the anterior 
route which is dominated by the aqueous humor outflow. These entities, for example antibodies, 
tend to remain within the vitreous for a longer time with half-lives reaching 100 hours.26 Next to the 
intrinsic flow processes taking place within the eye, drug distribution is likely also influenced by the 
vitreous humor motion associated with eye movement (i.e. saccadic movement). However, the 
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impact of this motion on intravitreal drug delivery is hard to predict since its influence has until now 
mainly been studied in vitreous substitutes.27,28 
Inner Limiting Membrane 
The ILM forms the structural boundary between the vitreous and the retina and is mainly composed 
of collagen type IV, laminin and fibronectin which form an intertwined network.29 Essentially, this 
extracellular matrix represents the basement membrane of the Müller cells and thus aligns with their 
endfeet (Figure 2.2).30 There is strong evidence that the lens and ciliary body are the primary 
production sites for ILM proteins during embryogenesis.29,31 The ILM has proven essential for the 
early development of the eye, seeing its absence is associated with retinal abnormalities including an 
aberrant ganglion cell layer.32,33 In the fully developed eye, however, the ILM is likely not essential 
since ILM peeling is not correlated with severe adverse effects.34 Also, it was observed that the ILM 
of macaques is not regenerated even one year after its removal.35  
In rabbits the pore size of the ILM meshwork is estimated between 10 and 25 nm, yet it is unclear if 
this can be extrapolated to other species.36 Similar to the vitreous, the composition of the ILM is not 
consistent over the entire tissue but varies regionally.8 Also the thickness of the ILM differs per 
region, where the thickness of the foveal ILM is substantially thinner compared to parafoveal 
regions.37 Another important fact is that the ILM varies greatly between different species: 
Transmission electron microscopy (TEM) data revealed that the ILM of an adult mouse is merely 100 
nm thick while atomic force microscopy measurements proved that the ILM thickness of a human 
retina can measure up to 4 µm.37,38 It has furthermore been shown by several research groups that 
the ILM layer thickens with age.29,39 Since the thickness of the ILM undeniably influences its barrier 
function it is assumed that the barrier is more easily surmountable in smaller animals, such as mice, 
than in larger ones, like non-human primates and humans. 
There are many reports on the physical barrier role of the ILM in context of non-viral and viral gene 
delivery to the retina. IVT injection in vivo seldom leads to effective gene expression in larger animals 
than rodents, often because of the accumulation of the vectors at the ILM.40–43 In fact, Dalkara et al. 
elegantly demonstrated in rats that inducing mild enzymatic digestion of the ILM by protease 
treatment exceptionally enhanced the transfection efficiency of several AAV serotypes from the 
vitreous.44 Similarly, when the ILM is breached due to retinal disease, viral transduction is greatly 
improved when compared to ILMs in a healthy state. 45,46 Also Takahashi et al. witnessed that surgical 
ILM peeling substantially enhanced AAV transduction of the inner retina in cynomolgus monkeys.42 
Taken together, these observations convincingly substantiate the barrier role of the ILM for viral drug 
delivery to retinal targets. Interestingly, interaction of viral vectors with binding sites at the ILM (e.g. 
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laminin receptor or heparan sulfate) might enhance their accumulation at the vitreoretinal interface, 
allowing the vectors to further diffuse into the retina and produce gene expression.44,45,47–49 Be that 
as it may, too strong affinity of viral vectors to ILM binding sites might prevent the vectors to move 
beyond the ILM.49,50 
Several research groups have reported on the barrier role of the ILM toward non-viral particles, 
where a clear trend regarding particle charge is noticeable. Indeed, in rodent as well as bovine 
species positively charged NPs are virtually entirely obstructed by the ILM while neutral to negatively 
charged ones do penetrate into the retina.15,51 Regarding particle size the trend is less apparent since 
the majority of studies has been performed on rodents. In this species, particles up to 350 nm 
penetrated into the retina, though it is not certain this observation can be extrapolated to larger 
species such as cow or human.15,20,36,52 Peculiarly, Bourges et al. detected that highly negative 
polylactide particles of ~150 nm and neutral ones of ~350 nm accumulated at the ILM 1 h after IVT 
injection followed by penetration into the rat retina.52 This suggests that, similar to viral vectors, 
presence of binding sites in the ILM might facilitate the diffusion of carriers into the retina.  
Also for macromolecules the ILM reduces or even blocks retinal passage depending on the 
physicochemical properties of the molecule. While negatively charged 20 kDa sized dextrans passed 
the ILM smoothly, positively charged molecules of the same size were virtually all blocked by the 
ILM.51 Since even negatively charged dextrans of 2000 kDa in size penetrated more efficiently into 
the bovine retina than 20 kDa positively charged molecules, it is obvious that charge surely 
represents the dominant factor defining passage of macromolecules through the ILM.51  
Barriers encountered after subretinal injection 
A subretinal injection is an injection right below the neural retina, in between the photoreceptor (PR) 
layer and the retinal pigment epithelium (RPE) layer (Figure 2.1).53,54 A typical volume of around 150 
to 500 µl is injected in humans, leading to a transient detachment between these two layers.55,56 
Complications are relatively common and more severe when compared to e.g. IVT injection, as this 
retinal detachment can result in PR death and loss of vision. The whole procedure is also quite 
invasive, as subretinal injection is usually preceded by full anesthesia and a vitrectomy.57 Despite the 
drawbacks of this administration route, it is very effective to deliver therapeutics right at the target 
site. Subretinal injections are therefore mostly applied for larger entities such as gene vectors or cells 
that are therapeutically relatively ineffective using other administration routes.58 As a matter of fact, 
subretinal injection is the most clinically investigated delivery route for retinal gene therapy.59,60 
Since the injection site is so close to the retina, practically all barriers in the posterior segment are 
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circumvented. Gene expression is however often limited to the injection site, suggesting that the 
primary barrier for efficient therapy following subretinal injection is the retina itself.61  
Neural retina 
The retina is the tissue at the back of the eye that receives light and transmits it to the brain where 
the signals are further processed into an image. As described in Chapter 1 it is constituted of a neatly 
organized multilayered structure that allows interplay between its PRs, neurons and glial cells (Figure 
2.3). The barrier role of the retina can be attributed to its dense structure, which prevents free 
diffusion of (therapeutic) macromolecules and carriers. In light of this, Jackson et al. have observed 
that the retinal exclusion limit, i.e. the maximum molecule size able of freely diffusing through the 
retina, is dominantly defined by the inner and outer plexiform layer.62 This limit is approximately 76 
kDa for a fixed human retina, though since therapeutic antibodies such as bevacizumab (Mw 149 
kDa) have been reported to cross the entire thickness of the retina,63,64 we expect the molecular size 
limit to be higher in unfixed tissue. More recently, Tao et al. concluded from similar experiments that 
the inner and outer nuclear layers are the predominant diffusional barriers (Figure 2.3).65 While 
these observations are based on free diffusion it should be noted that active cellular transport of the 
drug (carrier) by a retinal cell type can ensure the distribution of macromolecules or drug carriers 
throughout the whole retina. 
 
Figure 2.3 │ Schematic drawing of the retina and blood-retina barrier (BRB). NFL: nerve fiber layer; GCL: 
ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: outer plexiform layer; ONL: outer 
nuclear layer; PRS: photoreceptor segments; RPE: retinal pigment epithelium. 1: ganglion cell; 2: astrocyte; 3: 
Müller cell; 4: amacrine cell; 5: horizontal cell; 6: bipolar cell; 7: photoreceptor cell. The inner BRB (iBRB) is 
formed by the tight juntions of the endothelial cells of the inner retinal vasculature. The Müller cells and 
astrocytes influence the endothelial cells through the secretion of growth factors and transfer of nutrients and 
waste products. The outer BRB (oBRB) is composed of the tight junctions of the RPE cells.  
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Besides static hindering the diffusion of therapeutics, certain components within the retina might 
interact with subretinally injected therapeutics.66,67 Similar to the vitreous and the ILM, GAGs which 
are present in the interphotoreceptormatrix and on the surface of RPE cells, can bind therapeutic 
entities and in this way block their diffusion toward the target cells as suggested by Pitkänen et 
al.51,68 Finally, also the outer limiting membrane (OLM) represents a semipermeable barrier, limiting 
the diffusion of entities out of the extracellular space that surrounds the PR segments into the ONL. 
As an example, 150 kDa FITC – dextran had great difficulty in exiting the subretinal space in the rabbit 
retina while its 10 kDa version easily diffused up to the vitreous.68a In any case, the diffusional barrier 
can easily explain why gene expression after subretinal injection is more than often limited to the 
outer retina and RPE layer.69 Clinical trials administering gene vectors by subretinal injection 
therefore mainly focus on diseases that have an initial causative mutation in the PRs or RPE cells. 
Barriers encountered after intravenous administration 
Intravenous administration, or injection in the blood stream, is a widely applied administration route 
in the clinic (Figure 2.1), including in ophthalmology. A few examples of intravenously administered 
therapeutics for ocular diseases are anti-inflammatory drugs for uveitis,70 antibiotics for 
endophthalmitis70 and verteporfin for choroidal neovascularization.71 While intravenous 
administration leaves the eye untouched and is therefore less invasive, the bioavailability of drugs in 
the retina after this type of administration is very low (< 5%).72 This is partly attributed to the 
marginal fraction of blood flow in the eye compared to the blood flow of other organs like the liver.73 
Intravenous injection therefore also requires higher volumes of the therapeutic to be administered 
to achieve therapeutic levels in the eye which inevitably raises the chance of unwanted off-target 
effects. Furthermore, it is well-established that the binding of serum proteins followed by recognition 
by the immune system can lead to rapid clearance of the therapeutics.74 Nevertheless, researchers 
agree that there might be a future for ocular therapy via intravenous administration if efficient ocular 
targeting can be achieved. However, the efficient delivery in the eye of the therapeutic entity via the 
bloodstream is no guarantee for success. On the contrary, the presence of the blood-retinal barrier 
(BRB) within the eye signifies a major restriction for the permeation of compounds from the ocular 
blood flow into the retina.75  
Blood-Retinal Barrier 
The BRB contributes to the control of retinal homeostasis by tightly regulating the exchange of fluid 
and molecules between the blood and the retina and restricting the entry of hazardous molecules. 
This BRB support of retinal integrity is fundamental, which is illustrated by the fact that its 
breakdown is associated with vision loss.76 The BRB is constituted of an inner (iBRB) and outer barrier 
(oBRB) represented by respectively the tight junctions of the inner retinal vasculature and the RPE 
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cells in the outer retina (Figure 2.3). In the iBRB these tight junctions, also referred to as zonula 
occludens, are intertwined with adherens and gap junctions into sophisticated junction structures 
that strictly control paracellular transport.77 Molecularly, intercellular junctions are constituted of a 
complex collection of proteins including occludin and claudin proteins.78 On top of these junctions, 
the transcellular transport of the iBRB is also restricted thanks to the absence of fenestrations in the 
endothelial cells as well as the lack of transport vesicles. Together, these features result in a high 
transendothelial resistance which is comparable to that of the blood-brain-barrier.79 Next to the 
primary role of endothelial cells in the iBRB, other retinal cell types also influence the barrier 
function. Surely, the basal lamina of endothelial cells are connected to the so-called neurovascular 
unit which involves pericytes, Müller cells, astrocytes and microglia.79a Whereas pericytes mainly 
influence the endothelial cells through the secretion of growth factors,80 glial cells also offer support 
through the transfer of nutrients and waste products.77,81  
For therapeutics to reach the oBRB, they must first escape the choroidal blood flow. Conveniently, in 
contrast to the capillaries of the inner vasculature, the endothelial cells of the choroidal capillaries 
are fenestrated allowing leakage of larger molecules like proteins.82,83 The choriocapillaries therefore 
represent no bottleneck for the systemic delivery of therapeutics into the eye.78 Similarly, the Bruch’s 
membrane, which lies in between the choroid and RPE layer, does not restrict macromolecular 
diffusion into the neuroretina.78 The choroid-retinal transfer of macromolecules is in fact 
predominantly limited by the junctional complexes between the RPE cells. Similar to those of the 
iBRB, these complexes are constituted of an entanglement of tight, gap and adherens junctions.83 In 
addition, the uneven distribution of RPE membrane proteins also adds to the function of the oBRB.78 
Fascinatingly, junctional complexes are not static structures yet their strands open and reseal to 
allow passage of molecules. Indeed, transfer of fluid and its components is limited yet elegantly 
regulated by several types of transport routes allowing the RPE to perform one of its primary 
functions i.e. preserving the ion, water and nutrient balance of the retina.84,85 Next to passive 
diffusion through the tight junctions, transport routes include active transport by pump proteins and 
transcytosis by means of invaginating vesicles.84  
 Seeing the strictly regulated transport of endogenous molecules across the BRB, it is not surprising 
the BRB represents a crucial hurdle for systemic delivery of foreign molecules in the retina. Initial 
studies with small hydrophilic molecules such as fluorescein have shown limited permeability of the 
oBRB, where inward diffusion (choroid to retina) is much lower than in the opposite direction.86–88 It 
seems that sufficiently small solutes (< 0.4 nm) can diffuse freely through the pores of the junction 
network while the larger ones (> 0.4 nm) are dependent on the ability of the junctions to break open 
and close.79 A systematic study looking into the permeation of differently sized FITC-dextrans up to 
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80 kDa in isolated bovine RPE-choroid tissue also revealed that the permeability of macromolecules 
decreases dramatically with increasing size with an insignificant permeability starting from 20 kDa.88 
Since the choroid poses no hurdle for permeation of the size ranges studied, it can be assumed the 
limitations observed are likely solely attributed to the RPE layer.  
In addition to size, other physicochemical features of the entity such as charge and hydrophilicity 
influence to which extent the oBRB serves as a barrier.89 The diffusion of ions, and likely therefore 
also of charged compounds, is hypothesized to be influenced by the charge features of the claudin 
proteins present in the junctions.79 Pitkänen et al. tested the permeation of several similarly sized β-
blockers in function of their lipophilicity and found that the more lipophilic ones crossed the oBRB 
substantially more efficiently.88 Trends regarding physicochemistry of macromolecules that allows 
permeation of the iBRB are very similar, with hydrophilic substances again having great difficulty in 
overcoming this barrier.90 Furthermore, Bellhorn et al. observed that dextrans as small as 3 kDa were 
unable of entering the retina through the oBRB nor the iBRB.91 Generally, it is suggested that small 
hydrophilic compounds migrate through the paracellular network of junctions, while lipophilic 
molecules benefit from the transcellular route.88 The iBRB and oBRB exhibit influx transporters for 
physiological substrates like the glucose transporter and L-type amino acid transporter. Designing 
drugs that resemble these transporter substrates could therefore be a strategy to enhance delivery 
across the BRB into the retina. Efflux pumps, on the other hand, work counteractive by shuttling the 
therapeutic back to the bloodstream.92 The most well-known efflux pump is likely P-glycoprotein 
which is present on RPE cells as well as on the endothelial cells of the iBRB.93,94 Proposed strategies 
to prevent this shuttling are the design of therapeutics in such a way they are not recognized by 
efflux pumps, and/or the co-administration of efflux pump inhibitors (e.g. tariquidar or 
dexverapamil).92,95  
Besides macromolecules, larger drug delivery vehicles like NPs have also been evaluated on their 
ability to cross the BRB in vivo - and intriguingly, with some success. In this regard, Kim et al. 
observed in mice that intravenously administrated gold NPs of 100 nm were excluded while their 
smaller counterparts of 20 nm were present within the retina.96 Similarly, AAV 9 vectors have also 
been reported to efficiently transduct the retina after systemic delivery, especially in the neonatal 
mouse with less developed vasculature.97,98 Seeing both particles are likely too large to passively 
diffuse through the junctional complexes, it is hypothesized that active processes such as transcytosis 
mediate their transport through the BRB.96 Plasmid-loaded liposomes of greater size (~85 nm) are 
also reported to cross the BRB in mice, since gene expression was detected in the RPE as well as the 
inner retina. Interestingly, these liposomes were decorated with antibodies targeted against the 
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transferrin receptor present in the BRB causing receptor-mediated transcytosis of the particles across 
the BRB into the retina.99  
Similar as observed with the ILM, it is suggested that disease states associated with compromised 
BRB integrity might make systemic delivery of ocular therapeutics more feasible.77,100,101 With this in 
mind, several strategies have been proposed to transiently manipulate the permeability of the BRB, 
such as the induction of ocular hypotony, treatment with vasoactive compounds or siRNA-mediated 
downregulation of tight junction proteins.75,77,102  
Barriers encountered after suprachoroidal administration 
Suprachoroidal administration involves injection into the suprachoroidal space (SCS), i.e. the virtual 
space between the sclera and the choroid (Figure 2.1). Under normal conditions this border is not an 
existent space, but it can open up under the influence of the pressure applied by injection and 
incorporate fluid volumes up to 200 µl.100 Strikingly, a study in ex vivo porcine eyes revealed that the 
injected material spreads out across the inner surface of the eye within 8 seconds.103 Suprachoroidal 
administration offers the advantage of bypassing several burdensome barriers such as the ILM and 
the sclera, whereby it often results in higher bioavailability in comparison to IVT injection and 
periocular administration, respectively.104 The most promising method to reach the SCS currently 
investigated is likely the use of microneedles (maximum 1 mm in length), which might find its way to 
the clinic soon. These microneedles penetrate through the sclera to deliver into the SCS in a safe and 
minimally invasive way.105–107 Suprachoroidal injection is rumored to be an ideal route to target the 
posterior segment. However, depending on the final target tissue several barriers should be taken 
into account. To reach the retina, both the RPE and the choroid should be successfully passed while 
for treatment of choroidal diseases (e.g. choroidal neovascularization) only the high choroidal 
circulation represents a potential hurdle.1,108,109 Since the RPE has been extensively discussed above 
we will focus here on the choroid.  
Choroid 
The choroid is the highly vascularized layer lying between the RPE layer and the sclera, with as 
primary function the delivery of oxygen and nutrients from the blood flow into the outer retina. The 
choroidal tissue is approximately 200 µm thick at birth and thins with age.110,111 Anatomically, the 
choroid is usually divided into five layers: the Bruch’s membrane, the choriocapillary layer, two 
vascular layers and the suprachoroidea which is closest to the sclera (Figure 2.4).112 The Bruch’s 
membrane contains collagen and elastin and its inner and outer layer is represented by the 
basement membranes of the RPE cells and choriocapillaries, respectively.113 The capillaries in the 
choriocapillary layer are highly fenestrated, allowing the passage of nutrients as well as larger 
molecules such as proteins.112 The underlying vascular layers contain small arteries and increasingly 
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larger blood vessels toward the sclera. Finally, the suprachoroid forms the border between the 
choroid and the sclera, and contains both collagen fibers and cell types from the stromal tissue such 
as melanocytes and fibroblasts.112  
 
Figure 2.4 │ Schematic drawing of the choroid and sclera. The choroid is divided into five different layers. The 
Bruch’s membrane aligning with the retinal pigment epithelium (RPE) layer, the choriocapillaris with 
fenestrated capillaries, two vascular layers with larger vessels toward the sclera, and the suprachoroid located 
next to the sclera. The sclera is constituted of collagen bundles, proteoglycans and glycoproteins. The thickness 
and orientation of the collagen bundles depends on the region in the eye as well as the tissue depth within the 
sclera. Figure adapted from 
112
.  
Technically, the choroid has two barrier roles. On the one hand it functions as a molecular sieve while 
on the other hand the choroidal blood flow functions as an important clearance mechanism. 
Naturally, the ability of certain therapeutics to reach their retinal targets will be defined by their 
ability to overcome both the static physical barrier as well as the dynamic barrier. Luckily, the barrier 
roles in relation to the physicochemical characteristics of the compounds are becoming increasingly 
clear.  
The physical permeability of the choroidal tissue has been investigated with small molecules, 
macromolecules and particles. In case of small molecules, several groups found that injection of 
sodium fluorescein (NaF) and contrast agents into the SCS leads to the rapid spread of fluid around 
the SCS.103,107,114,115 Tyagi et al. found that the rate and level of delivery of NaF into the retina after 
suprachoroidal administration was higher when compared to periocular and IVT injection.114 As 
expected, the diffusivity into the posterior segment depends on molecular weight. When FITC-
dextrans with a molecular weight of 4 and 40 kDa were injected into the SCS of a rabbit ex vivo eye 
model, the delivery of the 4 kDa molecule in the vitreous and retina was substantially higher 
compared to its larger counterpart.115 In the same report, also the permeability of various Beta-
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blockers with differing lipophilicity was evaluated. Higher lipophilicity correlated with increased 
choroidal and retinal delivery, most likely due to the interaction of lipophilic compounds to binding 
sites in the choroid and retina such as cellular membranes and melanin.116  
The diffusivity of nano-and microparticles was tested ex vivo on porcine tissues.106 After injecting 
particles into the SCS using a microneedle, 20 and 100 nm particles were found in the SCS as well as 
in the sclera, while 500 and 1000 nm particles could not diffuse into other tissues but the SCS. 
Strikingly, not only the physicochemistry of the therapeutic entity influences its bioavailability, also 
the injection site at which it is originally deposited can have an impact. In fact, Chiang et al. defined 
another anatomical barrier for the circumferential spread of particles across the SCS that was 
independent of the particle size, i.e. ciliary arteries. In rabbit eyes they observed that particles 
injected on one side of the posterior ciliary artery were unable of diffusing to its opposite side.117  
An additional and likely greater hurdle than the static barrier function of the choroid is its circulation. 
It is established that the choroidal circulation is extraordinarily high when compared to other organs, 
this to supply the metabolically active RPE cells with the necessary oxygen and nutrients.104,114 Many 
groups have looked into the influence of choroidal circulation on the delivery of drugs in ocular 
tissues.100 Many compounds such as fluorescently labeled dextrans of 40 and 250 kDa, bevacizumab 
and NaF have indeed been found to be rapidly cleared post-injection, usually within hours.100,107,114,118 
In contrast, larger nondegradable particles of 20 nm up to 10 µm in size were detected in the SCS for 
two months.107 This lack of clearance is in line with the predicted maximal pore size of the 
fenestrated choriocapillaries which is estimated to lie between 6 and 12 nm.119 The above-mentioned 
observations indicate that sustained release systems such as nano-or microparticles can have great 
potential since their controlled release might be able to compensate for the swift removal of the 
therapeutic.120,121  
Barriers encountered after transscleral administration 
Transscleral drug delivery, often referred to as periocular drug delivery, is an umbrella term for 
different administration routes including subconjunctival, sub-tenon, peribulbar and retrobulbar 
routes (Figure 2.1). While all these routes could be applied to reach the retina, we will not further 
discuss barriers specific to subconjunctival administration since this chapter primarily focuses on the 
barriers present at the back of the eye. The exact procedures and injection locations of these 
techniques are summarized in a review by Raghava et al.122 These type of injections, especially sub-
tenon, are already applied in the clinic for e.g. applying local anaesthesia for ocular surgery.122 The 
transscleral routes, which are less invasive than IVT injections, take advantage of the large surface 
area of the sclera.123,124 Furthermore, relatively large volumes can be administered with a single 
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injection, with up to 4 ml and 5 ml for sub-tenon and retrobulbar injection, respectively.122 The 
periocular route is definitely a valuable one for treatment of diseases of the middle and outer coat of 
the eye. Its potential for treating retinal diseases is, however, still a matter of debate, as therapeutic 
concentrations within the retina remain quite low.125 Therapeutics should indeed overcome static 
barriers such as the sclera, choroid and the RPE layer, whilst also encountering dynamic barriers like 
choroidal blood flow and episcleral flow.124,126 The combination of these various barriers makes 
periocular delivery a challenge. Since the RPE layer and choroid are already extensively discussed 
above, we limit our focus in this section on the sclera. 
Sclera 
The sclera or the white of the eye is the outer opaque layer of the ocular globe that blends into the 
transparent cornea at the front of the eye. The opacity of the sclera is no coincidence since it 
prevents internal light scattering to ensure an optimal retinal image.127 The human scleral thickness is 
not consistent but averages around 0.5 mm at the limbus to approximately 1 mm at the optic 
nerve.127,128 The sclera has several mechanical functions such as general support of the eye, 
maintaining the shape of the eye during its movement and protecting the eye against external 
injuries as well as increased internal ocular pressure.129,130  
Microscopically, several regions can be differentiated from the outside to the inner side of the sclera, 
including the episclera, the stromal tissue and the lamina fusca.127 On a molecular level, the sclera is 
built up from the typical components of connective tissue i.e. collagen, proteoglycans and 
glycoproteins. The predominant structural protein, collagen type I, forms fibers and fiber bundles 
with varying thickness and orientation depending on the region and tissue depth.130 In the episclera, 
a thin vascularized layer, the collagen fibers connect to the blood vessel walls or the underlying 
stromal tissue.127 The outer regions of the stromal tissue contain thinner bundles with lamellar 
characteristics, while their counterparts in the inner layers of the stroma are generally thicker and 
orientated in a multitude of directions.130 Finally, the collagen bundles of the lamina fusca are smaller 
and strongly intertwine to integrate into the choroidal layer below.127 Remarkably, similar to the 
sclera the corneal tissue is also based on collagen fibers, yet the cornea has a highly transparent 
appearance. This contrast in opacity can be explained by the different ultrastructure of the two 
tissues: while the collagen fibers of the sclera are quite thick and compactly organized, their corneal 
counterparts are thinner, strictly longitudinally oriented and more widely separated.131 Next to 
collagen fibrils also a small fraction of elastic fibers runs through the scleral tissue which adds to the 
viscoelastic properties of the tissue.132 Notably, the sclera is not acellular but contains fibroblasts 
responsible for the synthesis and turnover of the scleral matrix.132  
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The permeability of the sclera and its barrier role has been extensively described in literature in 
context of a wide range of compounds ranging from antibiotics to dextrans.126 Considering the dense 
structure of the sclera, it represents a physical barrier toward many therapeutics. Successful passage 
through the complex fiber network has proven to be highly dependent on the molecular weight of 
the compound, where larger molecules have more trouble diffusing than smaller ones (< 70 
kDa).124,133–137 On the other hand, clearance values for macromolecules are much lower than for 
smaller molecules.124 Apart from molecular weight, Ambati et al. revealed that molecular radius is an 
even better predictor of permeability, as globular proteins permeated faster through the sclera than 
linear dextrans with similar molecular weight.134 Still, the same molecular radius does not necessarily 
result in similar permeability coefficients. In fact, Cheruvu et al. found that negatively charged 
solutes permeated across the sclera more effectively than positively charged ones despite their 
comparable radii.116 This is a logic consequence of the matrix structure seeing the sclera contains 
proteoglycans that are negatively charged at physiological pH.138 Too many negative charges on 
macromolecules, on the other hand, might also inhibit permeation due to charge repulsion.124 Next 
to size and charge also lipophilicity has an influence on scleral permeation, where hydrophilic 
molecules more readily diffuse through the sclera than lipophilic ones as observed in scleral tissue of 
multiple species.89,116,126,139 This is likely due to the aqueous nature of the sclera owing to the 
hydrated proteoglycans.126 Importantly, choroidal bioavailability is often also low for hydrophilic 
molecules since the largest part of the drug that reaches the choroid is likely next cleared by the 
choroidal blood flow.126  
Regarding nano-and microparticles, there are only limited reports on penetration of ocular tissues 
after periocular administration. Amrite et al. looked into the influence of particle size on the 
retention at the injection site by comparing the disposition of 20 nm, 200 nm and 2 µm sized 
polystyrene particles in vivo in rats. Except for a very limited amount of 20 nm particles, no particles 
were present in the ocular tissues after injection.140,141 Additionally, 20 nm but not larger particles 
were rapidly cleared from the injection site, with only 15% remaining one day post-administration.140 
Also in bovine ex vivo experiments only 0.46% of the 20 nm particles were able to cross the sclera.141 
Successful delivery of particles to the ocular tissues after periocular administration is therefore 
dependent on a challenging balance. While smaller particles can penetrate into ocular tissues but are 
cleared rapidly from the injection site, larger particles are retained but are unable of reaching the 
retina. Drug delivery strategies concentrating on nano- and microparticles therefore tend to focus on 
particles as vehicles for sustained delivery.1,122,142 Besides from particle design, research groups also 
look into clever modifications of the technique by which it is delivered, like the application of hollow 
microneedles penetrating into the sclera.143  
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In all cases, it should be noted that the scleral thickness can differ greatly among species  which has a 
direct impact on the permeability of the sclera.144 In light of this, the study of Nicoli et al. serves as a 
leading example: they found porcine sclera to be twice as thick as human sclera which reflected in 
the fact that in comparison the permeability of human sclera was up to three times higher.145 In 
contrast, the rabbit sclera is approximately twice as thin as the human sclera which yet again should 
be taken into account when extrapolating results based on this species to the human situation 144. 
Similar to the other structures of the eye, aging also affects the sclera which yet again can influence 
its permeability. Indeed, it has been reported that the hydration of the sclera decreases with age and 
seeing permeability declines with decreasing hydration this can certainly have an impact on drug 
distribution.136,146 The age of the animals used during sclera permeation studies is therefore a factor 
than can add to experimental variability.  
3. IN VITRO AND EX VIVO METHODS TO STUDY BARRIER ROLES 
Barrier-specific methods 
Methods to study the vitreous 
Over the last two decades several methods have been developed to improve our understanding of 
the vitreous structure and the behavior of therapeutics within it, ranging from rather straightforward 
in vitro methods to more relevant though more complex ex vivo techniques. This is likely owing to 
the advancement of technology in general combined with the integration of the 3R principle 
regarding animal experiments (reduction, refinement and replacement).142  
Prior to starting experiments on vitreous, it is important to note that the vitreous structure varies 
across different species.9 For example, it is estimated that the collagen content is up to five times 
lower in bovine vitreous compared to its human counterpart.7 These species-specific variations 
should be taken into account since the impact of the vitreous as a barrier could be over-or 
underestimated in comparison with the human situation.9 Overall, large animal models such as cow, 
pig and non-human primates are significantly more representative for the human vitreous structure. 
Seeing the small volume of vitreous present in the mouse eye, vitreous isolation and quantification of 
its components is troublesome.147 Hence, the composition of mouse vitreous is less documented and 
it is unclear if mice are relevant animal models to test the in vivo potential of a drug delivery system. 
Notably, even within one species the structure of the vitreous can vary: it is well established that the 
vitreous gel loses its gel-like appearance and liquefies with age, which implies that the migration of 
therapeutics toward the retina could also be age-dependent.10  
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The most straightforward in vitro experiments to study the barrier role of vitreous are performed on 
isolated vitreous. In the earliest experiments, diffusivity of a fluorescent dye such as fluorescein was 
measured in the isolated vitreous (often bovine) based on the concentrations measured with a 
fluorometer.23,148,149 While most of these studies only considered passive diffusion, Xu et al. included 
the influence of convection by applying a custom-built diffusion cell and numerical modeling.23 To 
investigate the barrier role of vitreous for larger structures, like NPs, the use of fluorescence 
microscopy to evaluate binding of (fluorescent) NPs to vitreous components could be a first 
preliminary experiment. For more accurate interpretations, the diffusion of fluorescent small 
molecules as well as NPs in isolated vitreous can also be assessed by Fluorescence Recovery After 
Photobleaching (FRAP). In this microscopy technique, fluorescent components are permanently 
bleached in a small area of the vitreous by a high intensity laser. Next, diffusion of surrounding 
fluorescent molecules into the bleached area causes the recovery of fluorescence, which is measured 
over time using a low intensity laser. Based on the fluorescence recovery, the diffusion coefficient 
and fraction of (im)mobile molecules can be precisely calculated.14,22  
Isolated vitreous can also be used in cell culture experiments. Pitkänen et al., for example, applied a 
thin layer of freshly isolated bovine vitreous on top of an RPE cell culture after which DNA-complexes 
were supplemented on top. The following transfection and uptake studies revealed that the 
presence of vitreous nearly entirely blocked particle uptake and thus gene transfer.12 Since these in 
vitro methods are very straightforward, they are certainly valuable for providing a first impression 
whether or not the vitreous hampers the efficiency of a certain therapeutic. However, it is well-
known that without the support of the eye the vitreous loses its typical structure due to outflow of 
hyaluronic acid.150 Therefore, tests on isolated vitreous could lead to biased results which is the 
principal limitation of these in vitro methods. Ex vivo methods on the other hand, are usually more 
representative for the in vivo tissue structures as the vitreous is (partially) maintained in its natural 
environment.  
The ex vivo models of Martens et al. and Xu et al. are ideally suited for studying the drug delivery of 
larger entities like viral or non-viral gene carriers.16,21,151 Both models share the same principle: 
fluorescent NPs are injected in the vitreous of a cadaveric cow eye after which their diffusion is 
followed by particle tracking microscopy. Tracking each particle in function of time allows to 
calculate a distribution of diffusion coefficients that is highly representative for the Brownian motion 
taking place. Though both models are quite similar, the dissection and subsequent set-up are slightly 
different: while Xu et al. disposes the entire anterior part of the eye resulting in an eye-cup and 
exposure of the vitreous, Martens et al. only removes the cornea and lens so that the hyaloid 
membrane and the rest of the eye remains intact. In the latter model, particles are therefore allowed 
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to diffuse for 24 h instead of less than an hour in the exposed vitreous. On the other hand, in the 
system of Martens et al. NPs are intravitreally injected unusually close to the hyaloid membrane 
owing to working distance limitations of the objective lens needed for single particle tracking.151 Xu 
et al., in contrast, injects the NP suspension in the central vitreous, which is likely more 
representative for the IVT injections taking place in the clinic.16 All these ex vivo methods are though 
less straightforward, highly relevant for drug delivery studies since they allow us to study the static 
barrier functions of tissues from larger more representative animals without proceeding to costly and 
often unnecessary in vivo experiments. It is important to recognize, however, that information on the 
influence of dynamic barrier roles such as for example the anterior-posterior convective flow, is lost. 
Furthermore, the above-mentioned assays do not take into account the potential influence of 
vitreous humor motion during eye rotations on the dispersion of therapeutics in the vitreous.27 To 
look into these factors affecting the delivery of a drug (vehicle), in vivo studies are still unique and 
necessary. 
Methods to study the blood-retinal barrier 
Studies with the goal to investigate the potential of therapeutics to permeate the BRB can be roughly 
subdivided in two categories: in vitro studies based on endothelial or epithelial cell cultures, and ex 
vivo studies based on isolated RPE/choroid tissue in diffusion chambers (discussed in section 
Diffusion chambers). The most straightforward and thus most applied in vitro experimental set-up 
involves the culture of BRB cell types on specialized filter systems of which the most frequently used 
is the Transwell system. These filters can be coated with e.g. laminin and/or fibronectin to mimic 
extracellular matrices and allow cells to grow in a polarized fashion.152 The permeability of 
macromolecules through the iBRB or oBRB can then be evaluated in vitro by quantifying the fraction 
of macromolecules, applied at the apical side, that crossed the BRB and reached the basal medium at 
specific time points. This quantification can be done by a diversity of methods ranging from 
fluorescence measurements with a plate reader to mass spectrometry.153–157 Naturally, the 
permeability of the compounds through the blank filter system should also be determined to account 
for potential barrier properties of the filter itself.153  
These in vitro barrier studies can be performed on immortalized cell lines or primary cultures, where 
both options have their merits and disadvantages. Whereas cell lines are straightforward to culture 
and store, and allow comparison of test results between different research groups, they are often 
not truly representative of the in vivo setting, especially when it comes to barrier function.79 
Employing primary cultures, on the other hand, can be troublesome in practical terms owing to 
complex isolation protocols. Moreover, the isolated cell population is often more heterogeneous 
which complicates the interpretation of results.153 Nevertheless, these cultures are regarded as more 
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representative. It should be noted that finding cell culture conditions that result in the most 
representative phenotype is known to be a universal challenge.79,158 Indeed, culture conditions can 
greatly influence the characteristics of e.g. the RPE layer, which might have an impact on its barrier 
function. In fact, it is well established that the RPE layer exhibits variations related to species and 
age, which implies that when working with primary cell cultures animals should be carefully 
selected.79 It has furthermore been reported that even within the same RPE layer microenvironments 
can be distinguished, which can further add to tissue variability.159 A critical review on the culture 
options for RPE and influence of culture conditions on its properties has been published recently by 
Rizzolo et al.79  
Recently, several groups have made progress in the development of more advanced co-cultures of 
multiple BRB cell types.160–162 An elegant example of this is the work of Wisniewska-Kruk et al. who 
managed to mimic the iBRB by co-culture of primary endothelial cells, pericytes and astrocytes. In 
brief, they allowed pericytes and astrocytes to adhere to the bottom of the Transwell filter after 
which endothelial cells were cultured on top of the filter. After a few days of culture, permeability 
studies were performed as usual: fluorescent dextrans and other tracers were added to the top 
compartment after which their presence in the bottom compartment was measured.162  
General methods for barrier investigation 
Retinal explants 
The culture of retinal explants is a widely applied method in a variety of ocular studies, especially in 
fundamental research and retinal drug delivery. Similar to polarized ocular cell types, explants are 
typically cultured on specialized membranes (e.g. Transwell filters) that allow adding substances 
below the filter and/or on top of the explant. Except for the commercially available filter systems, 
this experimental set-up does not require special equipment and is therefore readily accessible for 
each research group.  
Retinal explant culture can help to define to which extent the neural retina or ILM represents a 
barrier to the diffusion of therapeutics. Interestingly, the orientation of the explant, i.e. PR-side up or 
down, can be altered depending on the research question investigated.69,163 To investigate the 
penetration of intravitreally injected therapeutics into the retina, isolated explants are typically 
cultured with PR-side down. Even when detaching the vitreous from the retina while dissecting, the 
ILM usually remains largely intact, especially in larger species such as cow or human. Therefore, 
therapeutics or drug carriers can be dropped on top of the explant to follow transfer through the ILM 
into the retina. When looking into subretinal injection there are generally two options: therapeutic 
entities are applied directly on top of the retinal explants (PR side upwards) on a Transwell insert,69 
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or the therapeutic entities are placed on the filter and covered with the retinal explants (PR side 
down).163 After a certain time point (e.g. 24 hours), the penetration of the entity can then be 
examined by microscopy after preparing cryosections. It should be noted, however, that it is always 
important to prevent overflow to the other side of the retina when applying a larger volume of 
therapeutics on top of the retina, since this can result in biased interpretations.  
As discussed in Chapter 3, we recently developed an ex vivo model based on bovine eyes, in which 
the vitreous remains attached to the ILM and retina during dissection and explant culture, ensuring 
an intact vitreoretinal interface. After dissection and explant culture, fluorescent therapeutics or 
drug carriers can be injected into the vitreous after which the extent and route of retinal entry can be 
defined by confocal microscopy.164 
Diffusion chambers 
While the retinal explants described above allow for valuable estimations of the extent and relative 
rate at which certain entities penetrate into the retina, studies performed using a diffusion chamber 
can provide us with accurate absolute diffusional rates. The Ussing chamber, originally developed to 
look into ion transport across epithelial membranes, has led to the advancement of the 
understanding of transport of molecules through tissues in many fields including the ocular one.165,166 
In this Ussing chamber system, the studied tissue is mounted in such a way that it forms the physical 
barrier between two halves of one chamber. One of these halves contains the tested compound, 
while the second half merely contains a buffer with the same osmolarity and if necessary, antibiotics. 
After a certain time point (e.g. 24 hours) the rate of diffusion through the tissue can be measured by 
detecting the compound in the opposite half with for example a spectrophotometer. To monitor the 
viability and integrity of the studied barrier during these experiments the transepithelial electrical 
resistance (TEER) can be assessed. This resistance can be measured in a non-invasive way by placing 
an electrode pair in both halves of the Ussing chamber that can detect voltage and current.77,89,167 
Next to these quantitative measurements, the location of the compounds within the tissue can be 
examined after the conventional cryosection protocol followed by microscopy. The Ussing diffusion 
chamber and its variations can be used to study almost every barrier discussed in this chapter. In 
fact, studies applying a diffusion chamber have been reported on the ILM,62 retinal tissue,62,65 the 
oBRB,87,88,168 the choroid,116 and the sclera.116,169,170 The application of a diffusion chamber indeed 
offers several advantages. For instance, depending on the barrier you aim to investigate a certain 
side of the tissue can be directed toward the donor or the receiver chamber. As with the retinal 
explants described above, changing the orientation of the retina toward the donor chamber for 
example allows you to focus on the ILM or the PR layer.62 In case of transscleral administration for 
retinal targets, a diffusion chamber allows to define for your compound which physical barrier 
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signifies the dominant hurdle (the choroid or the sclera) simply by mounting scleral tissue with and 
without choroid in the chamber.116  
While these experiments can provide us with highly valuable qualitative and quantitative 
information, certainly for diffusion of macromolecules, they are less accessible since they require 
uncommon instrumentation that might not be available in every research group. It should also be 
noted that while the Ussing chamber is a commercially available diffusion system, some groups apply 
the same principle but make use of a custom-designed set-up.65  
Perfused eye models 
Originally developed in the early 80s for biological studies, the isolated perfused eye model has been 
optimized in multiple species over the years ranging from cat to human while focus has also switched 
toward drug delivery.171–176 In this technique, an entire mammalian eye is isolated after which a 
ciliary artery is cannulated to supply it with carefully composed perfusion fluid. By means of a 
peristaltic pump, the eye is then perfused while keeping it moist. Next, pharmacokinetic and drug 
distribution studies following administration of a therapeutic can be performed by quantification of 
the therapeutic in the different ocular tissues using mass spectrometry or fluorometry. In addition, 
examination of tissue cryosections can aid to define the exact (cellular) location of the therapeutic 
(carrier). Many drug delivery studies have already been done based on this model, usually focusing 
on intravitreal 174,175,177 or suprachoroidal drug delivery.106,115,178 Patel et al. added an interesting 
feature to the common ex vivo eye model by inserting a cannula connected to an irrigating solution 
through the optic nerve into the vitreous.106 In this fashion, they mimicked an elevated intraocular 
pressure and evaluated its effect on particle delivery by hollow microneedles.  
Well-established advantages of this system over in vivo experiments are among others: no influence 
of anaesthesia, no limitation on applied drug concentration and complete control over physiological 
environment while reducing animal usage.175 Thanks to the perfusion, the model also allows to look 
into the influence of clearance mechanisms, like the choroidal circulation, on drug delivery.178 
Nevertheless, it remains a great difficulty to fully mimic the remarkably complex in vivo conditions. In 
addition, the viability of the perfused ex vivo eye is limited to around 9 hours which can form a 
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4. CONCLUSION  
In the past decade, a lot of effort of industry and academia has gone to the design of new drug 
delivery vehicles and advanced administration techniques to treat blinding diseases that find their 
origin at the back of the eye. Nevertheless, despite this effort and the resulting progress therapeutic 
efficacy remains limited, especially in case of larger entities such as nucleic acids. This inefficient 
delivery of therapeutics is usually due to the many physiological barriers encountered by the 
therapeutic entity. Each administration route to target the posterior segment has it specific barriers, 
benefits and disadvantages (Figure 2.1). For example, while subretinal injection theoretically involves 
the least barriers, it is at the same time a highly invasive technique. IVT injection, on the other hand, 
is a highly safe and feasible administration method, but comes with challenging drug delivery barriers 
such as the vitreous and the ILM. The balance between efficacy and safety therefore remains difficult 
to maintain. Interestingly, the ideal physicochemical characteristics of a therapeutic (carrier) depend 
on the barrier it needs to overcome and therefore also on the preferred administration route (Table 
2.1). The sclera and vitreous are for example more permeable for hydrophilic compounds while the 
choroid and retina are easier to cross for lipophilic ones. In view of the complexity of the various 
barriers we encourage drug delivery researchers to systematically explore which physicochemistry 
(e.g. size, charge and hydrophilicity/hydrophobicity) a therapeutic needs to surmount every barrier 
of importance for the chosen delivery route. To perform these studies, a whole variety of in vitro and 
ex vivo methods is available. In vitro studies on ocular cell cultures can be powerful to provide 
preliminary results on the intrinsic therapeutic potential of new compounds and to evaluate if the 
vitreous represents an obstacle for transfection. In addition, intelligently designed ex vivo 
experiments can be as valuable as in vivo studies – if not more. Indeed, ex vivo studies, which are in 
line with the worldwide resolution to implement the 3R principle, allow to look into tissues of larger 
animals that have a physiology resembling the human one. It is expected that the increasing 
knowledge of the exact barrier composition, and especially, the interspecies variability will help to 
further define which model is most related to the complex in vivo human situation by preventing 
over-or underestimation of species-dependent barrier functions. Finally, it is well established that 
age and disease can affect the composition and/or the integrity of nearly each barrier discussed in 
this review. Therefore, the development of standardized in vitro and ex vivo disease models next to 
the existing in vivo ones could be an important field of research to evaluate the delivery of drugs and 
carriers to diseased or aged tissues. Overall, we are confident that the increasing barrier knowledge 
and the proper use of in vitro and ex vivo methods will continue to boost the design and optimization 
of drug delivery systems that are successful in treating disease targets at the back of the eye. In light 
of this philosophy, we have developed a novel ex vivo model to thoroughly investigate the barrier 
role of the vitreoretinal interface, as will be discussed in Chapter 3. 
 
Table 2.1 │ Overview of the preferred physicochemical features necessary to cross the different barriers. A: intravitreal injection; B: transscleral administration; C: systemic 
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Retinal gene delivery via intravitreal injection is hampered by various physiological barriers 
present in the eye of which the vitreoretinal (VR) interface represents the most serious hurdle. In 
this chapter we present a retinal explant model especially designed to study the role of this 
interface as a barrier for the penetration of vectors into the retina. In contrast to all existing 
explant models, the developed model is bovine-derived and more importantly, keeps the 
vitreous attached to the retina at all times to guarantee an intact VR interface. After ex vivo 
intravitreal injection into the living retinal explant, the route of fluorescent carriers across the VR 
interface can be tracked. By applying two different imaging methods on this model we 
discovered that the transfer through the VR barrier is size-dependent since 40 nm polystyrene 
particles are more easily taken up in the retina than 100 and 200 nm sized particles. In addition, 
we found that removing the vitreous, as commonly done for culture of conventional explants, 
leads to an overestimation of particle uptake, and conclude that the ultimate barrier to 
overcome for retinal uptake is undoubtedly the inner limiting membrane. Damaging this matrix 
resulted in a massive increase in particle transfer into the retina. In conclusion, we have 
developed a highly relevant ex vivo model that maximally mimics the human in vivo physiology 
which can be applied as a representative test set-up to assess the potential of promising drug 
delivery carriers to cross the VR interface. 
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1. INTRODUCTION 
As discussed in Chapter 2, there are several administration routes available to reach the back of 
the eye. Currently, roughly 75 % of clinical trials are based on subretinal injection as gene 
delivery method.1 However, subretinal injections are mainly efficient to reach cells surrounding 
the injection spot, i.e. photoreceptors (PR) or RPE cells. Hence, the majority of retinal gene 
therapy trials are also focused on treatment of the outer retina. Nevertheless, the inner retina 
harbors important target cells as well including retinal ganglion cells (RGCs) as target for Leber 
Hereditary Optic Neuropathy (LHON),2 Müller cells for neurotrophic strategies,3 and bipolar and 
amacrine cells for optogenetic therapy (cfr. Chapter 1).4 It is, however, not at all evident to reach 
these cell types via subretinal injection.  
An alternative method to reach the inner retina is intravitreal (IVT) injection, a technique that is 
considered safe, minimally invasive and relatively easy to perform.5 Nonetheless, the transfer of 
(high molecular weight) drugs and nanosized particles carrying drugs into the retina after IVT 
injection remains troublesome, primarily because of the presence of the vitreoretinal (VR) 
interface. Figure 3.1 shows that this interface consists of three structures: peripheral vitreous, 
the inner limiting membrane (ILM) and Müller cell endfeet. As discussed in Chapter 2, both the 
vitreous and the ILM represent important drug delivery barriers. Indeed, the vitreous, a 
transparent gel composed of collagen fibrils filled up with hyaluronic acid, may hamper the 
mobility of carriers preventing them to reach the retina.6–8 The ILM has an extracellular matrix 
structure composed of a collagen IV network intertwined with proteoglycans, laminin and 
fibronectin.9,10 It represents a physical border between the vitreous and the retina and functions 
as a sieve that more than often impedes the transfer of drug carriers into the retina.11–13 Once 
drug carriers pass the vitreous and ILM they encounter retinal cells, where the first cell type they 
face is likely the Müller cell, a glial cell of which the endfeet align with the ILM.  
 
Figure 3.1 │ Schematic drawing of the vitreoretinal interface. M: Müller cell; G: Ganglion cell; ILM: inner 
limiting membrane; VR: vitreoretinal; N: nerve fiber 
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Aiming for the delivery of nucleic acids in retinal cells, several groups have reported successful 
penetration of both non-viral as well as viral gene carriers through the entire VR interface of 
rodents, resulting in gene expression in the retina. In animals larger than rodents, however, IVT 
injection rarely results in effective gene expression.11,12,14–17 Interspecies differences greatly 
hamper the extrapolation of successful IVT therapies in rodents to larger animal models and 
humans. This is likely because the VR interface is substantially more difficult to overcome in 
larger species.18 Indeed, as mentioned in Chapter 2, the anatomy of the rodent eye and the 
structure of its vitreous and ILM is less representative for human physiology.19,20 As an example, 
the thickness of the mouse ILM is estimated to be around 100 nm, while a parafoveal thickness 
of up to 4 µm is measured in human eyes.21,22 In light of this, some research groups perform drug 
delivery studies directly on explants of larger species.23,24 Nevertheless, in these studies the 
vitreous is separated from the retina so that information regarding the VR interface is lost. 
Therefore there is an urgent need for models with an intact VR interface based on larger animals 
since it is expected these will be more representative for the human VR interface. As argued in 
Chapter 2, we are convinced that such relevant ex vivo models will become highly useful in 
research which aims for drug delivery into the retina. 
To address this need, we developed an ex vivo explant model that is bovine-derived and most 
importantly, guarantees an intact VR interface by keeping the vitreous attached to the retina at 
all times. Drugs or drug carriers can be injected ex vivo into the vitreous of the VR explant after 
which their potential to cross the VR interface as well as their transport route into the retina can 
be examined by microscopy. In this chapter we present the methodology of this novel VR explant 
and validate its retinal morphology and viability. We furthermore demonstrate the potential of 
the model in drug delivery research by studying how the size of nanosized polystyrene (PS) 
nanoparticles (NPs) influences their transport over the VR interface. Finally, we apply the 
presented model to draw conclusions on the drug delivery barrier role of the separate parts of 
the VR interface. 
2. METHODS 
Materials 
Carboxylated polystyrene beads (FluoSpheres®) were purchased from Molecular Probes™: 40nm 
(8795), 100nm (F8800), 200nm (F8809). Dyes for Müller cell and viability staining were obtained 
from Invitrogen: Hoechst 33342 (H3570), FM® 1-43 (T3163), Mitotracker® Deep Red (M22426), 
Propidium iodide (P3566). Antibodies against glutamine synthetase (ab73593) and Collagen IV 
(ab6586) were purchased from Abcam; AlexaFluor® 647 tagged secondary antibody (A27040) 
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was obtained from Invitrogen. Cell culture materials were mostly acquired from Gibco™: CO2 
Independent medium (18045088), Neurobasal®-A medium (10888022), Advanced DMEM 
medium (12491023), B-27® supplement (17504044), Penicillin-streptomycin (15140122), L-
Glutamine (25030081), GlutaMAX™ Supplement (35050061), Trypsin-EDTA 0,25% (25200072), 
epidermal growth factor (Sigma, E9644). 
Nanoparticle characterization 
The hydrodynamic size and zeta potential of the FluoSpheres® are determined using a Malvern 
Zetasizer Nano (Malvern Instruments, Worcestershire, U.K.). For this purpose the FluoSpheres® 
are diluted a thousand times in HEPES buffer (25mM, pH 7.2) prior to performing the 
measurements at 25 °C. Size measurements are done in triplicate with three runs per replicate 
and presented based on the number distribution. The zeta potentials are calculated from the 
electrophoretic mobility of the FluoSpheres based on the Henry equation considering the 
Smoluchowski approximation. Zeta potential measurements are done in triplicate with two runs 
per replicate.  
Dissection and culture of a conventional retinal explant 
Fresh bovine eyes are obtained from the local slaughterhouse where they are enucleated up to 
30 min after the animal is sacrificed. The eyes are transported and kept in ice cold CO2 
independent medium until dissection. After removing all extra-ocular connective tissue and 
disinfecting the eyes by soaking them in 20% ethanol, the sclera is punctured with a 21G needle 
around 10 mm below the limbus. This hole next serves as an entry point for the scissors used to 
bisect the eye. After bisection of the eye, the vitreous is removed and the posterior eye cup is 
filled with cold CO2 independent medium. Next, 3 to 4 flaps are cut in the eyecup, preferably 
along large veins. While the whole structure is submerged in medium, a trephine blade (Beaver®) 
with 10 mm diameter is used to isolate a circular piece of retina from each flap. The explant is 
then removed from the eyecup by gently pipetting medium below. Two of these explants are 
then placed on a dry 75mm Transwell® explant filter after which the explant filter is moistened 
with explant culture medium (Neurobasal®-A, 1% B-27® supplement, 1% Penicillin-streptomycin, 
0,5% L-glutamine) and 10 ml of the same medium is added below the explant filter. Finally, the 
explants are incubated at 37°C and 5% CO2. 
Dissection and culture of a vitreoretinal explant 
Our newly developed dissection protocol differs from the conventional one by the preservation 
of vitreous and an intact ILM during dissection. The preparation of this so-called “vitreoretinal 
explant” is shown in Figure 3.2. Before dissection, isolated bovine eyes are gently warmed by 20 
– 30 minutes incubation in CO2 independent medium at room temperature, a crucial step to 
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allow smooth separation of the retina from the RPE-choroid layer in step E of the protocol. As for 
conventional explants, the sclera is punctured with a 21G needle around 10 mm below the 
limbus (step A). In step B, the eye is bisected so that a posterior eye cup filled with vitreous gel 
remains. Next, at the rim of the eyecup the retina is gently detached from the choroid using a 
fine pincet, except at the side of the optic nerve (step C). Then, the vitreous is gently pulled 
down during which the attached retina should slide along (step D-E). After cutting the optic 
nerve (step F), the whole tissue is slid with vitreous side upwards into a culture dish of 10cm 
(Corning) filled with cold CO2 independent medium. In step G, a scalpel is used to cut up to three 
pieces of VR explant (up to 1,5 cm2) from the vitreous side downwards through the retina. 
Hereby the potentially damaged edges of the retinal tissue are avoided. In step I-K, a plastic 
Pasteur pipette is used to gently aspire the VR explant and to transfer it to a dry explant filter 
from a 75mm Transwell® dish (3419, Corning). Excess amounts of vitreous (e.g. lying next to the 
retina) can then be removed by aspiration of some vitreous using a plastic Pasteur pipette while 
cutting through the gel with scissors. Finally, 10 ml of supplemented Neurobasal®-A medium is 
added below the explant filter (Step L) and the VR explant is placed in an incubator with 5% CO2 
at 37°C.  
 
Figure 3.2 │ Step-by-step overview of the dissection protocol to culture a bovine vitreoretinal explant.  
Ex vivo intravitreal injection of nanoparticles 
Immediately after explant dissection, carboxylated PS beads (1,42*1015 NPs/ml) are injected 
(using a 30G needle) in the vitreous layer covering the retina. Multiple injections (about 50 µL 
per injection) within one VR explant are performed. The injections are done ‘horizontally’ to 
avoid direct transfer of NPs into the retina (Figure 3.2, M). As shown in step N each IVT injection 
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typically resulted in an ‘injection band’ (arrows) containing a high concentration of (fluorescent) 
beads. Following injection the beads then diffuse through the vitreous toward the retina. Since 
IVT injection is not possible in conventional retinal explants (as there is no remaining vitreous), 
25 µl of the carboxylated PS beads is applied on top of the explants. All explants are incubated 
with the PS beads at 37°C for 24 hours. 
Explant staining, fixation and “direct imaging”  
Explants are stained by the injection of a mixture of dyes in the vitreous covering the retina, 
followed by incubation at 37°C for 2 hours. Nuclei are stained with 10 µg/ml Hoechst, lipid 
membranes with 20 µg/ml FM-43 and Müller cells with 2 µM Mitotracker Deep red following the 
protocol of Uckermann et al.25. To evaluate retinal cell viability, a mixture of Propidium Iodide 
and Hoechst is added to the explant culture medium below the explant filter resulting in a final 
concentration of 10 µg/ml for both dyes. After dye incubation the explants are fixed by replacing 
the explant culture medium with 4% paraformaldehyde (in PBS) during 2 hours at 4°C. After 
fixation, the fixative is replaced by PBS for imaging.  
 
Figure 3.3 │Schematic drawing of the set-up applied for “direct imaging” of the vitreoretinal explant. 
Fixed ex vivo explants are imaged with a confocal microscope (C1-si, Nikon) directly or after 
preparing cryosections (see below). For “direct imaging”, a 60x water dipping objective (NIR, 
Apo) with a large working distance (2,8 mm) is pushed on top of the vitreous which allows to 
image from the vitreous until the ganglion cell layer (Figure 3.3).  
Explant cryosectioning and immunohistochemistry 
After fixation, the fixative below the explant filter is removed and replaced by 30% sucrose and 
incubated overnight at 4°C. After snap freezing the samples in Tissue-Tek® O.C.T. (Sakura) with 
liquid nitrogen, 14 µm sections are cut with a cryostat (Leica).  
 
 
Figure 3.4 │Workflow applied for cryosectioning of the retina and cryosection imaging. 
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For reliability of our results we applied the workflow drawn in Figure 3.4: 16 sections are 
analyzed per retina, resulting from 4 distinct retina regions. These retinal sections are 
permeabilized with 0,1% Triton for 5 min prior to a 1 hour incubation at room temperature with 
5% goat serum in PBS as a blocking step. Next, sections are incubated overnight at 4°C with 
1:200 rabbit antibody against Collagen IV. Finally, after a 1 hour incubation at room temperature 
with goat anti-rabbit Alexafluor 647 conjugated secondary antibody and 10 µg/ml Hoechst, the 
sections are mounted with Vectashield (Vector Laboratories) and prepared for imaging. The 
cryosection imaging is done with a confocal microscope (C1-si, Nikon) using a 10x objective (CFI 
Plan Apochromat, Nikon) and a 60x water objective (NIR Apo, Nikon).  
Uptake of nanoparticles by the retina: cryosection image processing for semi-
quantitative analysis 
To analyse the uptake of the PS beads by the retina, following the workflow presented in Figure 
3.4, (minimally) two images are taken per retinal section, resulting in at least 32 images per 
retinal explant. Image analysis is done with FIJI (NIH) as follows: using the Polygon Tool a region 
of interest (ROI) is drawn around the retinal area below the ILM. Then, the area outside this ROI, 
i.e. above the ILM, is colored black using the ‘clear tool’ so only particles present within the ROI 
(retina) would be counted. The number of particles within the ROI is counted using the ‘analyze 
particles’ tool. Finally, the surface area of the ROI is measured by applying the ‘measure’ tool in 
the ROI manager so that the number of counted particles can be recalculated per 1000 µm2. 
Based on these results, the various sections are categorized in three categories i.e. samples 
containing a low (< 10), higher (10-30) or very high (> 30) amount of particles per 1000 µm2.  
3. RESULTS 
Vitreoretinal explant morphology and viability 
The VR explant differs from the conventional explant by the presence of an intact VR interface. 
Despite this seemingly small difference, the search for a dissection protocol suitable to obtain 
the VR explant was intensive. The dissection protocol as presented in Figure 3.2 resulted in an 
explant that keeps a layer of vitreous attached to the retina. Next, we visualized the ganglion cell 
layer (GCL) and nerve fiber layer (NFL) of the VR explant by staining for Müller cells and lipid 
membranes. Figure 3.5 shows that a large portion of this layer is taken in by a patchwork of 
Müller cell endfeet (red color) separated by lipid membranes (green color). Nerve fibers run 
unidirectional through these patchworks, while other dye-less cell types such as RGCs are 
randomly scattered within this layer. 
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Figure 3.5 │ Confocal view of the GCL/NFL layer as obtained through “direct imaging” (Figure 3.3). Müller 
cells (red) are stained with Mitotracker Deep Red, lipid membranes and nerve fibers (green) with FM-43. 
Scale bar: 20 µm. 
When we compare the morphology of the bovine GCL/NFL layer with the morphology of 
Mitotracker-stained tissue of others species as presented in literature (Figure 3.6), the 
morphology of the bovine GCL/NFL layer highly relates to that of the human retina. Interestingly, 
bovine vitreous also has a similar structure as human vitreous and has therefore been frequently 
applied in ex vivo models developed for IVT drug delivery studies.7,20,26–28  
 
Figure 3.6 │ Confocal view of the GCL/NFL layer of different species stained for Müller cells. Bovine 
retinal tissue was stained by Mitotracker Deep Red (own data); human, rat and rabbit tissues were stained 
with Mitotracker Orange, data  taken from 
25
. 
Next, we aimed to assess if the dissection protocol and explant culture conditions maintain the 
integrity and viability of the various retinal layers. VR explants were stained with the nuclear 
label Hoechst to identify the various layers and check gross retinal morphology. Also, the cell-
impermeable (red) dye Propidium Iodide (PI) was added to identify cell viability. The cryosections 
in Figure 3.7 show that the architecture of the retina is nicely preserved and all retinal layers can 
be easily distinguished. In addition, a layer of vitreous gel is clearly attached at the side of the 
ILM as indicated by the arrows. Also note that the number of PI-positive cells is very limited at 
both time points from which we conclude that the explant is viable for at least 48 hours.  
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Figure 3.7 │ Cryosections showing gross morphology and tissue viability of vitreoretinal explants. Nuclei 
are stained with Hoechst (blue), dead cells are stained with propidium iodide (PI, red). Arrows indicate the 
vitreous layer. Scale bar: 100 µm.  
Influence of nanoparticle size on the transfer through the vitreoretinal interface 
studied by direct imaging of the VR explant  
Following the successful characterization of the morphology and viability of the VR explant, we 
applied the model to study, for the first time, the size dependent penetration of polystyrene (PS) 
beads over the intact VR interface of a large animal. The three selected sizes of the PS beads 
correlate with the sizes of (intravitreally injected) gene carriers currently under investigation for 
the treatment of retinal diseases: 40 nm ranges at the upper size limit of viral vectors, while the 
100 and 200 nm sized beads represent the size of most common non-viral vectors. Table 3.1 
represents the size and zeta-potential (a measure for the surface charge) of the carboxylated PS 
beads dispersed in HEPES buffer, as measured by DLS. As expected, the particle sizes were highly 
reproducible and all particles were negatively charged due to the carboxylated surface. This 
negative charge is of importance since negatively charged entities are known to diffuse well 
through the vitreous, increasing their potential to reach the retina. 
 
Table 3.1 │ Size and zeta-potential of the carboxylated PS beads in HEPES buffer as measured by DLS 
(n=3). 
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As described above, the PS beads were administered into the VR explant by multiple 50 µl ex vivo 
IVT injections. 24 Hours post injection, the transfer of the NPs from the vitreous into the retina 
was investigated using the direct imaging method. Here, a water dipping objective is gently 
pushed on top of the vitreous to image the vitreous and NFL/GCL layer (Figure 3.3). Figure 3.8A 
demonstrates the transfer of green PS beads through the VR interface into the NFL/GCL layer (of 
which the Müller cell endfeet are stained in red). Our data shows that only 40 nm particles can 
be spotted in the retina, while 100 nm and 200 nm NPs do not appear in the NFL/GCL layer. Note 
that, on the micro-scale, the position of the retina as it occurs in Figure 3.8 is not entirely flat. 
Therefore, images were often taken in which the vitreous (right top side) appears bright green as 
it is heavily loaded with green PS beads, while the rest of the image displays Müller cell endfeet 
and nerve fibers. Remarkably, 40 nm particles that were able of crossing the VR interface tended 
to selectively co-localize with the Mitotracker-stained Müller cells. Indeed, 40 nm PS beads were 
only present in the mosaic of red islands representing Müller cells, though not in the blood 
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Figure 3.8 │Transfer of (green) PS beads through the VR interface, as visualized by “direct imaging” (Fig. 
3.3). Müller cells (red) are stained with Mitotracker Deep Red, cell nuclei (blue) with Hoechst. A) 40 nm 
particles enter the Müller cells, 100 and 200 nm particles remain in the vitreous (indicated with “V”). Scale 
bar: 25µm. For optimal contrast we refer the reader to the pdf version. B) Co-localization of 40 nm PS 
beads (green) with Müller cells. Asterisks (*) indicate blood vessels, number signs (#) indicate nerve fibers. 
Scale bar: 25 µm.  
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Influence of nanoparticle size on the transfer through the vitreoretinal interface 
studied by cryosection imaging of the vitreoretinal explant 
We further investigated the uptake of differently sized PS beads in the VR explant by cryosection 
imaging. Considering our interest in the VR interface, we visualized the ILM by staining it with 
(red) antibodies against Collagen IV. Typically this resulted in images as presented in Figure 3.9, 
where the vitreous, which appears as bright green due to the high number of PS beads, nicely 
aligns with the intact ILM. Based on these images, we estimated the thickness of the ILM to be 
around 2 µm, which correlates well with the average thickness of fixed human ILM (~ 2-4 µm) 
reported before.21,22  
 
Figure 3.9 │ Cryosection image of a bovine VR explant. Green: 100 nm polystyrene beads injected in the 
vitreous; Red: ILM stained for collagen, which also stains retinal blood vessels (*); Blue: Hoechst staining of 
nuclei. Scale bar 50 µm. 
To rule out any bias, cryosection preparation was performed complying with the workflow drawn 
in Figure 3.4 followed by image processing, resulting in at least 32 images that were analyzed per 
replicate of a given NP size. We opted for this systematic and objective approach based on the 
initial observation that NP uptake often greatly varied between different explants and even 
between different locations within one explant. Figure 3.10B shows the number of NPs that 
penetrated in the retina, subdivided in categories of low (< 10 NPs), intermediate (10-30 NPs) 
and high (> 30 NPs) penetration per 1000µm2 of retina. The size-dependent uptake of the PS 
beads confirms the trend observed in Figure 3.8. Indeed, the majority of sections originating 
from explants incubated with 40 nm NPs contain a large amount of beads inside the retina 
(Figure 3.10B, black bar) while the opposite is true for the 100 and 200 nm sized NPs. Figure 
3.10A shows representative images of the most occurring situation for each particle size i.e. high 
(> 30 NPs/1000µm2 as seen with 40 nm NPs), low (10-30 NPs/1000 µm² as observed with 100 nm 
NPs) and medium (< 10 NPs/1000µm2 for 200 nm NPs) penetration. Also on these images, the 
high VR transfer into the retina of 40 nm beads in comparison with the larger particles is clearly 
noticeable.  
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Figure 3.10 │ Transfer of (green) PS beads through the VR interface, as visualized by cryosection imaging.     
A) Representative cryosection images showing the transport of PS beads through the vitreoretinal 
interface, 24 h after injecting the PS beads in the vitreous of the VR explant. ILM and blood vessels are 
stained  by anti-collagen antibodies (red), nuclei (blue) with Hoechst, particles are shown in green. Note 
that the contrast in the middle panel is enhanced to optimally visualize the PS beads, while the brightness 
of the PS beads is reduced in the right panel to illustrate the perfect alignment of the vitreous and ILM. 
The scale square in the top left image represents 1000 µm
2
 (31,6 µm x 31,6 µm). Scale bar: 31,6 µm. B) 
Semi-quantitative analysis of transport of PS beads through the VR interface after 24 h incubation. (n = 3) 
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Relevance of the vitreous and ILM as drug delivery barriers  
To illustrate the importance of an ex vivo model that keeps the entire VR interface intact we 
have compared the transport of 100 nm sized PS beads into the retina using respectively our VR 
explants and conventional explants without vitreous. As can be derived from Figure 3.11B, the 
transfer of particles into the retina observed using conventional explants was clearly higher. In 
fact, the fraction of sections containing > 30 NPs per 1000 µm2 nearly tripled (11 to 31%). We 
furthermore observed that absence of vitreous allowed larger particle aggregates to enter the 
retina (Figure 3.11A, - vitreous). In view of these observations, it is evident that tearing off the 
vitreous significantly affects the transport of NPs into the retina which may result in an 
inaccurate estimation of the potential of NPs to cross the VR interface. To further explore to 
which extent the ILM is a transport barrier for NPs we purposely sought for spots in the retinal 
sections with a compromised ILM. It has indeed been reported before that the ILM can be 
severely damaged by tearing of the vitreous.29 A typical image of this case is shown in Figure 
3.11A (-ILM) where the ILM is absent in the center of the image, a condition which clearly results 
in unusually high NP transport. 
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Figure 3.11 │ Transfer of 100 nm PS beads in explants with compromised barriers. A) Representative 
cryosection images showing the transport of 100 nm sized PS beads into the retina, 24 h after applying the 
beads on the explants. Top row: no vitreous, bottom row: no ILM. ILM and blood vessels (red) are stained 
by anti-COLIV antibodies, nuclei (blue) with Hoechst, particles are shown in green. Scale bar: 20 µm. B) 
Semi-quantitative analysis of 100 nm PS bead uptake in vitreoretinal explants compared to conventional 
explants without vitreous (n = 3).  
4. DISCUSSION 
IVT injection is globally a daily employed administration technique for the delivery of 
therapeutics to the retina, such as anti-VEGF medication or antibiotics. For the delivery of gene 
carriers, on the other hand, subretinal injection is clinically the most investigated technique, 
especially for targeting PRs or RPE cells in the outer retina. We, and others, however strongly 
believe IVT injection can be a worthy alternative for gene delivery to the retina, especially when 
(widespread) expression over the inner retinal tissue should be obtained.8,30 Yet, to ensure 
effective gene therapy after IVT injection, gene carriers have to pass the VR interface before 
reaching the retina. As extensively discussed in Chapter 2, three parts of this VR interface can be 
considered as a hurdle: peripheral vitreous, the ILM and Müller cell endfeet (Figure 3.1). 
Strikingly, gene carriers often efficiently overcome these hurdles in small animal in vivo studies, 
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usually on rodents, though this success is rarely extrapolated to larger animal models like pigs.18 
Based on our knowledge on interspecies differences in ocular anatomy and barrier structure this 
does not entirely come as a surprise: the combination of the smaller volume of vitreous (5 – 20 
µl),31 its more liquid composition and the reduced ILM thickness make the VR interface in mice 
hardly representative for the human situation.32 For this reason several research groups focus on 
the culture of large animal retinal explants, however, this usually implies detachment of the 
vitreous gel so information on the VR interface is lost.23,24 We therefore aimed to bridge the gap 
between these ex vivo models and the eventual in vivo situation in large animals and humans, by 
developing a novel ex vivo explant model based on bovine eyes that maintains the entire VR 
interface intact. We show that our VR explant remains viable for at least two days and its 
morphology is rather human-like (Figure 3.6-3.7). We furthermore demonstrate that our model 
is ideally suited to study the penetration of particles across the VR interface into the retina after 
IVT injection.  
Conveniently, our VR explant model allows for two ways of imaging, where both ways have their 
merits. The direct imaging method (Figure 3.3) is faster, less labour-intensive and requires for 
less tissue manipulation which results in optimal integrity of the whole tissue. The observable 
tissue depth is however limited to the ganglion cell layer. On the other hand, cryosection 
preparation and imaging is rather labour-intensive but gives a full cross-section of all retinal 
layers and allows to stain for a plethora of markers by immunostaining (Figure 3.4). 
As highlighted in Chapter 2 working ex vivo comes with several advantages, which is why we 
purposely opted for this approach. Firstly, highly relevant drug delivery studies can be performed 
on representative large animal species such as pig, cow or even human donor eyes; this without 
the high costs that accompany the care and housing of larger species as required for in vivo 
studies. Secondly, ex vivo assays are convenient and accessible: eyes can be easily obtained from 
local slaughterhouses, and only basic cell culture and dissection materials are required to culture 
our VR model, making it feasible for every researcher. Finally, the application of ex vivo assays is 
in line with the worldwide aim to implement the 3R principle (replacement, reduction and 
refinement), originally introduced by Russell and Burch as guidelines for more ethical and less 
use of laboratory animals.33  
To demonstrate the value and functionality of our VR explant for drug delivery we looked into 
the size-dependent transfer of NPs through the VR interface into the retina. To this end, we 
decided to use commercially available carboxylated polystyrene beads, since these particles are 
highly fluorescent, well characterized and monodisperse as confirmed by our DLS measurements 
(Table 3.1). Furthermore, these particles have potential to penetrate into the retina after IVT 
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injection as: 1) the NP sizes are lower than the estimated mesh size of the vitreal collagen 
network (550 nm) 20 2) negatively charged particles exhibit ideal vitreal mobility and do not 
aggregate in the vitreous,20,34–37 and 3) in contrast to positively charged particles, negatively 
charged ones have been reported before to cross the ILM.11,12 As anticipated, the PS beads did 
effectively enter the retina and more importantly, a clear size-dependent trend was noticeable 
using both imaging methods (Figure 3.8 and 3.10): 40 nm PS beads more easily entered the 
retina from the vitreous than 100 and 200 nm sized beads. It is essential to note that for a given 
particle size, the number of NPs that crossed the VR interface varied greatly between different 
retinal explants and even for different locations within the same retinal explant. For this reason 
the retinal section data were presented as a distribution rather than only showing the most 
occurring observation. A potential explanation for this variety in uptake within and between VR 
explants is that the ILM thickness varies depending on the retinal region,10 as well as on the age 
of the animal.9,38 In addition, although the same particle concentration and injection volumes 
were injected into the vitreous of the various VR explants, the injection location and the 
thickness of the vitreous layer largely determine the actual NP concentrations across the vitreous 
and the retina.  
Once NPs passed the VR interface, they were generally located in the inner retinal layers, which 
is in line with the rationale of exploring IVT injection as a valuable strategy for gene therapy, 
primarily for targeting cell types in the inner retina. Using the direct imaging method we further 
observed that 40 nm particles co-localized specifically with Müller cell endfeet (Figure 3.8B), an 
observation also made by Koo et al. with human serum albumin based NPs in rats.11,34 Since the 
Müller cell endfeet abut in the ILM, these cells are likely the first ones particles encounter after 
IVT injection. Also our in vitro uptake studies demonstrate that bovine primary Müller cells 
efficiently endocytose polystyrene beads (data not shown). Unfortunately, we were unable to 
confirm a clear co-localisation of NPs and Müller cells using cryosection imaging.  
Interestingly, while 100 nm sized particles had difficulty crossing the VR interface in our hands, 
some reports discuss the easy entry of larger particles into the retina.11,34,39,40 Koo et al. for 
example found 350 nm sized negatively charged human serum albumin particles to enter the 
retina in rats after IVT injection.11 Similarly, neutral polylactide particles of the same size were 
reported to accumulate at the ILM followed by smooth penetration into the rat retina as well.39 
Also solid lipid nanoparticles of 230 nm resulted in efficient transfection across nearly all retinal 
layers after IVT injection in mice.40 It should be noted, however, that all these observations were 
made in rodents, which could account for the contrast with our data obtained in bovine eyes.  
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To illustrate the importance of preserving the VR interface and to explore the barrier role of the 
vitreous, we have investigated the uptake of 100 nm sized NPs in conventional explants without 
vitreous. Removing the vitreous had a positive effect on retinal uptake, since the fraction of 
retinal sections containing high amounts of NPs increased and larger NP aggregates were able to 
enter the inner layers of the retina (Figure 3.11A and B). Notably, the vitreous does not 
represent a major barrier for these negatively charged 100 nm PS beads since they are known to 
have good vitreal mobility 41. We therefore expect the effect of vitreous removal to be more 
pronounced for positively charged particles that are obstructed by their interaction with the 
negatively charged components of the vitreous,7,11,20,34,41,42 and for particles that are larger than 
the mesh size of the vitreal network (~550 nm).20 Next to losing information on the barrier 
function of the vitreous for a particular NP, tearing off the vitreous also influences the barrier 
function of the ILM. In fact, Russell et al. found that vitreous separation commonly results in ILM 
breaks, ILM evulsion and sporadically even loss of inner retinal layers in cynomolgus monkeys.29 
An example of ILM separation upon vitreous removal can be seen in Figure 3.11A, a condition 
that clearly results in massive NP uptake in the retina. A similar observation was made by Gan et 
al. who witnessed enhanced penetration of liponanoparticles through the disintegrated ILM of 
rats suffering from uveitis when compared to healthy rats.13 Also, Dalkara et al. witnessed 
enhanced retinal transduction by viral vectors following mild enzymatic digestion of the ILM.43 
Considering these observations and the spectacular contrast in retinal delivery seen between a 
retina with and without the ILM in this chapter, it is obvious that the ILM is a crucial barrier for 
gene therapy. Surely, it functions as a sieve that defines the type and number of particles 
presented to the inner retinal cells.  
The significant role of the vitreous and ILM as a barrier for drug delivery and the influence of 
vitreous removal on the integrity of both of them again highlights the necessity of the model 
presented in this chapter. Certainly, our bovine-derived VR explant could be highly valuable as a 
relevant set-up to assess if promising particles, showing favorable in vitro results, are competent 
in crossing the different hurdles connected to the VR interface. However, despite its value, some 
general remarks can be made. It should be noted that by isolating the vitreous along with the 
retina, the vitreous loses the natural support of the eyecup, causing a partial collapse of the 
vitreal collagen network.44 While potential (unwanted) interactions of particles with the vitreal 
components will still be detected in our model, we refer the reader to other advanced models, 
such as the one developed by our research group, when exact diffusional rates of fluorescent 
particles in intact vitreous are to be determined.26 Along the same line, the vitreous volume in 
which nanoparticles are injected in the vitreoretinal explant is significantly lower than in case of 
a clinical intravitreal injection. When evaluating therapeutic carriers applying our model it is 
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therefore important to estimate a dose that is as much as possible corrected for the diffusion 
that needs to take place prior to arrival of carriers at the retina. Secondly, while the VR explant 
greatly mimics the in vivo situation, certain dynamic processes present in the living eye are not 
taken into account such as clearance mechanisms, potential immune reactions, and the anterior-
posterior flow present in the vitreous.27The currently available ex vivo system that most closely 
resembles the in vivo situation, is the perfused eye model (cfr. Chapter 2). In this approach, an 
entire eye is isolated, cannulated and perfused, keeping the eye globe perfectly intact.45,46 This 
eye integrity is highly beneficial, although it comes with the disadvantage that these perfused 
eyes are only viable for a limited time (~ 9 hours). In contrast, our VR explant remains viable for 
at least 2 days, making it more suitable to evaluate retinal uptake of carriers after IVT injection. 
For long-term follow up of gene carriers, however, in vivo studies remain indispensable as for 
example retinal gene expression usually only reveals itself after 2 weeks.14,47  
5. CONCLUSION 
For future research we argue that further detailed characterization of the properties and 
composition of the vitreous and ILM across species could help to identify which models are the 
most suited for IVT drug delivery studies with the retina as main target. Thanks to the valuable 
research performed on especially developed large animal models we have the knowledge to 
smartly design vectors able of overcoming the vitreous as a barrier. In contrast, owing to the 
diversity of vectors studied on a variety of species the physicochemical requirements to 
efficiently cross the ILM is way less coherent. Well-designed systematic studies into which 
particle properties do result in successful retinal entry from the vitreous could therefore form a 
sound foundation for future design of ‘the’ optimal gene carrier administered by IVT injection. 
We are strongly convinced that advanced ex vivo models, such as the one presented in this 
chapter could have great significance in reaching this goal. Surely, our VR explant is currently the 
most representative ex vivo model on the market that is viable for a sufficiently long time to 
study carrier uptake. Moreover, our ex vivo approach is readily accessible, relatively cheap and 
transferrable to other large species like pig or human. 
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Neuroprotection is a mutation-independent therapeutic strategy that seeks to enhance the 
survival of neuronal cell types through delivery of neuroprotective factors. The Müller cell, a glial 
cell type appreciated for its unique morphology and neuroprotective functions, could be 
regarded as an ideal target for this strategy by functioning as a secretion platform within the 
retina following uptake of a transgene of our choice. In this in vitro study we aimed to investigate 
the capability of Müller cells to take up a standard liposomal vector (i.e. lipofectamine 2000) and 
process its pDNA or mRNA cargo into GFP protein. By doing so, we found that mRNA lipoplexes 
outperformed pDNA lipoplexes in Müller cell transfection. We furthermore explored the Müller 
cell’s performance in stressful circumstances by examining lipoplex-induced transfection 
efficiency and cytotoxicity in hypoxic, hyperglycemic and oxidatively stressed cells – conditions 
linked to diabetic retinopathy and glaucoma. None of the stress factors substantially altered GFP 
expression in Müller cells. Interestingly, hyperglycemia seemed to have a protective effect 
against lipoplex-induced toxicity while hypoxia and oxidative stress led to a slightly higher 
toxicity. In conclusion, our study indicates that mRNA-lipoplexes have potential in transfecting 
Müller cells in healthy as well as diseased conditions. 
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1. INTRODUCTION 
As mentioned in Chapter 1, Müller cells are a dominant glial cell type in the retina and provide 
support to their surrounding neurons through a myriad of functions. On top of this natural 
neuroprotective behavior, Müller cells also exhibit several beneficial properties which render 
them ideal targets for gene transfer. Indeed, their exceptional radial morphology allows them to 
interact with each neuronal cell type while their endfeet, which abut in the ILM, make the Müller 
cell a reachable target via IVT injection. In contrast to neurons and photoreceptors (PRs), Müller 
cells are furthermore remarkably resistant to stress allowing them to survive in advanced stages 
of retinal diseases.1,2 Based on these advantageous characteristics, we, and others, believe that 
the Müller cell could play a prominent role in ocular neuroprotection by performing as a 
secretion platform within the retina (cfr. Chapter 1).1,3,4 In this strategy, illustrated in Figure 4.1, 
gene vectors carrying genes encoding for neuroprotective factors are delivered to Müller cells 
after which they secrete the factors into their surroundings, thus enhancing neuron survival. 
 
Figure 4.1 │ The Müller cell as a secretion platform for neurotrophic factors. M: Müller cell; NFL: nerve 
fiber layer; GCL: ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: outer 
plexiform layer; ONL: outer nuclear layer; PRS: photoreceptors. 
 
This concept was already explored in the 90’s by Di Polo et al. who applied IVT injected viral 
vectors carrying a transgene of brain-derived neurotrophic factor (BDNF) to Müller cells in 
axotomized rats. More importantly, the expression of BDNF that followed led to the prolonged 
survival of the injured retinal ganglion cells (RGCs).5 Several research groups performed similar 
studies with viral vectors, resulting in extended survival of RGCs in glaucoma animal models by 
expression of ciliary neurotrophic factor (CNTF),6,7 as well as delay of retinal degeneration in 
retinitis pigmentosa by glial cell-derived neurotrophic factor (GDNF) expression.1 Although all 
these successes were achieved with viral vectors, the high production cost and associated safety 
issues connected to viruses still remain a concern. Consequently, there has been a growing 
interest toward nanoparticle-based technology (NPs) for retinal gene therapy partly due to their 
high payload, easy surface modification and relatively straightforward scale-up (cfr. Chapter 1).8 
Among non-viral particles, the most extensively researched particle is undoubtedly the 
liposome.8–11 Lipid mixtures, usually containing cationic and neutral lipids, can bind negatively 
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charged nucleic acids (NAs), forming lipid-NA complexes called lipoplexes (Figure 4.2). The 
packaging of NAs in these lipoplexes substantially enhances transfection efficiency by protecting 
the NAs from degradation and enhancing cellular uptake and endosomal escape due to their 
interaction with the cellular and endosomal membranes, resulting in efficient NA cargo release 
into the cytosol.8,12 The liposomal transfection agent applied in our study is Lipofectamine 2000 
(LF2000), a universally applied commercial carrier in in vitro studies.  
 
Figure 4.2 │ Schematic drawing of a mRNA-loaded lipoplex.  
 
In this study we have focused on pDNA as well as mRNA as therapeutic genes. The use of pDNA is 
well-established in the field of retinal gene therapy due to its stability and long-term expression. 
Surely, nearly all reports on non-viral transfection in retinal cells are based on plasmid DNA.13 
Exploring mRNA as therapeutic gene therefore might seem as an unconventional choice. The 
predominant disadvantage of applying mRNA is evidently its transient expression which renders 
mRNA useful for only a few specific applications. However, its stability and immunogenicity can 
be positively tuned by the incorporation of naturally occurring modified nucleosides.14 This 
enhanced stability and reduced immunogenicity can both result in a prolonged expression of the 
mRNA - as confirmed by our group (data not shown). In context of retinal disease, mRNA might 
have an important advantage over the commonly applied pDNA: it exerts its function in the 
cytosol which implies that, in contrast to pDNA, transfection efficiency is not dependent on cell 
division. This is a relevant asset when targeting the adult retina since many retinal cell types, 
including the Müller cells, are post-mitotic. 
Neuroprotection has been proposed as a treatment strategy for glaucoma and diabetic 
retinopathy, two leading causes of vision loss which we briefly discussed in Chapter 1.15–20 We 
therefore wished to explore the influence of stress factors associated with these retinopathies 
on Müller cell transfection. We selected three pathological conditions that are easily simulated in 
vitro. As a first stress factor we have selected oxidative stress since this anomaly has been 
detected in several experimental (animal) models of glaucoma as well as diabetic retinopathy.21–
23 We further selected hyperglycemia since this is the fundamental cause of diabetic retinopathy 
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and elevated glucose levels are known to engender a variety of metabolic abnormalities and 
oxidative stress.23 Finally, we chose hypoxia as a stress factor since diabetic retinopathy is 
correlated with decreased retinal blood flow 24 and hypoxic tissue has also been detected in 
glaucomatous eyes.25,26  
Taken together, in this preliminary study we explored the readiness of Müller cells to take up 
lipoplexes and process their NA cargo into proteins. We furthermore sought to compare the 
expression profiles of mRNA and pDNA in healthy Müller cells and assess the therapeutic 
potential of mRNA. Finally, we examined if pathogenic stimuli, as present in diseased retinal 
tissue, could influence the transfection efficiency and/or toxicity induced by lipoplexes in vitro.  
2. METHODS 
Cell culture 
Immortalized human Müller cells (MIO-M1) were a kind gift from Astrid Limb (Institute of 
Ophthalmology, University College London, London U.K.).27 The MIO-M1 cells were cultured 
using DMEM GlutaMAX™ with low glucose (Gibco®, Paisly, UK) supplemented with 10% fetal 
bovine serum (Hyclone®, Cramilton, UK), 1% L-glutamine (Gibco®, Paisly, UK) and 2% penicillin – 
streptomycine solution (Gibco®, Paisly, UK). Cells were passaged at 80% confluency and 
incubated at 37°C with 5.0% CO2. 
Plasmid purification and mRNA synthesis 
gWIZ GFP (Promega, Leiden, The Netherlands) was amplified in transformed E. Coli bacteria and 
isolated from this bacteria suspension using a Qiafilter Plasmid Giga Kit (Qiagen, Venlo, The 
Netherlands). pDNA concentration was determined on a NanoDrop 2000c (Thermo Fisher 
Scientific, Rockford, IL, USA) and adjusted to a final concentration of 1 µg/µl with HEPES buffer 
(20 mM, pH 7.2). GFP mRNA was produced by in vitro transcription from gWIZ GFP plasmids. The 
plasmids were purified using a QIAquick PCR purification kit (Qiagen, Venlo, The Netherlands) 
and linearized using SpeI restriction enzymes (Promega, Leiden, The Netherlands). Linearized 
plasmids were used as templates for the in vitro transcription reaction using the T7 mMessage 
mMachine kit (Ambion, Life Technologies, Ghent, Belgium). The resulting capped mRNAs were 
purified using a RNeasy Mini kit (Qiagen, Venlo, The Netherlands). The mRNA concentration was 
determined on a NanoDrop 2000c and adjusted to a concentration of  1 µg/µl as done for pDNA.  
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Lipoplex preparation 
The lipoplexes were prepared according to the manufacturer’s protocol applying a ratio of 1:3 
(µg pDNA/mRNA to µL reagent). Briefly, the transfection agent Lipofectamine™2000 (Invitrogen) 
was diluted in OptiMEM and was left to incubate for 10 minutes at room temperature. The pDNA 
or mRNA (stock 1µg/µL) was prepared by diluting it in OptiMEM after which it was added in an 
equal volume to the diluted transfection reagent. After a 5 min incubation allowing for 
complexation of the NAs with Lipofectamine, the lipoplexes were ready for use.  
Lipoplex characterization 
The hydrodynamic size and zeta potential of the lipoplexes were determined using a Malvern 
Zetasizer Nano (Malvern Instruments, Worcestershire, U.K.). For this purpose the lipoplexes 
were diluted in HEPES buffer prior to performing the measurements at 25 °C. Size measurements 
were done in triplicate with three runs per replicate and presented based on the number 
distribution. The zeta potentials were calculated from the electrophoretic mobility based on the 
Henry equation considering the Smoluchowski approximation. Zeta  potential measurements 
were done in triplicate with two runs per replicate.  
Nanoparticle incubation 
Müller cells were seeded in a 24 well plate at a cell density of 10.000 cells per well applying 500 
µl of medium per well. After 5 days of culture, 100 µl of the lipoplexes, prepared using the 
standard protocol in OptiMEM, was added to the cells and allowed to incubate for 24 hours at 
37°C.  
Stress incubation 
Müller cells were exposed to stress factors for 48 hours in total: 24 hours prior to lipoplex 
incubation and during the 24 h lipoplex incubation. To induce oxidative stress, cells were 
exposed to 75 µM Tert-butyl hydroxyperoxide (TBHP, 458139, Sigma-Aldrich, USA). To mimic 
hypoxia, the cell-containing well plates were placed in an incubator with 2% O2 (instead of 21%) 
at 37°C and 5% CO2. To generate hyperglycemia, glucose (G8644, Sigma-Aldrich, USA) was added 
to the cell culture medium to reach a final concentration of 25mM. Note that basic Müller cell 
culture medium (DMEM GlutaMAX™)  already contains 5 mM of glucose. 
Flow cytometry 
All flow cytometry experiments were performed on 24 well plates. After stress and/or lipoplex 
treatment, cell culture medium was removed and cells were washed once with 500 µl PBS. Next, 
the cells were detached by applying 300 µl of 0.25% Trypsin-EDTA (Gibco®, Paisly, UK) after 
which the trypsin was neutralized by adding 500 µl of cell culture medium. This cell suspension 
was transferred to FACS tubes followed by a centrifugation step of 5 min at 300g. Then, the 
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supernatant was removed and the cells were re-suspended in FACS buffer (1% FBS, 0.1% sodium 
azide in PBS-). After performing this wash cycle twice, the cells were re-suspended in 300 µl FACS 
buffer and measured with a CytoFLEX™ (Beckman Coulter, Nederland). Data analysis was done 
with Flowjo software (Tree Star Inc.). 
MTT cell viability 
Müller cells were seeded in a 24 well plate at a cell density of 10.000 cells per well  and cultured 
for 5 days. After stress and/or NP treatment the medium was removed and the cells were 
washed once with PBS (Gibco®, Paisly, UK). Next, fresh cell culture medium containing 5 mg/ml 
of MTT reagent (Sigma-Aldrich, USA) was added to the cells and incubated for 3 h at 37°C. After 
this incubation step, the medium was carefully removed and the formazan crystals were 
dissolved by incubation with 100% DMSO on a shaker for 1 h at room temperature. Finally, the 
absorbance was measured at 590 nm and 690 (background) with an Envision plate reader (Perkin 
Elmer, Zaventem, Belgium). The percentage of viability was then calculated by comparison with 
untreated cells representing 100% viability.  
Statistical analysis 
All experiments were analyzed for statistical significance with a one or two-way ANOVA followed 
by the Bonferroni post hoc test to estimate significance between treated groups, or followed by 
the Dunnett post hoc test when compared to an untreated group. The results were considered 
as statistically significant if p < 0.05. The number of asterisks in the figures indicate the statistical 
significance as follows: *p<0.05; **p<0.01; ***p<0.001. All statistical analysis was performed 
with Graphpad Prism 5 software (San Diego, CA). Values are reported as the mean with Standard 
Error (SEM). 
3. RESULTS 
Nanoparticle characterization  
Figure 4.3 shows that pDNA and mRNA complexes had a similar size in HEPES buffer i.e. ~600 
nm. Their zeta potential, a measure for their surface charge, were both negative though differed 
significantly: pDNA lipoplexes had a zeta potential  of around -10 mV while their mRNA 
counterparts exhibited a zeta potential of – 25 mV. This overall negative charge could be 
explained by the fact that the positively charged LF is neutralized by its complexation with the 
negatively charged NAs. Despite the significant difference in charge between both lipoplexes, 
their uptake was similar in MIO-M1 cells (data not shown).  
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Figure 4.3 │ Characterization of lipofectamine 2000 – NA complexes by dynamic light scattering. A) size 
B) zeta-potential. Error bars represent the SEM (n ≥ 3). 
Transfection of healthy Müller cells by mRNA and pDNA-lipoplexes 
To explore the potential difference in gene expression profile generated by pDNA and mRNA we 
exposed Müller cells to a dose range of NA-loaded lipoplexes from 0.2 to 1 µg for 24 hours. As 
shown in Figure 4.4A, the transfection efficiency with NPs containing mRNA was remarkably 
higher than for pDNA, with transfection maxima of 81 (± 3%) and 21 (±1 %) respectively. While a 
dose-dependent increase in transfection efficiency is apparent for pDNA between 0.2 µg  to 0.4 
µg, the transfection potential of mRNA did not augment significantly after 0.2 µg. Furthermore, 
while a seemingly downward trend is visually observed at highest dosages for pDNA, this effect is 
not significant.  
 
 
Figure 4.4 │ Transfection of healthy Müller cells by mRNA and pDNA lipoplexes. A) Transfection efficiency 
B) mean fluorescence intensity (MFI). Error bars represent the SEM (n≥5). 
 
Interestingly, despite the great contrast in transfection efficiency between the two types of NA, 
the mean fluorescence intensity (MFI) of the cell populations are situated in the same range for 
all dosages for both NAs (Figure 4.4B). Similar to the trend observed in transfection efficiency, 
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pDNA does elicit a significant dose-dependent increase in MFI between 0.2 and 0.5 µg while no 
significant changes in MFI are observed with mRNA for dosages higher than 0.2 µg.  
 
Figure 4.5 │ Müller cell viability following transfection with DNA or mRNA lipoplexes. Both NPs induce 
significant cytotoxicity starting from a dose of 0.3 µg. Error bars represent the SEM (n≥3). 
 
Exposure of cells to NPs more than often leads to cellular stress and/or toxicity (cfr. Chapter 5).28 
To investigate the possible toxic effect of the lipoplexes on the Müller cells we have performed 
an MTT viability assay after 24 hour exposure to the NPs. As shown in Figure 4.5, both particles 
elicit a dose-dependent reduction in cell viability with significant toxicity initiating from a dose of 
0.3 µg (± 30% cell death). However, no significant contrast between pDNA and mRNA was 
detected at any dose. We can conclude that pDNA lipoplexes are less efficient but equally toxic 
transfection agents compared to mRNA lipoplexes. In light of this, we further investigated the 
influence of stress on Müller cell transfection with the most promising transfection agent, i.e. the 
mRNA lipoplexes. 
Transfection of stressed Müller cells by mRNA lipoplexes 
To investigate the influence of retinal disease on the lipoplex-induced transfection efficiency and 
cytotoxicity of Müller cells we exposed MIO-M1 cells to noxious stimuli in vitro. Oxidative stress 
was represented by incubation with TBHP, an organic peroxide that is frequently applied in cell 
culture studies. It causes oxidative stress by its decomposition in unstable alkoxyl and peroxyl 
radicals which next react with cellular components.29 To simulate diabetic retinopathy we 
exposed the cells to 25 mM of glucose, a concentration established in literature.30–32 Finally, cells 
were exposed to 2% of O2 instead of 21 % to imitate hypoxia. For all stress factors, cells were 
exposed to the stress for 24 hours prior to performing a 24 hour incubation with lipoplexes 
under stress conditions. This implies that the Müller cells were exposed to the noxious stimuli for 
48 hours before the assay readout. To look into the potential cytotoxicity induced by the stress 
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factors itself we have assessed cell viability with the MTT assay after 48 hour exposure to each 
stress factor separately. As shown in Figure 4.6A, 48 hour exposure to hyperglycemia provoked a 
small but insignificant increase in cell viability. Hypoxia did not result in any toxicity, while 75 µM 
TBHP elicited a drop in cell viability to 67%  (± 4).  
 
Figure 4.6 │ Müller cell viability after exposure to stress factors as measured by the MTT assay. A) 
Viability after 48 h exposure to noxious stimuli alone. B) Viability following transfection with mRNA in 
stressed cells. Error bars represent the SEM (n≥3). 
 
Also the combined toxicity of the mRNA lipoplexes and the stressful environment was assessed 
(Figure 4.6B). Interestingly, the viability of cells incubated with lipoplexes increased when 
combined with hyperglycemia. At a dose of 0.7 µg cell viability even augmented from 49% (± 4) 
to 71% (± 10) without and with hyperglycemia.  Compared to hyperglycemia, hypoxia had the 
opposite effect: viability of NP treated cells was significantly reduced upon exposure to a hypoxic 
environment, from 65 % (±5) to 40% (±5) and from 49% (±4) to 30% (±4) for a dose of 0.5 and 0.7 
µg, respectively. Treatment with TBHP, leading to moderate toxicity in untreated cells, did not 
significantly affect NP-mediated cytotoxicity. 
To look into the efficacy of lipoplexes to transfect stressed Müller cells we selected three 
dosages (0.3; 0.5; 0.7 µg) to identify possible dose-dependent trends. 0.7 µg was chosen as the 
highest dose since this elicited a 50 % reduction in cell viability in healthy conditions. Figure 4.7 
presents the percentage of transfected Müller cells as well as their MFI in healthy and stressed 
conditions. Though not significant, hypoxia seems to lead to a reduction in transfection efficiency 
as well as MFI. Furthermore, hyperglycemic conditions and oxidative stress do not significantly 
alter transfection efficiency nor the GFP expression per cell. 
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Figure 4.7 │ Transfection in Müller cells exposed to pathogenic stimuli. A) transfection efficiency B) MFI. 
Error bars represent the SEM (n≥3). 
4. DISCUSSION 
In this preliminary study we aimed to get an impression on NP-induced gene expression in in 
vitro cultured Müller cells. To this end we applied the most straightforward set-up: a commercial 
lipid carrier (LF2000) loaded with GFP-encoding NAs in an easy-to-culture Müller cell line. This 
was a purposeful choice since, rather than looking for an ideal drug delivery carrier, we sought to 
examine general  trends in Müller cell behavior toward NPs and/or stress. 
Comparison of Müller cell transfection and cytoxicity induced by mRNA and pDNA 
lipoplexes 
Characterization of the lipoplexes showed that mRNA and pDNA particles have a similar size 
which is rather large for a liposomal carrier, i.e. ~600 nm. Despite this similar size their zeta 
potential did differ, although both types of lipoplexes were clearly negatively charged (Figure 
4.3). Still, both lipoplexes were taken up at similar levels in Müller cells (data not shown).  
This comparable uptake did not result in similar levels of transfection efficiency. In contrast, 
mRNA-containing lipoplexes led to a 4 fold higher transfection efficiency in comparison to pDNA 
particles (Figure 4.4A). This great discrepancy is undoubtedly partly attributed to the basic 
difference in working mechanism and site of action between mRNA and pDNA: while pDNA 
requires transfer into the nucleus and transcription into mRNA, the GFP-encoding mRNA can be 
instantly translated into protein in the cytosol. Considering pDNA needs cell division to cross the 
nuclear envelope, it is likely that the rather slow division of MIO-M1 cells adds to the low 
transfection efficiency after 24 hours. Longer incubation times (≥ 48 hours) might therefore lead 
to a higher percentage of transfected cells. Nevertheless, it should be noted that the Müller cells 
in the adult retina are usually in a post-mitotic state which does not play in favor of pDNA. Once 
transfected the degree of expression per cell (MFI) was found to be similar for mRNA and pDNA. 
Overall, mRNA therefore achieves a more beneficial expression profile since the MFI is as high as 
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for pDNA though the number of GFP-expressing cells is substantially higher. Notably, we did not 
look into the duration of expression which is expected to be longer for pDNA.  
Next to efficacy, toxicity is an important parameter to consider when evaluating the potential of 
nanocarriers. To estimate particle-induced acute cytotoxicity we made use of the widely applied 
MTT assay. This assay revealed a rise in cytotoxicity with increasing dose for both lipoplexes 
(Figure 4.5). Based on the literature we expect this toxicity to be mainly attributed to the 
growing amount of lipid carrier rather than the nucleic acid fraction. Indeed, while liposomal 
carriers are often presented as relatively safe,11,33 several studies report on in vitro and in vivo 
toxicity induced by liposomes fabricated with cationic lipids.34,35 No significant difference in cell 
viability was detected between mRNA and pDNA-based lipoplexes. This observation is in line 
with our hypothesis that toxicity is caused by the lipid fraction, since the amount of lipid applied 
to the cells is exactly the same for both lipoplex formulations. When taking both protein 
expression and toxicity into account, we can conclude that mRNA is the preferred NA for 
transfection of Müller cells since low dosages of mRNA lipoplexes produced high transfection 
efficiency with limited cytotoxicity. 
Influence of noxious stimuli on transfection efficiency and toxicity of mRNA-lipoplexes 
As a next step we performed the very same experiments evaluating lipoplex-induced 
transfection efficacy and toxicity yet under influence of hyperglycemia, hypoxia and oxidative 
stress.  
Hyperglycemia 
Hyperglycemia was generated by culture of Müller cells in medium containing 25 mM of glucose. 
In cells exposed to hyperglycemia for 48 hours, a slight increase in cell viability was observed 
though this effect was not significant (Figure 4.6A). Interestingly, cell viability was also higher for 
all lipoplex dosages in glucose-treated cells compared to untreated ones, yet the difference in 
viability was only significant for the highest lipoplex dose (Figure 4.6B). It therefore seems that 
hyperglycemic conditions boost the survival of Müller cells exposed to lipoplexes and thus have a 
protective effect. Enhanced Müller cell viability under influence of elevated glucose levels in vitro 
has been noticed before by Vellanki et al. They hypothesize that hyperglycemia provokes 
augmented entry of calcium in Müller cells which next stimulates cell proliferation.32 In addition, 
studies in different cell types have shown that also other pathways can enhance cell proliferation 
as a response to hyperglycemia.36 It indeed seems logical that an increase in nutrient availability 
can stimulate the metabolism and simultaneously the proliferation of cells. Following this 
hypothesis an increase in the number of transfected cells could be expected, though this was not 
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detected. Notably, it is well-established that the diabetic retina is characterized by Müller cell 
gliosis which usually involves Müller proliferation.37,38 It is important to recognize that while 
these in vitro results indicate that hyperglycemia is beneficial, Müller cell gliosis and enhanced 
proliferation is in vivo accompanied by many Müller cell alterations of which some can have a 
harmful effect on the retina.38,39 Hyperglycemia did not influence transgene expression since the 
number of GFP transfected cells and the MFI of the transfected cells was comparable to cells in 
normoglycemia (Figure 4.7). We can conclude that hyperglycemia influences Müller cell survival, 
yet does not affect the cell’s ability to take up and process foreign mRNA. 
Hypoxia 
Exposure of Müller cells to hypoxia for 48 hours did not cause any cytotoxicity compared to cells 
cultured in normoxic conditions (Figure 4.6A). The same observation was made by Zhang et al. 
who did not detect significant apoptosis in hypoxic rat primary Müller cells.40 On the other hand, 
we should note that a hypoxic gaseous environment of 2% does not guarantee similar low 
oxygen levels will be reached in the cell culture medium.40a It is therefore possible that the cells 
did not experience hypoxia which could account for the lack of cytotoxicity we have observed. 
Still, based on the fact that the energy metabolism of Müller cells is largely based on glycolysis 
rather than the highly oxygen-dependent process of respiration, we did not expect hypoxia-
induced cytotoxicity.41 It is furthermore well-established that hypoxia can trigger the autophagy 
pathway,42 as observed in multiple retinal cell types such as retinal ganglion cells,43 PRs 44 and 
Müller cells.45 As will be explained in Chapter 5, autophagy is a cytoprotective pathway meant to 
enhance cell survival, and is activated upon exposure to a wide range of stress factors, including 
hypoxia.46,47 The lack of Müller cell death in response to hypoxia might therefore be due to the 
naturally adapted energy metabolism of the Müller cell in combination with its ability to 
upregulate autophagy when needed. However, for higher dosages (≥ 0.5 µg) the combined 
treatment of hypoxia and lipoplexes did lead to significant toxicity (Figure 4.6B). More 
importantly, the drop in cell viability was more substantial compared to lipoplex treatment 
alone. This observation was rather unanticipated considering the lack of cytotoxicity observed in 
hypoxic Müller cells. Yet, while the Müller cell can compensate for the hypoxia-induced stress, 
the addition of NP-elicited stress clearly exceeds the Müller cell’s ability to adapt, ultimately 
resulting in cell death. We therefore assume that the basic metabolism of the Müller cell is not 
highly oxygen-dependent, yet the coping mechanisms it upregulates to endure the lipoplexes, 
likely is. The Müller cell death following co-treatment might be mediated by autophagy and/or 
by apoptosis. The latter is a cell death pathway that is activated by hypoxia,48 as well as by our 
lipoplexes at doses above 0.7 µg (data not shown). This implies that, while autophagy could 
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prevent cell death in hypoxic cells, the combined treatment with lipoplexes might allow 
apoptosis to take the upper hand. Müller cells might also die from overactivation of the 
autophagy pathway. Indeed, next to hypoxia, Lipofectamine 2000 as well as liposomes have 
been reported to induce genuine autophagy.49,50 As discussed in Chapter 5, this overactivation 
might lead to excessive self-digestion eventually resulting in the observed cytotoxicity. Finally, 
there is a highly complex interplay between autophagy and apoptosis where both processes 
directly and/or indirectly influence each other (cfr. Chapter 5).48,51 It is therefore likely that both 
pathways play a role in the cell death observed by co-treatment of lipoplexes and hypoxia. When 
examining the data on transfection efficiency and level of gene expression (MFI) we can 
distinguish a clear but insignificant trend: for each dose tested, the transfection efficiency and 
MFI is slightly lower for hypoxia-treated cells than for cells kept in normoxia (Figure 4.7). Since 
liposomes are known to enter the cell via endocytosis, an active uptake process, this trend could 
be due to decreased uptake of the lipoplexes in hypoxic conditions.52,53 On the other hand, 
lipoplex uptake could be similar in both conditions but the translation of mRNA into the GFP 
protein might be affected by oxygen deprivation as stated by Andreev et al.54 Nevertheless, 
repetition of this data as well as further studies (e.g. cellular uptake) are necessary to define a 
conclusive trend and identify its underlying causes. Overall, we can summarize that hypoxia 
intensifies lipoplex-induced cytotoxicity but does not greatly affect the efficacy of the lipoplexes. 
Tert-butylhydroperoxide 
A 48 hour incubation with 75 µM of TBHP evoked significant Müller cell death (Figure 4.6A). 
Ostensibly this does not seem to correlate well with other reports in the field, since exposure to 
the peroxide H2O2 did not affect MIO-M1 cells,
55 and only elicited very limited apoptosis in rat 
primary Müller cells.40 In fact, we also applied H2O2 as an inducer of oxidative stress during our 
initial experiments and did not observe any cytotoxicity even at concentrations above 1500 µM 
(data not shown). We therefore decided to continue our studies with TBHP based on the 
following facts: 1) H2O2 is rapidly degraded and is eliminated from cell culture medium within the 
hour at concentrations around 100 µM,56 and 2) in contrast to H2O2, TBHP was found to evoke 
consistent cellular stress and was thus proposed as a more suited compound for studies 
investigating oxidative stress.29 It is well-established that generation of ROS and the associated 
oxidative stress can cause cellular damage on multiple levels including e.g. lipid peroxidation and 
DNA damage (cfr. Chapter 5).29 Consequently, the TBHP-induced cytotoxicity in Müller cells 
observed in our experiment is in line with these findings. Co-treatment of TBHP and lipoplexes 
did provoke more cytotoxicity than lipoplex treatment alone for all dosages tested, although the 
effect was never significant (Figure 4.6B). Seeing the separate treatments each evoked 
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substantial cell death we did anticipate the combined treatment to be even more harmful. It 
could therefore be valuable to repeat this experiment to allow us to conclude a definite trend. In 
spite of the extensive stress and accompanying cytotoxicity elicited by co-treatment of lipoplexes 
and TBHP, the transfection efficiency and MFI in TBHP-treated cells was similar compared to 
untreated cells (Figure 4.7). This is a hopeful outcome for our neuroprotective strategy since it 
seems that regardless of cellular toxicity, the surviving cells are able of maintaining a high rate of 
transgene expression.  
5. CONCLUSION 
The principal goal of this study was to explore the potential of mRNA and pDNA as a therapeutic 
for neuroprotection in healthy and diseased Müller cells. Here, we found that mRNA lipoplexes 
outperformed DNA lipoplexes in Müller cell transfection since both the number of transfected 
cells as well as the level of GFP expression was higher. To further examine the potential of mRNA 
in this context, future experiments should determine the transience of the mRNA-induced GFP 
expression since this is an important requirement for the neuroprotective strategy. Remarkably, 
none of the stress factors applied, greatly influenced the transfection efficiency or the MFI 
induced by mRNA lipoplexes. We did observe that hypoxia and oxidative stress sensitized Müller 
cells to lipoplex toxicity  while hyperglycemic conditions had the opposite effect. Naturally, the 
experimental set-up applied in this chapter is elementary since diseases usually lead to 
multifactorial changes in the cellular environment and the influence of surrounding cell types is 
absent in the Müller monoculture. Future experiments could therefore focus on confirming 
these trends in more complex systems such as non-dividing Müller cells and/or retinal explants. 
Since both diabetic retinopathy and glaucoma are chronic diseases, the influence of longer 
exposures to stress should also be evaluated. Nevertheless, these preliminary observations 
support the strategy to apply Müller cells as secretion platforms in the diseased retina since this 
suggests that, despite a stressful environment, Müller cells would be able of processing NPs and 
expressing the transgene of our choice.  
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In the middle of the biomedical nanotechnology boom, the self-digestion process of autophagy 
increasingly gained attention as researchers gradually discovered its relevance within the cell as 
well as its connection to cancer. Surely, by 2000 autophagy was rumored to become “the new 
apoptosis”, i.e. a process playing key roles in human pathophysiology. Logically, it was not long 
before nanotoxicological researchers were triggered by this fascinating pathway as well, which 
led to many studies exploring the influence of nanomedicines on this process – including Chapter 
6 of this thesis. As an introduction to this study, a primary aim of this chapter is therefore to 
introduce you to nanomedicine, nanotoxicology and the autophagy pathway. In this regard, we 
will discuss the most widely investigated nanoparticles (NPs) for biomedical applications, the 
common mechanisms of NP toxicity and the autophagy pathway along with available methods to 
study it. Finally, we will provide a look into the mechanisms by which NPs can affect the 
autophagy pathway in addition to an overview of the most interesting studies investigating NP-
autophagy interactions where we attempt to link NP physicochemistry to its effect on 
autophagy. 
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1. NANOMEDICINE 
While the concept of nanotechnology was introduced earlier, the technical inventions made in 
the 1980’s led to many discoveries that truly launched the ‘nano’ field. Indeed, it became 
increasingly clear that by miniaturization materials can acquire unique physical, chemical and/or 
optical properties. Examples of such interesting properties include a) the superparamagnetic 
nature of iron oxide nanoparticles (NPs),1 b) the very high fluorescent brightness and excellent 
photostability of Quantum Dots,2 c) the localized surface plasmon resonance effect of silver or 
gold NPs,3 and d) the high rigidity of carbon nanotubes.4 Even though these materials were 
initially developed for industrial use, the same properties had also awoken the interest of the 
medical and biological communities, since these properties can be harnessed to create novel and 
powerful therapeutic and/or diagnostic tools. As such, nanomedicine was born as the scientific 
discipline in which these NPs are utilized for medical purposes. NPs certainly exhibit many 
advantageous features that can be exploited to solve some principal issues present in 
conventional medicine. Firstly, NPs enable the delivery of poorly soluble therapeutics and 
provide protection against their degradation. Additionally, their design can be tailored based on 
the desired target and delivery mode (e.g. controlled release). Decoration of the NP surface with 
targeting moieties can furthermore enhance target specificity and bioavailability when compared 
to conventional drugs. Yet, the most unique and powerful aspect of NPs is perhaps their 
multimodality which allows to apply one particle for both diagnostic as well as therapeutic 
purposes.5  
These promising aspects of NPs have led to an incredible boost in the number of engineered NPs, 
their fine-tuning, and explored applications. As an indication of the expansion of the nano field, it 
was estimated that almost 10 % of all articles indexed in Web of Science in 2016 involved 
nanotechnology.6  Generally, NPs can be divided into two categories i.e. soft and hard NPs. Soft 
NPs are mostly investigated for delivery purposes, while hard NPs are researched for diagnostics 
or novel types of therapy.5 Here, we will briefly describe the various types of NPs currently used 
in or explored for clinical settings, mainly in the field of cancer therapy (Figure 5.1). The principal 
focus will lie on introducing the different types of materials, a short description of their most 
important properties and an overview of their current and potential future applications. 
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Figure 5.1 │ Commonly investigated nanoparticles for medicine. Figure taken from 7  
Soft nanoparticles 
Soft NPs can be roughly subdivided into two principal categories being lipid-based and polymer-
based particles. Lipid-based particles are usually organized into liposomal structures, originally 
discovered by Bangham and colleagues in 1965.8 The most basic liposome is made up of an inner 
aqueous compartment that is separated from the outer aqueous compartment by a single lipid 
bilayer, though many different types of liposomes can be synthesized with varying size and/or 
number of lipid bilayers (Figure 5.2). Drugs can be enclosed either within the aqueous central 
cavity (for hydrophilic compounds) or embedded within the lipid layers (for hydrophobic 
compounds). Conveniently, the variety of lipids (e.g. neutral, negatively or positively charged) 
and potential incorporation of proteins or other lipophilic compounds allows easy fine-tuning of 
the liposomal composition and surface chemistry.9 This surface can be further functionalized 
with various smart ligands such as those presented in Figure 5.2. For clinical use, a common 
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surface molecule is poly(ethylene glycol) (PEG) as it reduces opsonization of the liposomes by 
immune components and proteins by which it increases blood circulation time through impeding 
liposomal clearance by the reticuloendothelial system.10 For improved targeting, several 
targeting ligands such as antibodies can be decorated on the surface of the liposome. As such, a 
great number of liposomal systems have been generated and put into clinical trials in 
combination with various therapeutic agents, mostly anti-cancer drugs.11,12 A full overview of the 
newer lipid-based vesicles can be found here 13. 
 
Figure 5.2 │ Schematic representation of lipid-based vesicles. A) Lipid vesicles can be classified depending 
on their size and lamellarity. SUV: small unilamellar vesicle; LUV: large unilamellar vesicle; GUV giant 
unilamellar vesicle; MLV: multilamellar vesicle; MVV: multivesicular vesicle. B) Structure of the lipid bilayer 




Next to lipid-based formulations, polymer-based NPs are also frequently employed as delivery 
systems especially for anti-cancer drugs. Similar to lipid-based carriers, the advances in chemical 
research have led to the discovery of a wide variety of different polymers that allow to smartly 
tailor the size, composition and surface functionality of polymer NPs.5 Furthermore, their drug 
release can be regulated through controlled degradation of the polymers or by stimulus 
activation such as pH change, offering many exciting possibilities for clinical applications.  Both 
natural and synthetic polymers can be used for drug delivery, many of which have been 
optimized to present high levels of biocompatibility.14 Co-polymers comprised of a hydrophilic 
and lipophilic block are applied to form polymeric micelles, since these block co-polymers 
automatically form core-shell structures in aquaous surroundings. These vehicles with size range 
from 20 to 100 nm are therefore ideal for the transport and delivery of more hydrophobic anti-
cancer agents.15 Consequently, many of the formulations investigated in clinical trials consist of 
polymeric micelles, either untargeted or bestowed with an antibody against a specific marker 
and containing hydrophobic compounds such as Paclitaxel or Cisplatin.14 
   
 Chapter 5 │ 123 
A special type of polymeric NPs are dendrimers (Figure 5.1). These are hyperbranched globular 
structures known for their high monodispersity and large drug payload.16 Drugs can be loaded 
into the interior part of the dendrimer or can be attached to the many surface groups at the 
periphery of the particle. Dendrimers are mainly studied for their drug delivery capacities, where 
research has been mainly focusing on anti-cancer agents and anti-viral treatment.17 
Hard nanoparticles 
Hard NPs represent a wide variety of compounds, including metal, metaloxide, semiconductor 
and carbon particles that are characterized by unique properties.18 Many chemical linking 
strategies are also available that allow the conjugation of chemical drugs, fluorophores or small 
compounds to these hard NPs in order to further enhance their application range. Given these 
exciting properties, hard NPs are currently receiving a lot of attention in view of possible 
biomedical applications.  
Metaloxide NPs are a broad collection of materials with many different applications. For 
example, titanium dioxide (TiO2) NPs are often used in pharmaceutical tablets because of their 
whitening effect, zinc oxide (ZnO) NPs are commonly added to sunscreens for their high UV 
absorbance and iron oxide NPs (IONPs; Fe2O3 or Fe3O4) are investigated in clinical settings as 
magnetic resonance imaging (MRI) contrast agents due to their superparamagnetic nature.19,20 
Cerium oxide (CeO2) NPs are also gaining attention since they can possibly be implemented to 
scavenge oxide radicals and prevent radical-mediated cell damage owing to their potent 
antioxidant capacity.21 
Metal NPs such as silver (Ag) or gold (Au) are increasingly being explored for clinical applications 
as delivery vehicles, diagnostic and/or therapeutic agents.22,23  Both Ag and Au NPs can be made 
in a variety of shapes and sizes through various chemical synthesis routes. AgNPs are widely used 
in consumer goods such as deodorants due to their potent antibacterial properties.23 Similarly, 
the same properties have led to their use in wound dressing. AuNP applications involve mostly 
diagnostic and photothermal therapies which are both based on their surface plasmon 
resonance (SPR) effect.24 This effect enhances the absorbance and scattering properties of the 
AuNPs dependent on the wavelength applied. Seeing these optical features can be tuned by 
varying NP size and shape, an immense diversity of AuNPs have been developed ranging from 
gold nanorods to nanocages (Figure 5.1).25 A leading example of enhanced drug delivery based 
on AuNPs is laser-induced photoporation, a technique our research group has gained expertise 
in. Here, AuNPs are irradiated by a short laser pulse by which the AuNPs heat up. The resulting 
evaporation of the water surrounding the AuNP surface creates an explosive vapour nanobubble. 
This bubble formation and subsequent collapse results in local high-pressure shock waves that 
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can locally disrupt their surroundings. Applying this photoporation method, our group has 
succeeded in the controlled intracellular delivery of macromolecules through the formation of 
transient openings in the cell membrane.26,27 
Other interesting materials are Quantum Dots (QDs), which consist of a semiconductor core with 
a narrow bandgap made up of elements from groups 12 and 16 (CdSe, CdTe, ZnS) or groups 13 
and 15 (InP, GaN) (Figure 5.1). For imaging purposes, these QDs offer many possibilities as their 
size-dependent broad excitation spectra and narrow emission spectra enable efficient 
multiplexing.28 However, many research groups, including ours (cfr. Chapter 6) have reported on 
the toxic effects of QDs or the heavy metals they contain which severely impedes their progress 
into clinical applications. Novel formulations such as Cd2+-free QDs are therefore being 
considered, but more research is needed before these materials can be used in clinical trials.29  
A last widely investigated class is carbon-based materials which amongst other materials 
includes fullerenes, carbon nanotubes and graphene (Figure 5.1). While these materials are 
mostly developed for industrial purposes, their exceptional properties have also been 
investigated for biomedical applications. As an example, their capacity to absorb near-infrared 
(NIR) light could be beneficial for in vivo imaging since NIR has shown to penetrate tissues more 
efficiently. Their outstanding tensile strength, on the other hand, is researched to enhance the 
mechanical strength of scaffold materials.  Also the drug delivery field could benefit from these 
materials considering their straightforward functionalization and ability to adsorb 
biomacromolecules (e.g. DNA).30  
2. NANOTOXICOLOGY 
The high interest in using NPs for medical applications and their increasing use in various 
technological applications and consumer goods (e.g. clothing and food products) has raised high 
concerns on their possible impact on human and environmental health. Indeed, due to the 
pertaining uncertainties concerning the potential danger of NPs and the lack of appropriate 
legislation, the nanotechnology industry is facing significant setbacks in their attempt to 
implement NPs in a clinical setting.31 It is therefore of vital importance to carefully characterize 
the toxicity of these NPs to enable the field of nanotechnology to fulfill some of its truly exciting 
possibilities in many aspects of human life. In view of this, the increasing production and use of 
NPs has led to the instilment of another scientific discipline: nanotoxicology.32 Nanotoxicology is 
referred to as the study on interactions between NPs and biological systems with an emphasis on 
establishing a relationship, if any, between the physicochemical properties of the NP and the 
toxicological responses.33 Although the area of nanotoxicology was initially a small niche within 
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the field of particle and fiber inhalation studies, the field has rapidly expanded to become an 
important stand-alone scientific discipline, encompassing multiple domains such as in vitro, in 
vivo, environmental and human toxicology.34 It is crucial that nanotoxicology is regarded as a 
distinct category of toxicology since standard toxicity assays, initially developed for the 
evaluation of chemical substances, are often inadequate for nanotoxicity assessment. This can 
be attributed to the different mechanisms leading to nanocytotoxicity, the specific behavior of 
the NPs in culture media and the possible interference of NPs with various toxicity assays.35–38 
Therefore the classical toxicity-testing paradigm needs to be optimized to be applicable for 
nanosafety evaluation.  
Generally, higher levels of toxicity are observed for NPs in comparison to their bulk material,33,39 
which is attributed to the higher surface area to volume ratio, possible surface reactivity and 
susceptibility to NP degradation and ion leaching.40,41 In addition, most chemicals induce cell 
damage through interactions with specific biomolecules, whereas a single NP may cause 
cytotoxicity via a combination of adverse events. A true general paradigm on how NPs evoke cell 
injury remains to be elucidated. However, it can be stated that cytotoxicity can be evoked via 4 
distinct categories of events: (i) effects related to induction of reactive oxygen species (ROS), (ii) 
effects due to direct interactions of the NPs with biomolecules, (iii) effects from leached ions and 
(iv) effects related to the protein corona.  
Nel et al. have put ROS induction forward as one of the main mechanisms through which 
inorganic NPs induce cytotoxicity, as this effect has been observed in a multitude of in vivo and in 
vitro studies.34,40,42–44 It is proposed that ROS can be induced either through intrinsic ROS 
generating properties of the NP or cell-mediated ROS generation. In the latter category, NPs can 
interfere with the anti-oxidative defense mechanism by reducing the activity of the anti-
oxidative defense enzymes.45 Furthermore NPs can activate several signaling pathways through 
interaction with cell surface receptors.46 Hereby stress-dependent signaling pathways are 
activated which alter gene expression of the anti-oxidant response element, leading to ROS 
overproduction.47 In addition, NPs can cause increased ROS production in the mitochondria 
through interference with the respiratory chain.47,48 Finally, several NPs are capable of activating 
NADPH oxidase, thereby inducing ROS production.49 In the first category (intrinsic ROS 
generating properties), NPs are intrinsically capable of generating ROS through the presence of 
reactive surface groups or surface bound radicals.40 In addition, transition metals present on the 
surface or leached from the NP in the acidic environment of the endo-lysosomes can generate 
ROS via Fenton chemistry.40,46 Overall, ROS induction can be a consequence of a single or a 
combination of the abovementioned events. Furthermore, Nel et al. proposed a tired response 
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of the cells to elevated ROS levels which has been confirmed in in vitro and in vivo studies for 
different NPs. In general limited ROS levels induce an anti-oxidative response, medium ROS 
levels evoke a proliferative and inflammatory response and persistently high levels of oxidative 
stress induce apoptotic and necrotic signaling pathways.40  
The induction of ROS can have a multitude of downstream effects. Indeed, ROS is known to 
induce general cell damage, as it can interact with DNA, proteins, lipids and organelles.40 First, 
oxidative DNA damage influences gene expression or can induce mutagenesis or apoptosis in 
case of insufficient repair mechanisms.50 Secondly, proteins can be activated or inactivated as a 
consequence of ROS presence.51 ROS can furthermore cause actin stress fiber formation and 
therefore alter the cell’s morphology, motility and adhesion.52,53 Persistent ROS induction will 
trigger a stress response leading to the production of cytokines and the induction of an 
inflammatory response. If ROS is not neutralized in a timely fashion, a feed-forward loop keeps 
stimulating both ROS and cytokine production leading to immunotoxicity.40 Due to lipid 
peroxidation, membranes can be damaged, which in turn leads to malfunctioning organelles. 
Indeed, the mitochondria, endoplasmatic reticulum (ER) and lysosomes are reported to suffer 
from ROS.54 This secondary ROS damage can in turn lead to downstream effects such as altered 
signaling and a perturbed calcium homeostasis. 54 In addition, both ER stress and lysosomal 
destabilization can induce autophagy and an inflammatory response.55 
The second main mechanism through which NPs induce adverse effects is by direct interaction 
with biomolecules, such as DNA, proteins and lipids, which in turn leads to downstream effects. 
Notably, most ROS-related events may also occur through direct NP-biomolecule interactions. 
For instance, NPs can alter gene expression via interactions with signal transduction pathways, 
interference with epigenetic gene regulation or the transcriptional or translational machinery 
through their perinuclear localisation.50,56,57 In addition, very small NPs with a diameter below 5 
nm may directly interact with DNA and alter its expression.58 Studies furthermore show that NPs 
can interact with components of the cytoskeleton thereby potentially altering cell morphology as 
well as signal transduction.59–61 In addition, NPs were shown to interfere with receptor-ligand 
interactions and signalling pathways.62 Comparable to ROS-induced damage, NPs are capable of 
damaging membranes and organelles such as the mitochondria and lysosomes. This may in turn 
evoke autophagy or an inflammatory response.56,63 Finally, NPs are also capable of directly 
evoking ER stress, which in turn leads to autophagy, increased calcium levels and potentially 
inflammation or apoptosis.63,64  
The third general element causing NPs to induce toxicity is their susceptibility to degradation. 
Depending on the uptake mechanisms and subsequent trafficking many NPs end up in the acidic 
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and degrading environment of the lysosomes.46,65 This environment can cause degradation or 
even dissolution of the NP, resulting in the leaching of free ions or an increase in reactive surface 
groups.46 The following impact on the cell’s wellbeing depends on the chemical composition of 
the NP. For cadmium (Cd)-containing QDs, for example, the leaching of highly toxic Cd2+-ions is 
considered to be the main cause of any observed toxicity.66,67 It has been shown for several NPs 
that the induced toxicity is more severe for the nanoparticulate form than its ionic counterpart. 
This is called the “Trojan Horse effect” as it can likely be attributed to a more efficient uptake of 
the NP through endocytosis compared to the free ionic form which consequently leads to 
elevated intracellular ionic concentrations.56  
Finally, it is known that NPs avidly bind serum proteins to their surface, creating a protein 
corona.68 The nature of this corona depends on the NPs physicochemical properties and the 
composition of the microenvironment (e.g. cell culture media) surrounding the NPs.33,69 The 
binding of serum proteins to the NP surface is an important determinant in how the cells ‘see’ 
the NPs and therefore influences NP uptake and toxicity.68,70,71 Additionally, proteins 
incorporated in this corona can undergo conformational changes because of which the cell may 
recognize them as an antigen and initiate an immune response.32,39 An immune response can 
furthermore be triggered by direct interactions of NPs with immune cells, complement activation 
and facilitation of antigen-specific hypersensitivity reaction through interactions with T 
lymphocytes or the release of chemokines and cytokines.72  
As mentioned earlier in this chapter, there is growing evidence that a wide variety of NPs are 
able of influencing autophagy in a diversity of cell types, implying that also autophagy changes 
might be a common cellular response toward NP uptake. Prior to examining this phenomenon, 
the next section will introduce the autophagy pathway, its involvement in cell death and 
available methods to study this intriguing process. 
3. AUTOPHAGY 
The efficient degradation of intracellular materials is of vital importance to ensure cytoplasmic 
quality control and guard cellular homeostasis. This degradation can occur via multiple cellular 
pathways including autophagy. Autophagy is a collective term for various selective and non-
selective processes comprising microautophagy, chaperone-mediated autophagy and 
macroautophagy. Microautophagy involves the formation of lysosomal invaginations resulting in 
a direct and non-specific sequestration of cytosolic components following breakdown.73 In case 
of chaperone-mediated autophagy, which is a highly specific process, unfolded proteins are 
recognized and bound by a chaperone complex, resulting in their translocation into the lysosome 
128 │ Chapter 5   
lumen.74 However, in most cases and also in this chapter the designation ‘autophagy’ refers to 
the process of macroautophagy. 
Macroautophagy, or simply autophagy is an evolutionarily conserved process that is coordinated 
by key proteins encoded by autophagy-related genes, i.e. Atg genes. It warrants cytoplasmic 
quality control through the degradation of excessive or damaged cytoplasmic components such 
as organelles or aggregated proteins. It is usually present at a basal level but can be induced as a 
cytoprotective mechanism in case of cell stress. For instance, during starvation autophagy aids to 
overcome the food drop by degrading and recycling less essential cytoplasmic materials.  
Autophagy process 
The process of autophagy initiates with the synthesis of a phagophore that, while sequestering 
cytoplasmic cargo, elongates and closes to form a double-membraned autophagosome (Figure 
5.3). During the creation of this autophagosome, cytoplasmic microtubule-associated protein 1 
light chain 3 (LC3-I) is activated by lipidation, forming LC3-II, and incorporated into the 
autophagosomal membrane. Next, the autophagosome fuses with a lysosome that supplies the 
acidic pH and enzymes for degradation of the cargo carried by the autophagosome. 
Alternatively, a lysosome can merge with an amphisome, i.e. the end product of an endosome-
autophagosome fusion. In this way, also newly ingested material can be targeted for degradation 
by autophagy. In the resulting vesicle, the auto(phago)lysosome, the cargo is degraded after 
which the resulting macromolecules are transported into the cytoplasm by permeases. Hereby 
the necessary energy and/or building blocks for the de novo synthesis of cellular components are 
provided. Since during this step also the inner membrane of the autolysosome is degraded, the 
LC3-II within the vesicle is lysed while the LC3-II on the outside is recycled back to LC3-I. The 
overall process from autophagosome maturation to its degradation is often referred to as 
autophagy flux (Figure 5.3).75,76  
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Figure 5.3 │ Overview of the mechanistic steps of autophagy. Figure adjusted from 75. 
 
A key aspect of autophagy is the ability to engulf a portion of the cytoplasm by which it 
selectively removes certain proteins, pathogens or complete organelles such as mitochondria. 
This cargo selectivity is mediated by the protein p62 that, due to its multiple binding domains, 
can create a direct link between LC3 and components targeted for autophagy.77 As will be 
discussed later, p62 is selectively degraded by autophagy and is therefore frequently used as a 
marker for autophagy flux.78,79 The most reported and actively studied pathways known to 
coordinate the level of autophagy are focused around the convergence point mammalian target 
of rapamycin complex 1 (mTORC1), a serine/threonine kinase that can directly tune autophagy 
through its interaction with multiple Atg proteins that are essential for autophagy initiation. On 
the other hand mTORC1 can indirectly stimulate autophagy via TFEB, a transcription factor that 
upon activation translocates to the nucleus where it promotes transcription of lysosomal and 
autophagic genes. The phosphorylation status of mTORC1 itself depends on the action of 
multiple upstream mediators of which the activity is driven by the nutrient level and energy 
status of the cell.80 Indeed, besides performing its housekeeper functions at a basal level, 
autophagy also serves as a cytoprotective pathway upon activation by triggers that represent a 
certain form of stress. For example, nutrient starvation leads to autophagy upregulation, 
promoting the breakdown of less essential cellular components to macromolecules ready to be 
recycled.81 Invading pathogens can also stimulate autophagy leading to their selective removal.82 
Additionally, oxidative stress elicited by ROS formation, can also give rise to autophagy, hereby 
promoting the degradation of the ROS-damaged organelles, typically mitochondria. As 
mitochondria are the predominant sources of ROS and are also sensitive to ROS-induced 
damage, they are seen as the main regulators of ROS-induced autophagy.83 
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Autophagic cell death 
The process of autophagy has generally been labeled as a pro-survival pathway, however, it has 
been argued that excessive self-digestion can result in autophagic cell death (ACD).84 Albeit not 
abundant, there are some studies that report on autophagy performing a pro-death role - as 
revised in a review by Shen et al.,85 which has led to the generation of the term ACD. On the 
other hand, ACD has long been relatively unexplored, which resulted in different interpretations 
and considerable misuse of the term. The process of cell death is indeed often very complex and 
during its progress, damaged cells typically display various markers representative of different 
cell death pathways such as apoptosis and autophagy. Although morphological changes typical 
for autophagy can often be observed, it remains unclear whether autophagy is a true killer, a 
mere side phenomenon accompanying death or rather an unsuccessful attempt to save the 
cell.85,86  
In order to overcome these issues, the definition of ACD has evolved from merely comprising 
morphological changes (i.e. autophagic vacuoles) to a list of clear biochemical requirements 
drafted by the Nomenclature Committee on Cell Death.87 In line with this, Shen et al. argue the 
term ACD is only justified when the observations made meet the following standards: 1) cell 
death must be apoptosis-independent, 2) autophagy inhibition, preferably by the knockdown of 
minimum two relevant Atg genes,87 prevents the observed cell death and 3) an increase in 
autophagy flux is detected.85 Specialists agree that on top of the above-mentioned criteria, ACD 
must be a separate death pathway that stands alone, and cases by which autophagy promotes 
other cell death pathways (e.g. apoptosis) must be excluded.88,89 In conclusion, it is important for 
any researcher to understand that autophagy in itself can either be pro-survival or pro-death and 
that the co-occurrence of cell death and autophagy does not automatically imply that autophagy 
in itself is leading to cell death. Interestingly, however, NPs have been introduced as potential 
inducers of autophagy as well as ACD as will be discussed later on in this chapter.90 
Over the last decade it has gradually been revealed that autophagy and apoptosis are 
interconnected at several levels. Autophagy can influence apoptosis by direct interaction of 
autophagy proteins with the apoptotic machinery, by autophagic degradation of apoptotic 
factors and/or by providing a platform for caspase activation. Likewise, apoptotic proteins can 
affect autophagy through interaction with and/or caspase-mediated cleavage of its proteins. It is 
thus proposed autophagy can induce cell death by 1) the dismantling of the cell through self-
digestion and 2) the promotion of apoptosis.91 The cellular decision to activate a certain cell 
death pathway is likely to depend on the cellular stresses involved; yet, given its role in damage 
control it is suggested that autophagy affects the onset of cell death. For example, when 
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autophagy is dysfunctional or not able to restore the ATP level, apoptosis or necrosis is 
initiated.92 It is important to note that cell death is a dynamic phenomenon and multiple cell 
death types are often co-observed within the same cell.93  
Methods to study autophagy 
As a result of the increasing interest in autophagy, multiple methods have been developed in the 
past years to detect various autophagic markers. The most widely examined markers are LC3, 
p62 and mTOR. The following section presents a short overview of the most extensively used 
methods to detect these markers. For a complete overview of available methods we refer the 
reader to 94. 
Initially, transmission electron microscopy (TEM) used to be the only key technique to detect 
autophagy, and it still remains an important method today as it can provide highly detailed 
ultrastructural information like autophagosomal cargo and potential inclusion of NPs (Figure 
5.4).95 TEM allows detection of the distinct steps of the process based on the specific 
morphology of the autophagic organelles; yet, since autophagy is a dynamic process identifying 
these structures can be troublesome and thus requires special expertise.96 
 
Figure 5.4 │ TEM image of starved mouse fibroblasts. Arrows indicate double-membraned 
autophagosomes, and double arrows indicate autolysosomes/amphisomes. Arrowheads designate 




To date, LC3, which is selectively incorporated into autophagic membranes, has been the most 
specific and therefore also the most analyzed autophagy marker. It is indeed well established 
that autophagosomes can be visualized by fluorescence microscopy by antibody staining for LC3 
or transfection of cell cultures with the GFP-LC3 construct. Accordingly, LC3 is usually diffusely 
scattered throughout the cytoplasm while autophagosomal accumulation can be identified as 
distinct puncta (Figure 5.5).98–100 Since upon incorporation into the autophagosome LC3-I is 
conjugated with phosphatidylethanolamine to form LC3-II, LC3’s molecular weight differs 
sufficiently to cause a visible mobility shift on Western Blot gels. Hence, changes in the amount 
132 │ Chapter 5   
of autophagosomes – which corresponds to the ratio of LC3-II/LC3-I – can also be detected by 
Western blotting.101  
 




We must emphasize that these methods are based on static measurements of autophagosome 
accumulation and therefore do not allow to differentiate between the induction of autophagy or 
an impaired autophagy flux since both result in higher numbers of autophagosomes. An impaired 
autophagy flux can readily be determined by the above-mentioned LC3 Western Blot 
experiment in the presence of lysosomal protease inhibitors (e.g. pepstatin A) or buffers (e.g. 
chloroquine, ammonium chloride) that inhibit LC3-II degradation. If the amount of LC3-II remains 
the same in the presence and absence of the inhibitor it can be concluded that the increased 
level of LC3-II is likely the result of an autophagy flux blockage. Alternatively, if the level of LC3-II 
further exceeds in presence of lysosomal inhibitors, the initially observed LC3-II accumulation is 
due to autophagy upregulation. 101 Autophagy flux can also be evaluated based on other 
Western Blot experiments such as GFP-LC3 cleavage. Since GFP is relatively resistant to 
lysosomal hydrolysis the amount of free GFP can be detected as a measure of autophagosome 
degradation.97 In addition to LC3, an increase in the level of p62 can also indicate a potential 
blockage of autophagy flux.78 The turnover of autophagosomes into autolysosomes can be 
visualized by means of autophagosome-lysosome colocalization studies using LC3-labeling and 
lysosomal markers (e.g. LAMP-1 or LysoTracker®).99 This maturation can be assessed 
microscopically as well as via flow cytometry using for instance, an mRFP-GFP tandem 
fluorescent-tagged LC3 (tfLC3). As GFP is pH-sensitive and more prone to quenching than mRFP, 
the various autophagic vesicles can be distinguished through their different fluorescence signal; 
autophagosomes will show both signals (i.e. yellow) while after lysosomal fusion GFP is 
quenched and thus autolysosomes can be identified as mRFP-positive vesicles.102,103 Flow 
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cytometry can also be applied to determine the total fluorescence intensity of GFP-LC3 as a 
measure of autophagic activity.104 
Another approach could be to evaluate the activity of mTOR and its interacting proteins. This is 
usually examined to study the effect of various stimuli (including NPs) on the status of autophagy 
and/or the mechanism behind an observed induction or inhibition. Since the activity of these 
proteins depends on their phosphorylation status, Western Blotting by means of phospho-
specific antibodies is the favored method. In this way the activity of mTOR can be measured 
directly by analyzing its phosphorylation level or indirectly by determining the activity of its 
substrates (e.g. p70S6K) or upstream mediators (e.g. Akt).105 Whereas in vitro detection of 
autophagy has seen a positive progress over the past years, in vivo methods are not yet 
thoroughly developed. As a consequence in vivo monitoring of autophagy remains limited, 
although there are some methods being suggested such as imaging tissue samples of transgenic 
mice expressing fluorescently tagged LC3 or staining of tissue sections with LC3-antibodies.106  
When evaluating the influence of NPs on autophagy it is essential to include controls that help to 
reliably verify and interpret observed changes in autophagic activity. There are multiple 
autophagy-modulating chemicals and conditions widely used in autophagy research. The most 
extensively applied chemical inducer is rapamycin, which directly inhibits mTORC1 and thus 
stimulates autophagy.107 More natural stimuli of autophagy are serum starvation and amino acid 
deprivation, which can be used as a positive control in studies with the aim of identifying 
autophagy inducers (e.g. NPs).97 3-Methyladenine (3-MA) and Wortmannin are both known to 
negatively regulate autophagy through inhibition of phosphatidylinositol-3 kinase (PI3K),108 and 
are commonly used to identify the role of autophagy in NP-induced cell death. Furthermore, 
chemicals that influence lysosomal activity by alkalinization of its acidic lumen (e.g. 
chloroquine)109 or inhibition of lysosomal enzymes (e.g. pepstatin A) can inhibit autophagosome-
lysosome fusion and/or block the breakdown of the sequestered cargo in the autolysosome. 
These type of chemicals can be applied to mimic disruptions in autophagy flux. It is important to 
note that these chemicals can influence other cellular processes that can indirectly affect 
autophagy. It is therefore recommended to combine chemical modulation with other 
approaches such as genetic inhibition or functional knockdown of relevant Atg genes.97,99 
In conclusion, to study the complex and dynamic process of autophagy a number of different 
assays and detection techniques are required to accurately and reliably link certain effects to the 
modulation of autophagy. It is however necessary to comprehend that assays based on 
autophagosome detection not necessarily provide information on the status of autophagy flux. 
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Also, since each of the above-described methods has its advantages and flaws, we advise to 
combine several assays when evaluating autophagy - as we have done in Chapter 6.  
4. NANOPARTICLE-INDUCED AUTOPHAGIC CHANGES 
Over the last decade, an increasing number of nanotoxicological studies have reported on the 
ability of diverse types of NPs to modulate autophagy in various cell types.63 Even more, it has 
been suggested that autophagic changes might be a common cellular response to NP uptake.110 
Since autophagy is essential to maintain cellular homeostasis, these findings could have great 
toxicological impact. In fact, insufficient or defective autophagy is argued to lie at the origin of 
multiple pathologies including cancer,111–113 neurodegenerative diseases,114,115 myopathies,116 
autoimmune diseases117 and metabolic diseases.118 Unfortunately, this may also imply that NPs 
capable of disrupting autophagy may result in or contribute to the development of these 
pathologies. In the context of disease, it is pivotal to appreciate the complexity of the autophagic 
process and that the impact of autophagy induction or inhibition on cell or animal physiology can 
vary and is often ambiguous. For example, autophagy induction can have beneficial effects on 
healthy cells by boosting their survival capacity or enhancing immune reactivity by improved 
presentation of antigens in dendritic cells,119,120 but also on diseased cells by ameliorated 
clearance of dysfunctional organelles or protein aggregates in myopathies or neurodegenerative 
diseases.121–124 On the other hand, uncontrolled induction of autophagy could lead to massive 
cell death and organ failure.125 Apart from toxicological effects, the induction of autophagy could 
aid the cell to overcome NP-associated stress, as such lowering NP-associated toxicity. Yet, its 
induction might also hamper the functionality of NPs, for instance, by enclosing and degrading 
drug loaded nanocarriers or fluorescent NPs in autophagosomes in this way reducing their 
efficacy.126–128 
Considering these observations, it is relevant to define the influence of NPs on autophagy from a 
toxicological as well as from a therapeutic point of view. In the following section we therefore 
seek to summarize the underlying mechanisms by which NPs can affect autophagy.  
Mechanisms of nanoparticle-induced autophagic changes 
As visualized in Figure 5.6, NPs can enter the autophagy pathway via multiple routes, yet they all 
initiate with endocytosis.  
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Figure 5.6 │ Routes via which NPs can enter the autophagic pathway. 1) NPs able of escaping the 
endosome (e.g. by proton sponge effect) can be captured by autophagosomes 2) Following endocytosis, 
the NPs are enclosed in endosomes that next fuse with autophagosomes to form amphisomes. 3) NPs that 





Similar to entry routes, NPs can affect the autophagy pathway through various mechanisms. As 
explained earlier in this chapter, one of the key mechanisms by which NPs elicit cellular toxicity is 
by formation of ROS. This ROS formation can next damage the entire cytoplasmic environment 
including organelles, proteins and lipids. As a result, autophagy will be activated to attempt to 
restore this stressful situation by removal of the respective components. Mitochondria are 
specifically sensitive to ROS and are therefore often specifically removed by autophagy (i.e. 
mitophagy). It is important to note that not only the secondary effects of ROS (e.g. mitochondrial 
damage) but also increased levels of ROS as such are able of tuning the level of autophagy by 
altering the activity of different intracellular signaling molecules.130–132 Autophagy has been 
shown to be regulated by different types of ROS, and ROS-mediated autophagy is involved in 
various pathologies, including cancer.131 Since metal-oxide particles and heavy metal-containing 
NPs are generally more prone to inducing oxidative stress, those may have high autophagy-
modulating properties.131 
Since the majority of NPs enter the cell through endocytosis, the lysosomes are also frequently a 
target for their toxicity. NPs can cause lysosomal dysfunction by alkalinization of its lumen, NP 
overload, oxidative damage to lysosomes or cytoskeleton disruption.129,133,134 These dysfunctions 
can indirectly upregulate autophagy as a mechanism for the cell to compensate for insufficient 
degradative capacity. The signaling link between lysosomal sensing of stress and autophagy is 
effected by  Transcription Factor EB (TFEB), a main regulator of the Coordinated Lysosomal 
Expression and Regulation (CLEAR) network.135 Upon starvation and lysosomal stress TFEB will 
detach from the sensing machinery present on the lysosome and translocate to the nucleus 
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where it will boost the transcription of lysosomal and autophagic genes.136 For this reason, non-
degradable NPs (for instance Au NPs) or formulations containing compounds that cannot be 
efficiently metabolized (e.g. cationic lipids) that are taken up by endocytosis at high doses are 
more likely to result in autophagy disruption. 
NPs can also directly influence autophagy-related signaling pathways or gene expression of 
relevant autophagy genes.129 It has further been hypothesized that NPs can be directed toward 
autophagic degradation in a manner similar to pathogens and cytoplasmic material.128 In 
practice, this involves NP ubiquitination and binding of p62 which links the NPs to the autophagic 
machinery.137–139 Accordingly, autophagy induction might be a way to try to eliminate these 
foreign particles.  
Impact of nanoparticles on autophagy 
In this section we provide an overview of the most interesting reports on NP-mediated 
autophagy alterations. At the same time, we aim to link specific physicochemical characteristics 
to the autophagic response of the cell.  
Influence of hard nanoparticles on autophagy 
Gold Nanoparticles 
Several research groups have shown alterations in autophagic activity upon treatment with 
different types of Au NPs. Ma et al. demonstrated an Au NP-mediated mTOR-independent 
accumulation of autophagosomes owing to a blockage of autophagosome degradation. The 
lysosomal impairment elicited by these gold particles, demonstrated by lysosomal enlargement 
and alkalinization, probably accounts for this blockage. Interestingly, in line with the observed 
size-dependent uptake, larger particles (50 nm) were more potent autophagy flux disruptors 
compared to their smaller equivalents (10 and 25 nm). We could indeed hypothesize that larger 
NPs can have a greater effect on the lysosomal degradative potential than a large number of 
smaller particles which can be more readily degraded. Besides size preliminary results further 
uncovered a potential charge-dependent autophagy response with more autophagosome 
accumulation upon treatment with positively charged NP compared to equally sized negative 
ones.140 Certainly, it is well-known that positively charged NPs are more able to destabilize or 
permeabilize the lysosomal membrane than negative ones. 
Several groups reported on autophagy stimulation triggered by oxidative stress induced by Au 
NPs. FBS-coated Au NPs generated significant signs of oxidative stress in human lung fibroblasts, 
a probable cause of the simultaneously observed autophagosome accumulation.141 Oxidative 
stress was also detected in oral cancer cells in the presence of iron core-gold shell particles 
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(Fe@Au), although this was not the primary cause of NP toxicity. Notably, these particles 
provoked different levels of autophagy in cancerous and benign cells which further led to the 
hypothesis that the concurrently observed selective growth inhibition is caused by a different 
reaction of the cancerous and healthy mitochondria toward the induced stress.142  NPs of 
comparable composition, i.e. gold-coated iron oxide NPs, also activated autophagy in lung cancer 
cells.142  
Iron oxide nanoparticles 
Analogous to the Fe@Au NPs, bare IONPs selectively induced cytotoxicity in lung cancer cells 
while causing a minor decrease in cell viability in normal lung fibroblasts. The origin of this 
differential toxicity was suggested to be oxidative stress and subsequent autophagy upregulation 
via the AMPK-Akt-mTOR pathway, which was supported by the observed mitochondrial damage 
and ATP depletion.143 Bare IONPs also provoked oxidative stress in macrophages and human 
cerebral endothelial cells, although we argue that the proposed autophagy induction stated by 
the authors conflicts with the increased levels of p62.143,144 Magnetite (Fe3O4) particles were 
shown to enhance autophagosome levels through lysosomal impairment and mitochondrial 
damage.145 Remarkably, an elegant study of Huang et al. demonstrated that IONPs elicited a rise 
in autophagosomes in a dispersity-dependent manner: aggregated particles induced substantial 
autophagic disruption while well-dispersed particles did not.146 Comparable to size-related 
effects, the accumulation of large NP aggregates in the endosomes and/or lysosomes could be 
responsible for lysosomal impairment and at the same time autophagosome accumulation. 
Quantum Dots 
QDs of multiple compositions have been put forward as autophagy activators. Again, the 
changes in  autophagy are regularly put forth as a response to oxidative stress.136,147–150 As an 
illustration COOH-functionalized CdSe/ZnS QDs were able to provoke ROS-dependent LC3-II 
accumulation. Here, a ROS scavenger as well as 3-MA enhanced cell death indicating autophagy 
served as a protective mechanism against QD cytotoxicity.151 The latter finding is in contrast with 
a study conducted with similar COOH-conjugated CdTe QDs where 3-MA reduced cytotoxicity, 
suggestive of a pro-death role for autophagy.150 Graphene QDs along with streptavidine-coated 
core-shell ones were found to induce autophagy which in case of the streptavidin-coated QDs 
could be abrogated by antioxidant treatment.149 For the graphene QDs, ROS-dependency was 
also suggested, yet this was not experimentally demonstrated.148 Neibert et al. discovered that 
treatment with uncapped CdTe QDs significantly activated TFEB, which they identify as a cellular 
attempt to remove the damaged cytoplasmic material generated by QD treatment.136 
Interestingly, Seleverstov et al. reported on a size-dependent effect where smaller QDs 
modulated autophagy more extensively than their larger counterparts.147 This seems in contrast 
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with the previously discussed studies where larger particles consistently elicited a higher 
autophagic response. However, the total surface area of smaller QDs is substantially higher than 
for larger ones owing to their higher surface over volume ratio.152 This higher surface area could 
then result in raised levels of oxidative stress that in turn can influence autophagy. This aspect of 
size versus surface area clearly illustrates that it is often hard to predict the impact of NPs and 
their modifications on NP-cell interactions. It is therefore relevant to systematically investigate 
the influence of QD physicochemistry on their induced cellular effects. To this end, we have 
examined the impact of QD surface coating on the lysosomal and autophagic pathway, which we 
will discuss in Chapter 6. 
Carbon-based nanoparticles 
Various types of carbon-based NPs have been shown to alter autophagy. For instance, carboxyl 
functionalized carbon nanotubes (CNTs) affected autophagy in an mTOR dependent manner in 
A549 cells, conversely, differently functionalized particles (with poly(m-aminobenzenesulphonic 
acid or PEG) did not. Even so potential differences in uptake by the different CNTs were not 
examined, this does suggest that surface group characteristics may influence the impact of NPs 
on autophagy modulation. Interestingly, besides restoring cell viability in vitro, pre-treatment 
with 3-MA partly abrogated NP-mediated lung inflammation in mice indicating a role for 
autophagy in lung toxicity.153 
Furthermore, a detailed study of Wan et al. demonstrated that acid-functionalized CNTs and 
graphene oxides caused autophagosome accumulation by compromised autophagy flux in 
primary murine peritoneal macrophages. The underlying mechanism was clarified by means of 
LysoTracker staining and FITC-dextran labeling of NP treated cells, which revealed decreased 
lysosomal quantity and lysosomal membrane damage, respectively.154 Surely, as described 
above, it is well established lysosomal health strongly influences autophagy.129 It is noteworthy 
that, despite their comparable chemical composition and surface functionalization, CNT and 
graphene oxides affected autophagy to a different extent. This suggests physical characteristics 
might also influence autophagy modulation, yet a more thorough study is necessary to 
substantiate this. 154 Fullerenes have been correlated with autophagy induction as well as 
dysfunction. 154 For example, fullerene (C60) and Neodymium functionalized fullerenes (C60(Nd)) 
are presented as autophagy inducers,155,156 while Johnson-Lyles et al. suggest fullenerol NPs can 
disturb autophagy at high concentration. They hypothesize the observed NP-mediated 
cytoskeleton disruption results in autophagy dysfunction and consequently ATP depletion.157 
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Other hard nanoparticles 
A study describing the autophagic response of A549 cells and macrophages toward diversely 
shaped silica (SiO2) NPs reported that the cell type but not the geometry of the particles shaped 
this response.158 Also with silica particles a size-dependent autophagy response has been 
observed: 40 and 60 nm sized particles elevated autophagosome levels while 200 nm sized ones 
did not.159  
A great variety of rare-earth element based NPs were described to induce authentic autophagy 
in HeLa cells.155,160–163 Among these studies there was a remarkable example of how surface 
group characteristics can influence the autophagy-inducing potential of a NP. This was 
presented by Zhang et al., who were able to adapt the level of induction upon treatment with 
lanthanide-based upconversion NPs by coating them with different peptides.160 Another 
interesting example of size-dependent autophagy alteration was reported with neodymium 
oxide particles where non-nanoscale particles elicited less of an autophagic response.164 
Not only surface characteristics but also chemical composition has been brought forward as a 
way of tuning autophagy: treatment of HeLa cells with Nickel-Cobalt NPs with different molar 
concentrations of both components revealed that the higher the Ni component, the more potent 
the impact on cytotoxicity and autophagy. 165 
Influence of soft nanoparticles on autophagy 
Compared to the substantial amount of literature describing metallic NP-induced autophagy, the 
evidence for polymeric and lipid particles remains rather limited. However, several reports 
indicate that also these materials are capable of modulating autophagy.  
Liposomes 
Induction of autophagy has been observed in HeLa cells upon treatment with 
dioleoyltrimethylammonium propane (DOTAP), a cationic lipid commonly used as a transfection 
agent. The results not only suggest that DOTAP enhances autophagosome formation but also 
demonstrate that the induction is mTOR-independent.166 The autophagy activation may be 
caused by the fact that DOTAP is a synthetic lipid and the cell undergoes problems degrading it. 
As a result, the cell aims to increase its total degradative capacity by the induction of autophagy. 
Naturally, the fact that transfection agents as such are able of enhancing autophagy casts doubt 
on observations made in transfected cells, particularly if autophagy is the process examined. At 
the same time, this implies that inhibition of autophagy might aid to improve transfection 
efficiency. The latter hypothesis was corroborated by Roberts et al. who found that cationic 
liposomes were delivered to the autophagic pathway through endosome-autophagosome fusion, 
indicative of a cellular attempt to eliminate the foreign material. In addition, gene delivery and 
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expression was remarkably enhanced in autophagy-defective Atg5-/- cells.127 Interestingly, 
treatment with uncharged lipids (i.e. dioleoylphosphatidylethanolamine; DOPE) failed to alter 
autophagy.166 A finding that is in contrast with the ability of neutral PEGylated C6-ceramide 
nanoliposomes to activate fully functional autophagy in liver HepG2 cells.167 
Polymeric nanoparticles 
Autophagy modulation was observed upon treatment of macrophages with positively charged 
polymer (Eudragit RS) particles. In this case TEM showed significant localization of particles 
inside or in contact with mitochondria. Furthermore, substantial signs of oxidative stress were 
observed. The authors thus propose that the cell aims to remove the damaged mitochondria by 
triggering autophagy.168 
Cationic polyamidoamine (PAMAM) dendrimers of multiple generations (G3 to G8) have been 
proposed to induce autophagy in A549 lung cancer cells with involvement of the mTOR pathway. 
However, it was not specified if the increased level of LC3, assessed by microscopy and Western 
Blotting, was caused by an enhanced on-rate or decreased off-rate of autophagosomes, 
therefore, an autophagy blockage cannot be excluded.169 As PAMAM dendrimers have been 
reported to cause lysosomal alkalinization,170 potentially resulting in lysosomal impairment, a 
blockage of flux is rather likely. On the other hand it has been put forth that these dendrimers 
can affect mTOR activity during their endocytic uptake; the observed autophagy alteration could 
thus be a combination of multiple effects. Intriguingly, comparable with the conflicting findings 
obtained with differently charged lipids, anionic G5.5 PAMAM particles did not affect autophagic 
activity. Together, these data suggest that charge may have an impact on the autophagy-
inducing potential of NPs, however, without any uptake comparison between the various 
particles it cannot be excluded that this is merely because of differences in uptake efficiency.  
5. CONCLUSION 
In general, the field of nanotechnology is greatly expanding, increasing the public’s exposure to 
NPs at a fast pace. Since many of these (in)organic NPs have been proposed to be capable of 
altering autophagy, and since autophagy dysfunction itself is associated with multiple 
pathologies (e.g. neurodegenerative diseases), it is of vital medical and toxicological importance 
to determine the effect of NPs on autophagy and its consequences. To efficiently address this 
potential danger more in-depth research is necessary to determine the role of autophagy in 
these pathologies and at the same time the mechanisms by which NPs are able of altering this 
process. Throughout this chapter several NP properties were put forth as probable influencing 
factors on NP-mediated autophagy deregulation, including size, charge and chemical 
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composition. For most NPs, the extent of autophagy is presumably determined by a complex 
interplay of these different parameters. In general, the wide variety of NPs  and used cell types 
makes it difficult to draw any broad conclusions. There is therefore a great need for more 
systematic studies that will aid the design of NPs that do not affect autophagy at all or can be 
tuned to induce autophagy to our advantage. In Chapter 6 we aim to contribute to this objective 
by looking into the influence on autophagy of two identical particles that only differ in their 
surface modification. 
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In Chapter 5 we explained that autophagy dysfunction has been proposed to lie at the root of 
multiple diseases including cancer. We therefore consider it crucial from a toxicological point of 
view to investigate if nanoparticles (NPs) that are developed for biomedical applications 
interfere with this cellular process. Here, we study the highly promising ‘gradient alloyed’ 
quantum dots (QDs) that differ from conventional ones by their  gradient core composition 
which allows for better fluorescent properties. We carefully examined the toxicity of two 
identical gradient alloyed QDs, differing only in their surface coatings, namely 3-
mercaptopropionic acid (MPA) and polyethylene glycol (PEG). Next to more conventional 
toxicological endpoints like cytotoxicity and oxidative stress, we examined the influence of these 
QDs on the autophagy pathway. Our study shows that the cellular effects induced by QDs on 
HeLa cells were strongly dictated by the surface coat of the otherwise identical particles. MPA-
coated QDs proved to be highly biocompatible as a result of lysosomal activation and ROS 
reduction, two cellular responses that help the cell to cope with nanoparticle-induced stress. In 
contrast, PEGylated QDs were significantly more toxic due to increased ROS production and 
lysosomal impairment. This impairment next resulted in autophagy dysfunction which likely 
added to their toxic effects. Taken together, our study shows that coating QDs with MPA is a 
better strategy than PEGylation for long term cell tracking with minimal cytotoxicity. 
 
 
   
 Chapter 6 │ 155 
Table of Contents 
1. INTRODUCTION ........................................................................................................................... 156 
2. METHODS .................................................................................................................................... 158 
MATERIALS ........................................................................................................................................................ 158 
NANOPARTICLE CHARACTERIZATION ........................................................................................................................ 159 
CELL CULTURE .................................................................................................................................................... 159 
MTT CELL VIABILITY ............................................................................................................................................. 159 
CELLULAR UPTAKE, OXIDATIVE STRESS, LYSOSOMAL AND AUTOPHAGY MARKERS MEASURED BY FLOW CYTOMETRY .................. 160 
IMMUNOFLUORESCENCE STAINING FOR LAMP-1 AND LC3 ......................................................................................... 161 
WESTERN BLOT .................................................................................................................................................. 161 
STATISTICAL ANALYSIS .......................................................................................................................................... 162 
3. RESULTS ....................................................................................................................................... 162 
QUANTUM DOT CHARACTERIZATION ....................................................................................................................... 162 
UPTAKE AND INTRACELLULAR LOCALIZATION OF QUANTUM DOTS ................................................................................. 163 
QUANTUM DOT-INDUCED ACUTE TOXICITY AND OXIDATIVE STRESS ............................................................................... 164 
IMPACT OF QUANTUM DOTS ON LYSOSOMAL HEALTH ................................................................................................ 165 
IMPACT OF QUANTUM DOTS ON AUTOPHAGY ........................................................................................................... 167 
4. DISCUSSION ................................................................................................................................. 169 
5. CONCLUSION ............................................................................................................................... 173 
6. ACKNOWLEDGEMENTS................................................................................................................ 174 








156 │ Chapter 6   
1. INTRODUCTION 
As introduced in Chapter 5, nanotechnology is a rapidly evolving field with a growing potential 
for a wide range of applications. These applications naturally require the design of highly 
functional though biocompatible nanoparticles (NPs). Among the most extensively investigated 
NPs for biomedical imaging applications are Quantum Dots (QDs), semiconductor nanocrystals 
with a size ranging from 2 to 100 nm.1 They possess supremely advantageous optical properties 
including a very high and stable fluorescence intensity that is strongly resistant to 
photobleaching.2 In addition, they are known for their broad excitation spectrum and narrow 
emission profile enabling efficient multiplexing.3 Based on these features QDs have been 
promoted as eminent materials for in vivo and in vitro biomedical applications such as tumor 
visualization and intracellular trafficking.1,4–6 
With the aim to enhance the biocompatibility and optical properties of the conventional core-
shell QDs, many QD designs and compositions have been investigated. Recently, gradient alloyed 
(GA) QDs were developed (Figure 6.1).7 The gradient structure ensures that instead of the usual 
size-tunable emission of conventional QDs, the emission spectra of GA-QDs can be subtly altered 
by adjusting their chemical composition.8,9 This solves issues related to size limitation sometimes 
occurring in biological labeling and allows multiplexing of QDs without size-related changes in 
sensitivity.8,10  
 
Figure 6.1 │ Schematic design of a core-shell QD (A) and a gradient alloyed QD (B). A conventional core-
shell QD exists of a metal core enveloped by an inorganic shell and a coating that renders them water-
soluble and allows for further conjugation.
11
 In case of gradient alloyed QDs, the defined core-shell 
interface within the QD is replaced by a gradient composition.  
Despite their excellent properties, the translation of QDs in general toward biomedical 
applications is limited, mainly due to concerns about their toxicity. It is widely established that 
this toxicity, at least in vitro, is mainly attributed to the leaching of toxic cadmium ions and the 
formation of reactive oxygen species (ROS) that can induce secondary toxic effects such as DNA 
damage and apoptosis (cfr. Chapter 5).12–16 To avoid these toxic pathways, several groups are 
attempting to develop a more biocompatible QD core by synthesizing e.g. cadmium-free QDs.17,18 
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However, next to core composition, the surface chemistry of the QD can greatly influence 
toxicity by affecting its cellular interactions. 
As extensively discussed in Chapter 5, several research groups have recently reported that 
various types of NPs can modulate (macro)autophagy.19,20 Autophagy is a highly conserved 
catabolic process essential for maintaining cellular homeostasis (Figure 6.2). It is usually present 
at a basal level in every cell where it functions as a cytoplasmic housekeeper for organelle and 
protein quality control. In addition, autophagy serves as a cytoprotective process that is induced 
to support the cell in stressful conditions such as starvation or oxidative stress.21 Autophagy 
perturbations have been associated with the pathogenesis of multiple diseases including cancer, 
neurodegeneration and liver disease.22–24 To date, the exact influence of cellular NP exposure on 
the autophagic process remains unclear. Various studies have reported clear induction of 
autophagy, resulting in cell death,19 whereas others have described an inhibition on 
autophagosome clearance, which can also result in cell death.25 The direct induction of cell death 
through the autophagy process however remains a topic of debate, as autophagy is mainly a self-
preservation process and any alterations observed during cell death could simply be the result of 
secondary unrelated bystander effects of the cell trying to recover (cfr. Chapter 5).26 In line with 
the latter view, it has been suggested that the induction of autophagy could be beneficial, as the 
overall toxicity of NPs could be reduced by the protective effects of autophagy.27,28  
 
Figure 6.2 │ Overview of lysosomal and autophagosomal markers investigated in this study. As lysosomal 
markers we made use of: LAMP-1, a membrane protein selective for lysosomes;
29
 LysoTracker, a dye that 
primarily accumulates in lysosomes; and Derivatively Quenched Bovine Serum Albumn (DQ BSA), a dye 
that enters the cell via endocytosis and is therefore selectively degraded by the lysosomal pathway 
30
. To 
check for changes in autophagy we examined LC3, a protein selectively incorporated into the 
autophagosomal membrane, and p62 which is a protein that links LC3 to autophagosomal cargo. Since the 
buffer chloroquine (CLQ) induces lysosomal alkalinization we applied it throughout our study to mimick 
lysosomal impairment. Since this lysosomal impairment causes a block in autophagosome-lysosome fusion 
further down the line, we also used CLQ as a positive control for autophagosomal accumulation.
31
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Considering the impact of autophagy induction and inhibition as described above, we believe it is 
critical to characterize the influence of NPs on autophagy from a nanotoxicological point of 
view.19 However, despite abundant reports on NP-modulated autophagy, only a few studies exist 
related to QDs, where especially little attention has been paid to the potential harm induced by 
the highly promising GA-QDs.32 In addition, many of those studies are limited to one type of 
coating or lack data on intracellular uptake as debated in Chapter 5.19  
In this chapter we look into the influence of QD surface chemistry on the toxicity and its 
underlying causes by comparing two types of QDs that only differ in their coating. We opted for 
polyethylene glycol (PEG) as a coating since this is the most commonly applied coating strategy 
in biomedical applications to reduce unspecific protein binding and prevent aggregation. In 
addition, PEGylation is known to increase the blood circulation time of particles by preventing NP 
uptake by the reticuloendothelial system.33–35 As a second coating strategy we selected the short 
ligand 3-mercaptopropionic acid (MPA) based on previous reports that observed limited toxicity 
with this coating.29–31 We therefore wanted to analyze this promising observation further with a 
special focus on autophagy since the influence of MPA coating on this pathway remains 
unexplored so far. To this end, we examined the aggregation profile, cellular uptake, cytotoxicity 
and associated ROS levels of QDs, and studied their effect on lysosomes and autophagosomes - 
the two most essential organelles of the autophagy pathway (Figure 6.2).   
2. METHODS 
Materials 
Two types of spherically shaped Gradient Alloy Quantum Dots were purchased from Mesolight 
LLC (Little Rock, Arkansas, USA). Both types have a gradient CdSexS1-x core surrounded by a ZnS 
shell. (Figure 6.1).  The GA-QDs only differ in their surface coating: one particle is coated with 
polyethylene glycol (PEG) with terminating carboxyl groups while the other one is coated with 3-
mercaptopropionic acid (MPA). Both QDs have an emission maximum at 580nm and exhibit very 
similar quantum yields, i.e. 60% for PEG-QDs and 65% for MPA-QDs. All QD dispersions were 
diluted from the original colloidal suspensions that were stored in H2O with a concentration of 10 
µM for PEGylated QDs (stored at pH 7) and 15 µM for MPA-coated QDs (stored at pH 11). LC3-, 
p62-, actin and LAMP-1-antibodies were purchased from Cell Signaling (Beverly, USA); secondary 
AlexaFluor® tagged antibodies, LysoTracker®, DQ™ red BSA and CellROX®  were purchased from 
Molecular Probes™ (Invitrogen, Belgium). 
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Nanoparticle characterization 
The hydrodynamic size and zeta potential of the QDs were determined using a Malvern Zetasizer 
Nano (Malvern Instruments, Worcestershire, U.K.). For this purpose the QDs were diluted to a 
concentration of 20 nM in HEPES buffer or Phosphate buffer saline (PBS) prior to performing the  
measurements at 25 °C. The refractive index was set to 2.56 based on the QD manufacturer’s 
protocol (Mesolight). Size measurements were done in triplicate with three runs per replicate 
and presented based on the number distribution. The zeta potentials were calculated from the 
electrophoretic mobility based on the Henry equation considering the Smoluchowski 
approximation. Zeta potential measurements were done in triplicate with two runs per replicate. 
The stability of both QDs in cell culture media was assessed with Single Particle Tracking. For 
these measurements 20nM of PEG-QDs and 125nM of MPA-QDs were incubated in cell culture 
medium for 24 h at room temperature. After this incubation the samples were further diluted in 
cell culture medium (by gently pipetting) and transferred to a microscopy slide. Next, we 
recorded 30 movies of 5 seconds of the diffusing particles using a Sweptfield Confocal 
Microscope (Nikon® Eclipse Ti) equipped with a 60× (1.40 NA) oil immersion objective (Nikon®). 
After movie acquisition the trajectories of the particles were calculated using image processing 
software. Out of these trajectories the diffusion coefficient per particle was determined which 
was next converted into a size distribution. A detailed description of this technique and its 
benefits can be found here 39. 
Cell culture 
The cervical epithelial cancer cell line HeLa was purchased from ATCC (CCL-2). The stable GFP-
LC3 HeLa cell line was a kind gift from Prof. Felix Randow (MRC Laboratory of Molecular Biology, 
Cambridge, UK). Both cell types were cultured using DMEM/F12 cell culture media (Gibco®, 
Paisly, UK) supplemented with 10% fetal bovine serum (Hyclone®, Cramilton, UK), 1% L-
glutamine (Gibco®, Paisly, UK) and 2% penicillin – streptomycine solution (Gibco®, Paisly, UK). 
Cells were passaged at 80% confluency and incubated at 37°C with 5.0% CO2.  
MTT cell viability 
Cells were seeded in a 96 well plate at a cell density of 20.000 cells per well. After QD treatment 
the medium was removed and the cells were washed twice with PBS (Gibco®, Paisly, UK). Next, 
fresh medium containing 5 mg/ml of MTT reagent (Sigma-Aldrich, USA) was added to the cells 
and incubated for 3 h at 37°C. Following this incubation, the medium was carefully removed and 
the formazan crystals were dissolved by incubation with DMSO on a shaker for 1 h. Finally, the 
absorbance was measured at 590 nm and 690 (background) with an Envision plate reader (Perkin 
Elmer, Zaventem, Belgium). The percentage of viability was then calculated by comparison with 
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untreated cells representing 100% viability. To check for potential interference of the QDs with 
the MTT assay absorbance was also measured for several controls. The positive control (cells 
treated for 15 min with 0,1% Triton X-100) was compared to cells treated with QDs followed by 
incubation with Triton X-100. Also, culture medium containing QDs and incubated with MTT 
reagent was compared to culture medium only incubated with MTT reagent. In both cases, no 
significant change in the assay readout was detected between the controls.  
Cellular uptake, oxidative stress, lysosomal and autophagy markers measured by flow 
cytometry.  
All autophagy-related studies were performed in accordance to the guidelines published by 
Klionsky et al.40.  All flow cytometry experiments were at least performed in triplicate. For this 
purpose cells were seeded in a 24 well plate at a density of 60.000 cells per well. The general 
protocol was as follows: after 24 h of incubating the cells with QDs in full cell culture medium, 
the medium was removed after which a washing step with PBS was performed. Next, the cells 
were detached with 300 µl of 0.25% Trypsin-EDTA (Gibco®, Paisly, UK), followed by neutralizing 
the trypsin with 500 µl of cell culture medium and transferring the cell suspension to FACS tubes. 
The samples were next centrifuged at 300g for 5 min, the supernatant was removed, and the 
cells were resuspended in FACS buffer. This wash cycle was performed two times. Finally, the 
cells were resuspended in 300 µl of FACS buffer prior to analyzing them with a FACScalibur flow 
cytometer (BD, Erembodegem, Belgium). Data acquisition was performed with BD CellQuest™ 
software while the data analysis was done with Flowjo software (Tree Star Inc). The staining 
protocols for the respective experiments are described below.  
Cellular uptake. HeLa cells were incubated with 400 µl of medium containing the respective 
concentrations of QDs for 24 h. After this the flow cytometry protocol as described above was 
executed. 
LysoTracker® staining. This dye, which stains all lysosomal vesicles, was used to estimate QD-
induced changes in total lysosomal content. Cells were exposed to QDs for 24 h or to 50 µM of 
chloroquine for 4h. After a washing step with PBS, cells were incubated with 100 nM of 
LysoTracker Red® DND-99 for 30 min at 37°C. 
DQ™ Red BSA staining. This dye, which is degraded by the lysosomal pathway, was used to 
estimate QD-induced changes in the degradative capacity of lysosomes. After a 24 h incubation 
with QDs and a washing step with PBS the cells were treated with 10 µg/ml DQ BSA for 3 h at 
37°C, allowing the endocytic uptake of the fluorescent BSA. Chloroquine-treated and starved 
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cells were pre-incubated for 1 h with 50 µM chloroquine or serum-free medium prior to co-
incubation with DQ BSA so that the total treatment was each time 4 h.  
CellROX® staining. Cells were exposed to QDs for 24 h. After a washing step with PBS, cells were 
incubated with 5 µM of CellROX® Deep Red for 30 min at 37°C.  
GFP-LC3 detection. This protocol was based on a method described by Eng et al.41 Hela cells 
stably expressing GFP-LC3 were seeded in a 24 well plate with a density of 60.000 cells per well. 
The general flow cytometry protocol was followed except for the first washing step which was 
performed with 0.05% saponin (Sigma-Aldrich, USA) instead of PBS. This special washing step 
ensures that only the LC3 present on autophagosomal membranes, which is insoluble, remains 
intact. After the saponin washing step, two wash cycles with PBS were executed after which the 
samples were analyzed.  
Immunofluorescence staining for LAMP-1 and LC3 
For these experiments 100.000 cells were seeded in a 35 mm microscopy dish, left to adhere 
overnight and were then treated with QDs for 24 h, or with chloroquine or serum-free medium 
for 4 h. After a washing step with PBS, the cells were fixed using 2% paraformaldehyde (Sigma-
Aldrich, USA) for 15 min. Next, the fixative was removed and the cells were washed three times 
with PBS. The cells were next permeabilized by a 15 min incubation with 0.5% Tween 20 (Sigma-
Aldrich, USA) in PBS. After removing the permeabilization agent the cells were washed three 
times with blocking buffer (5% goat serum in PBS), after which they were incubated with 
blocking buffer for 15 min.  Adequately diluted primary rabbit antibodies were then applied to 
the cells and incubated for 1 h. After washing three times with blocking buffer, the cells were 
incubated with Goat anti-Rabbit Alexafluor® 647 antibodies (Life Technologies, Invitrogen, 
Belgium) for 1 h. After two final washing steps with PBS, the samples were kept in Vectashield 
antifade medium (Vector Laboratories, USA) at 4°C until imaging. All the steps of the 
immunostaining protocol were performed at room temperature. The samples were visualized 
with a Sweptfield Confocal microscope (Nikon, Belgium) using a 60x oil Plan Apo objective 
(Nikon, Belgium). Post-image processing of the images was done using ImageJ/FIJI software 
(NIH).  
Western Blot 
For this experiment 750.000 cells were seeded in a T25 flask. After treatment, the cell medium 
was removed and the cells were washed twice with ice cold PBS and harvested by scraping. The 
cell suspension was then centrifuged for 8 min at 1100 rpm at 4°C. The supernatant was 
removed and the cell pellet was resuspended in RIPA buffer (Sigma-Aldrich, USA) supplemented 
162 │ Chapter 6   
with protease inhibitors (Sigma-Aldrich, USA). This suspension was next centrifuged at 10 000 g 
for 10 min at 4°C after which the supernatants were collected and kept at -80°C until use. Protein 
concentrations were determined using the DC™ Protein Assay (BD, Erembodegem, Belgium). For 
Western blotting equal amounts of protein were loaded on a 12% SDS-PAGE gel and transferred 
onto a PVDF membrane (BD, Erembodegem, Belgium). After the transfer the blots were blocked 
with 5% bovine serum albumin (Sigma-Aldrich, USA) for 1 h at room temperature after which 
they were incubated overnight at 4°C with the designated primary antibodies diluted in blocking 
buffer. Next, the blots were incubated with HRP-conjugated secondary antibody (Cell Signaling, 
USA) for 1 h at room temperature. Finally the blots were visualized using the Bio-Rad 
ImmunStar™ WesternC™ chemiluminescent kit (Biorad) on a VersaDoc™ Imaging System 
(Biorad). 
Statistical Analysis 
All experiments were analyzed for statistical significance with a one-way ANOVA followed by the 
Bonferroni post hoc test to estimate significance between treated groups, or followed by the 
Dunnett post hoc test when compared to an untreated group. The results were considered as 
statistically significant if p < 0.05. The number of asterisks in the figures indicate the statistical 
significance as follows: *p<0.05; **p<0.01; ***p<0.001. All statistical analysis was performed 
with Graphpad Prism 5 software (San Diego, CA). 
3. RESULTS 
Quantum Dot characterization  
As described in Figure 6.3, DLS measurements showed that both QDs exhibit similar size (∼20 
nm) and zeta potential (∼ -22 mV) in HEPES buffer. A negative zeta potential could be expected 
for both QDs since MPA is a strong acid and the PEG chains have carboxyl end groups. To 
characterize the QDs in an ion-rich solution (similar to cell medium) we examined their size and 
zeta potential in PBS. In this buffer, the PEGylated QDs remain stable (∼20 nm), while the MPA-
coated ones form aggregates (Figure 6.3A). As expected, exposure to cell culture medium 
elicited a similar trend as in PBS: PEGylated QDs show an uniform size distribution while MPA-
QDs clearly aggregate as indicated by their very broad size distribution (Figure 6.3B).  In PBS the 
charge of PEGylated QDs is neutralized to -10 mV while MPA-coated QDs exhibit similar charge 
as in HEPES buffer, being -22 mV (Figure 6.3C).  
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Figure 6.3 │ Quantum dot characterization. A) QD size measured in HEPES and PBS by DLS; B) QD size 
measured in full medium by SPT, C) zeta-potential of the QDs in HEPES and PBS as measured by DLS. Error 
bars represent the SEM.  
Uptake and intracellular localization of Quantum Dots  
Uptake experiments (Figure 6.4) showed that PEGylated QDs are easily taken up at low 
concentrations, though the uptake does reach a plateau around 40 nM and decreases at 
concentrations above 60 nM. In contrast, MPA QDs are only efficiently taken up starting from a 
concentration of 80 nM, and their uptake increases proportionally to the administered dose. In 
order to study the intracellular effects later on, we continued our study with dosages of the two 
types of QDs that should result in comparable intracellular concentrations. Considering the 
similar quantum yield of both QDs we compared dosages that gave an identical average 
fluorescence intensity per cell, i.e. 20 nM PEG QDs and 125 nM MPA QDs, as well as 50 nM of 
PEG QDs and 175 nM of MPA QDs. As discussed in more detail later, Figure 6.6 shows that both 
QDs accumulate in the perinuclear region and co-localize strongly with lysosomes, indicating that 
both particles are taken up by endocytosis.  
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Figure 6.4 │  Uptake of QDs in HeLa cells. Uptake was determined by flow cytometry after 24h of QD 
exposure in full medium (n=3). The x-axis denotes the QD dosage: for PEGylated QDs this ranges from 20 
to 100nM, while for MPA-coated QDs this ranges from 80 to 200nM. PEGylated QDs are easily taken up at 
low concentrations though uptake reaches a maximum around 40 nM. MPA-coated QDs are taken up 
proportionally with increasing dosage, though are only taken up efficiently at higher concentrations. 20 
nM of PEGylated QDs leads to similar intracellular fluorescence levels as 125 nM of MPA-coated QDs. 
Similarly, incubation with 50 nM of PEGylated QDs results in similar intracellular fluorescence levels as 175 
nM of MPA-coated QDs. Error bars represent the SEM. 
Quantum Dot-induced acute toxicity and oxidative stress 
QD-induced cytotoxicity was determined based on reduction in cellular enzymatic activity. This 
was tested using the common MTT viability assay after a QD incubation of 24 h for a 
concentration range up to 200 nM. As shown in Figure 6.5A, MPA QDs did not evoke significant 
toxicity over the tested concentration range. In contrast, PEGylated QDs clearly elicited a dose 
dependent toxicity with a significant decrease in cell viability ranging from 80.6% (± 1.8) viability 
at 50 nM to 33.7% (± 1.2) viability at 200 nM. Next to enzymatic activity, we also determined 
cytotoxicity based on cell membrane rupture by measuring propidium iodide uptake which gave 
identical results (data not shown). The level of ROS, a measure for oxidative stress, was 
determined by incubation of QD treated cells with CellROX®, a dye that becomes fluorescent 
after oxidation by ROS. As shown in Figure 6.5B, a 24 h exposure of HeLa cells to PEGylated QDs 
gave rise to significantly higher levels of ROS: 123 (±4.3)% for 20 nM and 135 (±4.0)%  for 50 nM. 
Remarkably, in case of MPA QDs the oxidative stress level decreased, as the ROS levels were 
significantly reduced to 85 (±4.5)%  and 76 (± 5.1)%  for 125 nM and 175 nM respectively.  
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Figure 6.5 │ Quantum dot induced acute toxicity and oxidative stress. PEGylated QDs induce cytotoxicity 
and oxidative stress, MPA-coated QDs are non-toxic up to 200 nM and reduce oxidative stress. (A) relative 
viability compared to untreated cells (100%) determined by the MTT assay (n=6). (B) relative level of 
CellROX intensity compared to untreated cells (100%) determined by flow cytometry (n=6). Error bars 
represent the SEM.  
Impact of Quantum Dots on lysosomal health 
Until recently the lysosome was merely considered as the waste bag of the cell, since it degrades 
and recycles the content delivered to the lysosomal compartment following endocytosis or 
autophagy. However, thanks to recent reports further elucidating its functions, the lysosome is 
now more and more perceived as an essential organelle for protecting the cell’s homeostasis.42 
To our interest, its activity is also crucial to ensure a functional autophagy pathway (cfr. Chapter 
5). Therefore, we evaluated the effect of QDs on lysosomal abundance and functionality by 
examining several markers (as indicated in Figure 6.2). 
As a first indication, we incubated QD treated cells with the lysosome-staining dye LysoTracker 
and followed its intensity with flow cytometry as a measure for the amount and/or size of the 
lysosomal network.43 As a positive control we treated HeLa cells with 50 µM of chloroquine for 4 
h since it is widely established that this buffer elicits alkalinization of the lysosomal lumen which 
next evokes lysosomal swelling.44  As shown in Figure 6.6A, this treatment indeed led to an 
almost twofold increase (194 ±14%) in LysoTracker intensity. A 24 h incubation with 20 and 50 
nM PEGylated QDs resulted in an even more substantial increase up to 240 (±15)% and 248 (± 
24)% respectively. The rise in LysoTracker intensity for the MPA coated QDs was not as 
spectacular as for their PEGylated counterparts though a significant dose-dependent effect was 
apparent: 125 nM led to 162 (± 14)%  while 175 nM gave rise to 220 (± 26)%.  
To support this data we performed confocal microscopy on cells stained for LAMP-1, a lysosomal 
membrane marker.29 As illustrated in Figure 6.6B some lysosomes of chloroquine-treated cells 
appeared as swollen compared to those of untreated cells which supports the rise in LysoTracker 
intensity seen with flow cytometry. Instead, confocal images show that the increase in 
166 │ Chapter 6   
LysoTracker intensity in QD-treated cells seems rather due to an increase in the number of 
lysosomes. Moreover, we noticed there was a strong co-localization between lysosomes and 
both types of QDs, illustrating that both QDs were taken up by endocytosis and thus efficiently 
delivered to the lysosomal compartment.  
Figure 6.6 │ Impact of Quantum Dots on lysosomal health. PEGylated QDs induce lysosomal impairment, 
while MPA-coated ones cause lysosomal activation. (A) relative level of LysoTracker intensity compared to 
untreated cells (100%) determined by flow cytometry (n=4). (B) Confocal microscopy on LAMP-1 
immunostained cells after 24h of exposure to 50 nM PEGylated QDs, 175 nM of MPA-coated QDs or 4 h of 
50 µM chloroquine (CLQ). N indicates the nucleus, arrows indicate swollen lysosomes. Scale bar: 20 µm. 
(C) relative level of DQ BSA intensity compared to untreated cells (100%) determined by flow cytometry 
(n=4). Error bars represent the SEM.  
Finally, we examined the functionality of lysosomes of cells exposed to QDs, i.e. their ability of 
degrading lysosomal content. To this end, HeLa cells were incubated with the DQ BSA dye which 
consists of BSA proteins that are heavily labeled with fluorescent dyes so that a strong quenching 
effect takes place. Upon (lysosomal) degradation of DQ BSA into smaller fragments, this 
quenching effect is abolished, resulting in a bright fluorescent signal. In other words, an increase 
in fluorescence represents an increase in lysosomal protein degradation.  As a positive control 
for increased lysosomal activity, cells were incubated for 4 h with serum-free medium to mimic 
starvation. Figure 6.6C demonstrates that this treatment indeed gave rise to a substantial 
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increase in DQ BSA fluorescence (176 ±14% ). This in stark contrast to chloroquine-treated cells 
where the protein degradation capacity was almost halved (54 ±2.9% ). This is not surprising 
since it has repeatedly been reported that starvation and chloroquine result in upregulation of 
lysosomal activity and lysosomal impairment, respectively.45,46  Indeed, the alkalinization of 
lysosomal pH induced by chloroquine inhibits the degradative enzymes that are in need of an 
acidic environment. On the other hand, starvation stimulates lysosomal activity and autophagy 
as the cell attempts to compensate for the nutrient deficit.31,47  For the QDs, the effect on 
lysosomal degradation strongly depended on the type of coating. No substantial change in 
degradation was observed upon treatment with PEGylated QDs. MPA QDs, however, did 
significantly enhance DQ BSA fluorescence intensity up to 134 (± 5.4)%  with 175 nM. This 
signifies that MPA-QD uptake results in a starvation-like activation of lysosomal degradative 
capacity.  
Impact of Quantum Dots on autophagy 
Next, we focused on the most important organelle of the autophagy pathway i.e the 
autophagosome. The most widely investigated marker for autophagosomes is the protein LC3, 
which is present as two forms within the cell: the unactivated form, LC3-I, which is present in the 
cytosol and the active form LC3-II that is incorporated into the autophagosomal membrane 
(Figure 6.2). Consequently, the autophagy pathway can be studied by following the processing of 
LC3. To reliably interpret changes in autophagy we inspected LC3 by multiple techniques (cfr. 
Chapter 5), including (i) flow cytometry on HeLa cells stably expressing GFP-LC3 and (ii) western 
blotting on autophagosomal markers. As a first indication the level of GFP-LC3 was quantified by 
flow cytometry in a stably transfected GFP-LC3 HeLa cell line. When autophagosomes fuse with 
lysosomes the GFP will be quenched by the acidic pH.31,48 The fluorescence intensity level of GFP 
is therefore proportional to the amount of autophagosomes. Furthermore, the saponin 
extraction included in the sample preparation ensures that only the membrane-bound LC3 
contributes to the detected signal.41 A 4 h incubation with 50 µM of chloroquine was applied as a 
positive control for autophagosome accumulation throughout all autophagy experiments. The 
lysosomal impairment caused by chloroquine leads to a block in autophagosome-lysosome 
fusion which results in the accumulation of large autophagosomes positive for LC3-II (Figure 
6.2).31 Indeed, as shown in Figure 6.7A, chloroquine treatment resulted in more than a three-fold 
increase in GFP-LC3 fluorescence intensity compared to untreated cells (342 ±60%). Interestingly, 
the highest concentration of PEGylated QDs also elicited a significant increase in GFP-LC3 (175 
±26%) while MPA QD treatment did not.  
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Figure 6.7 │ Impact of Quantum Dots on autophagy. PEGylated QDs induce autophagy dysfunction, MPA-
coated QDs do not influence autophagic markers. (A) relative level of GFP-LC3 intensity compared to 
untreated cells (100%) determined by flow cytometry (n=6). Error bars represent the SEM. (B) Confocal 
microscopy on LC3-immunostained cells after 24h incubation of 50 nM PEGylated QDs, 175 nM of MPA-
coated QDs or 4 h of 50 µM chloroquine (CLQ). N indicates the nucleus, arrows indicate large 
autophagosomes. Scale bars: 20µm (C) Western blot on autophagic markers LC3 and p62.  
To support this data we performed confocal microscopy on HeLa cells stained for LC3 after 
treatment with PEG QDs, MPA QDs or chloroquine. Here, the confocal images in Figure 6.7B 
show that chloroquine-treated cells contain some larger autophagosomes compared to 
untreated cells while in case of PEG QD treatment the total autophagosomal content seemed 
higher. In contrast, MPA QD treatment did not appreciably affect autophagosomal abundance 
nor size. It should be noted that for both QDs there was little co-localization with 
autophagosomes. Since the QDs are not present in the cytosol the only way of entering the 
autophagy pathway would be via fusion of autophagosomes with QD-containing lysosomes. 
Seeing the lack of co-localization we can conclude that these fusion events do not take place.  
As mentioned in Chapter 5, the level of p62 is often studied to determine if the overall 
autophagy pathway is entirely functional. Since p62 is solely degraded by autophagy, a rise or fall 
of its protein level compared to the untreated condition corresponds with an autophagy 
blockade or upregulation respectively.49 Figure 6.7C shows the protein levels of p62 and LC3 as 
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determined by Western blotting. Interestingly, the level of p62 was higher for cells treated with 
50 nM of PEGylated QDs. As expected based on our observations by microscopy and flow 
cytometry, a higher level of LC3-II was  spotted upon incubation with PEGylated QDs at 50 nM.  
The rise in LC3-II induced by chloroquine was even more pronounced. In contrast, no change in 
both markers was detected upon incubation of HeLa cells with MPA-coated QDs.  
4. DISCUSSION 
In this chapter we apply a step-by-step approach to carefully examine the toxicity of QDs coated 
with two commonly applied surface ligands. Our data clearly accentuates that the choice of 
coating is crucial for the degree and mechanisms of toxicity induced by QDs on cells: while MPA 
coated QDs were highly biocompatible, PEGylated QDs were severely toxic at higher 
concentrations. A detailed investigation of the ROS production, lysosomal health and autophagy 
pathway gave some insight in the intracellular mechanisms that could account for these 
observations.  
MPA coated QDs   
Coating of QDs with the short ligand MPA was not sufficient to protect the particles from 
aggregation in buffer or cell culture medium. The aggregated particles were taken up efficiently, 
though only at higher concentrations. This could be expected since it has been observed before 
that NP agglomeration has a negative impact on cellular uptake.50–52 It is therefore likely that we 
need a higher dosage of MPA-coated QDs to reach similar intracellular fluorescence levels as 
PEGylated QDs because only the smaller NPs of the dispersion of MPA-QDs are able of entering 
the cells.53 Interestingly, Albanese et al. stated that the effect of particle aggregation on uptake 
might be cell-type dependent: gold nanoparticle aggregation led to a reduced uptake in HeLa 
cells while for a melanoma cell type the opposite was true.51  In any case, despite the efficient 
uptake of MPA-QDs, they did not inflict any toxicity on HeLa cells.  This biocompatibility 
corresponds with the findings of Nagy et al. who did not detect any cell death in primary human 
lung cells upon exposure to differently sized MPA-coated QDs, though they did not show any 
uptake data.37 Soenen et al., however, did detect significant toxicity with MPA-coated QDs 
starting from 50 nM.32 This difference with our data may be attributed to differences in 
aggregation: their MPA-QDs form smaller aggregates, which could lead to more efficient uptake 
and consequently toxicity at lower concentrations. This hypothesis was confirmed in vivo in mice 
where aggregated MPA-QDs exhibited less toxicity than their unaggregated counterparts.54 On 
the other hand, the discrepancy in toxicity could also be derived from cell type dependent 
effects.55,56  
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The most recognized mechanism of QD-induced toxicity is the production of ROS.57 Shifting ROS 
levels can indeed lead to a variety of secondary effects such as changes in cell signaling and DNA 
damage.16 In addition, ROS and oxidative stress are associated with multiple cell death pathways 
and have been identified as important regulators of autophagy (cfr. Chapter 5).58–60 Strikingly, 
incubation with MPA-coated QDs led to a significant reduction in ROS levels (Figure 6.5B). 
Though this observation was unexpected, an NP-induced reduction in ROS has been reported 
before.61 Specifically regarding QDs, studies have until now only reported that there is a lack of 
ROS induction by MPA-coated QDs.37,38  
Apart from ROS levels, we looked further into the impact of QD exposure on lysosomal health 
and autophagy. As a first step we evaluated the influence of QDs on the number and size of 
lysosomes. Here we found that treatment of HeLa cells with MPA-coated QDs elicited a 
significant expansion of the lysosomal compartment as indicated by the substantially increased 
levels of LysoTracker. This type of enlargement is a commonly reported phenomenon and has 
been described for various NPs including ZnO NPs, fullerenol NPs, polystyrene NPs and QDs.27,62–
64 Interestingly, the increase in lysosomal content  was accompanied by a rise in cellular 
degradation capacity, which is an indication for lysosomal activation. A boost in protein 
degradation was also observed by Chen et al. who, similar to our findings, detected an increase 
in LysoTracker staining and DQ BSA degradation upon treatment of human cerebral 
microvascular endothelial cells with aluminum NPs.65 In addition, Kenzaoui et al. observed 
lysosomal activation induced in brain-derived endothelial cells by multiple NPs such as iron oxide 
NPs and silica NPs.66 This kind of lysosomal activation, as caused by our MPA-coated QDs, is often 
accompanied by a similar activation of autophagy.  However, the unaltered level of p62 and LC3 
indicates that the autophagy pathway is fully functional though at a basal level. Similar to 
autophagy induction, this QD-induced lysosomal activation likely aids the cell in overcoming 
stress. In combination with the reduced oxidative stress, this could explain the lack of toxicity we 
observed upon exposure of HeLa cells to these QDs. Our findings thus confirm that MPA-coated 
QDs are quite biocompatible. Furthermore, our group recently reported that cells labeled with 
GA-QDs can be tracked 1.5 times longer than conventional core-shell QDs.32 In conclusion, the 
combination of this excellent functionality and biocompatibility makes these MPA-coated GA-
QDs very well suited for cell labeling applications. 
PEGylated QDs 
Unlike MPA coated QDs, PEGylated QDs do not agglomerate in ion-rich media, most likely due to 
the steric hindrance imparted by the PEG-chains which prevents particle-particle interactions.67 
As Pelaz et al. stated, PEGylation more than often leads to a reduction in cellular uptake which is 
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likely attributed to the lack of protein adsorption at the particle surface.68 On the other hand, the 
colloidal stability of our particles likely supports their uptake as stated before by Kirchner et 
al.53,69 Indeed the smaller and more neutral PEGylated QDs were clearly taken up more efficiently 
(even at lower extracellular concentrations) than the larger negatively charged MPA-coated QDs. 
Starting from 60 nM, however, the uptake of PEGylated QDs shows a downward trend. An 
explanation for this decrease in uptake might be the saturation of surface receptors essential for 
QD uptake, since it has been described before that neutral to negatively charged QDs are actively 
internalized by a variety of saturable endocytosis pathways including clathrin- and caveolae-
mediated endocytosis.70,71  Upon investigation of the intracellular location of both QDs we 
indeed found that after 24h they co-localize strongly with LAMP-1 stained lysosomes implying 
they are taken up via endocytosis. The decreased uptake of PEGylated QDs upon treatment with 
higher concentrations could also stem from QD-induced toxicity, as cytotoxicity tests revealed 
that PEGylated QDs were significantly toxic starting from 50 nM. 
Regarding QDs, a common strategy to prevent ROS induction is to limit the dissolution of 
cadmium ions from their core by the application of a surface coating.53 Clearly, high density 
PEGylation is not sufficient to prevent ROS production since exposure to 50 nM of PEGylated 
QDs significantly raised the level of ROS in HeLa cells. Since this observation correlates well with 
the cell death seen at this concentration, we suggest this ROS production is at least partly 
responsible for the observed cytotoxicity. In addition, these findings correspond well with the 
many reports on QD-induced cell death associated with oxidative stress.13,32,72 In any case, the 
difference in toxicity observed between the PEG- and MPA-coated QDs demonstrates that the 
type of surface functionalization can have a marked influence on the toxicity and ROS production 
of QDs. This observation was also made by Nagy et al., who observed less QD-induced toxicity 
with shorter negatively charged surface ligands compared to longer ligands - in our case 
represented by MPA and PEG respectively.37  
With regard to the lysosomes, PEGylated QDs resulted in an enlargement of the lysosomal 
compartment. Interestingly, despite the fact that PEGylated QDs gave rise to a more than 
twofold increase in LysoTracker, the degradation of DQ BSA did remain unchanged. We 
therefore suspect that at least a part of these lysosomes exhibit limited or no proteolytic activity 
and thus these QDs lead to lysosomal impairment. Lysosomal impairment is a frequently 
described mechanism of toxicity in cells exposed to various NPs as summarized in a review by 
Stern et al.73 The most extensively reported mechanism of lysosomal impairment involves 
lysosome membrane permeabilization. However, considering the high LysoTracker dye loading 
and LAMP-1 staining showing normal lysosomal morphology, we believe that in our case the 
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lysosomal membrane is intact. We therefore hypothesize that the mechanism underlying this 
impairment could be lysosomal overload as has previously been reported for several particles 
such as smoke particulates.73,74 Another mechanism that could contribute to the lack of 
degradation taking place within the lysosomes could be oxidative damage inflicted on the 
lysosomal enzymes by ROS produced during QD lysis.73 By any means, lysosomal dysfunction is 
undeniably a toxic parameter worth of investigation since it forms the basis of lysosomal storage 
disorders, a group of degenerative diseases that affect the nervous and musculoskeletal systems. 
In addition, lysosomal malfunction can give rise to an autophagy blockade through impaired 
autophagosome-lysosome fusion, a hypothesis we investigated further.75 
When looking into autophagosomal markers, treatment of HeLa cells with 50 nM of PEGylated 
QDs resulted in an elevation of LC3, indicative of an accumulation of autophagosomes. Since the 
p62 protein level was also increased, we conclude that  the accumulation of LC3 derives from a 
reduction in autophagosomal turn-over rather than autophagy induction. In other words, the 
autophagy pathway is not fully functional but blocked at its later stage i.e. at autophagosome-
lysosome fusion. Since no co-localization of QDs with autophagosomes was observed (Figure 
6.7), we conclude from this collection of data that PEGylated QDs induce autophagosome 
accumulation through lysosomal impairment. This theory is in line with observations made by 
Ma et al. who detected compromised degradation capacity induced by endocytosed AuNPs and 
consequently defective autophagosome-lysosome fusion in normal rat kidney cells.25 An 
impaired autophagy flux was also hypothesized by Wang et al. who witnessed an increase in the 
volume of acidic compartments and LC3-II levels upon exposure of human brain astrocytoma 
cells to polystyrene particles.64 In addition, the same conclusion was drawn based on similar 
observations in kidney cells treated with fullerenol NPs.63 At first sight our findings do seem in 
contrast with recent observations made by Huang et al who saw that NPs modulate autophagy in 
a dispersity-dependent manner where aggregated NPs induced severe autophagic effects while 
well-dispersed NPs did not.76 Our study indicates that MPA-QDs, which aggregate severely in 
extracellular medium, do not exert major effects on the autophagy pathway while our 
unaggregated PEGylated QDs clearly do. However, within the cell this phenomenon might be the 
opposite: as stated before it is likely that the large MPA-QD aggregates are not internalized by 
the cell while the smaller PEGylated QDs are taken up very efficiently and likely accumulate, and 
possibly aggregate massively inside the endo- and lysosomes. According to Huang et al. this high 
uptake and intracellular accumulation of NPs can next modulate autophagy, which is in line with 
our observations. Since autophagy usually encourages survival, especially in cells undergoing 
stress, it is not surprising that when this function is lost, cytotoxicity becomes inevitable.77 Our 
PEGylated QDs induce oxidative stress that undoubtedly leads to damaged cytoplasmic material. 
   
 Chapter 6 │ 173 
Where usually autophagy aids in the removal of these materials, this coping mechanism is now 
absent. The autophagy blockade combined with oxidative stress is therefore likely the underlying 
source of the QD-induced cytotoxicity we observed. This disrupted autophagy flux is a serious 
observation since this can lead to the accumulation of protein aggregates and damaged 
cytoplasmic organelles. This buildup of cytoplasmic waste can subsequently provoke genomic 
instability and tissue degeneration, which in turn has a huge impact on physiology.22 Surely, 
autophagy dysfunction is linked with the onset of many diseases including cancer, 
neurodegenerative and inflammatory diseases.22,78 
However, autophagy perturbation should not be regarded as threatening per se. Actually, in 
distinct cases it can be manipulated to our advantage. Recent reports have stated that inducing 
autophagy malfunction might be an ideal strategy to wipe out (resistant) cancer cells. It seems 
some types of cancer are highly dependent on autophagy for their survival, since autophagy 
allows them to overcome stressors like starvation, hypoxia and even chemotherapy.19,24 Blocking 
this cytoprotective process would in this case thus lead to their demise. In fact, the anti-cancer 
activity of chloroquine, a chemical we use as a positive control for autophagy blockade, is 
currently investigated in multiple clinical trials.79,80 In this regard, the effects induced by 
PEGylated QDs might allow us to combine diagnosis by tumor imaging with anti-cancer therapy. 
In conclusion, the oxidative stress and autophagy blockade caused by these PEGylated GA-QDs 
has detrimental effects for the cell, however, in cases where these effects are desirable like in 
anti-cancer therapy, these particles could be valuable. 
5. CONCLUSION 
The primary goal of this study was to define the toxicity and its origins of MPA-coated and 
PEGylated QDs with a special emphasis on the autophagy pathway. We observed that despite 
the fact the two studied QDs are completely identical except for their surface coating, their 
cellular effects induced in HeLa cells were remarkably different (summarized in Figure 6.8). This 
implies that rather than QD composition, the surface chemistry primarily defines the 
functionality and toxicity of the QD. Based on our results we conclude that MPA-coated QDs are 
highly biocompatible, where the lysosomal activation and ROS reduction induced by these QDs 
likely rescues the cell from potentially NP-induced toxic effects. In this respect, MPA-coated QDs 
seem promising candidates for cellular labeling. However, since this study is limited by its focus 
on ROS and autophagy, future research should involve screening for other toxic factors such as 
DNA damage. As expected, the PEGylated QDs proved to be more resistant to aggregation 
resulting in efficient cell labeling. However, these QDs exhibited significant toxicity owing to their 
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capacity to induce ROS production and autophagy malfunction through lysosomal impairment. 
Considering these toxic defects, the PEGylated QDs do not seem suitable for biomedical 
applications except for when autophagy dysfunction is actually desirable e.g. in anti-cancer 
therapy. In this regard, it could be valuable to investigate if combination therapy using a 
common chemotherapeutic and this QD might enhance the elimination of therapy-resistant 
cancer cells. Generally, our study highlights the importance of surface chemistry when it comes 
to nanotoxicology as well as the relevance of lysosomal and autophagy dysfunction as a NP-
induced toxicity mechanism.  
 
Figure 6.8 │  Overview of the distinct cellular effects of GA QDs coated with PEG or MPA.  
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The content of this thesis is subdivided into two main categories, yet both categories share a 
common topic i.e. nano. The first purpose of this chapter is therefore to review the recent 
progress and future goals of nano in context of toxicology and retinal gene therapy. On the other 
hand, since nano is in practice not as successful as initially anticipated, we will also highlight the 
predominant issues that currently limit nano to progress to the clinic along with conceptual 
guidelines that could help the field to advance (more) efficiently. Finally, having these guidelines 
in mind, we look into non-viral retinal gene delivery as a case study and attempt to envision how 
this research area should proceed. 
   
 Chapter 7 │ 183 
Table of Contents 
1. CURRENT STATE OF THE ART AND FUTURE GOALS ..................................................................... 184 
RETINAL GENE THERAPY ........................................................................................................................................ 184 
NANOMEDICINE AND NANOTOXICOLOGY .................................................................................................................. 187 
2. ISSUES & CHALLENGES LIMITING OUR PROGRESS IN NANO ....................................................... 190 
INEFFICIENT ENTHUSIASM ..................................................................................................................................... 190 
MISSING MODELS THAT MATTER ............................................................................................................................ 193 
3. RETINAL GENE DELIVERY BY NANOMEDICINES AFTER INTRAVITREAL INJECTION: HOW DO 
WE GET THERE? ................................................................................................................................... 195 
DESIGN OF SUCCESSFUL NANOPARTICLES .................................................................................................................. 195 
ADVANCED STRATEGIES TO ENHANCE RETINAL DELIVERY .............................................................................................. 197 
4. CONCLUSIONS ............................................................................................................................. 198 










184 │ Chapter 7   
1. CURRENT STATE OF THE ART AND FUTURE GOALS 
Retinal gene therapy 
Retinal gene therapy has seen astounding progress on many levels over the last 20 years. Our 
insight in the biology of the retina and pathophysiology of retinal diseases has indeed incredibly 
expanded. Moreover, since the discovery of the first blinding genetic defects in the 1980’s more 
than 250 disease-causing genes have been identified (Figure 7.1). This is partly attributed to the 
further development and decreasing costs of next-generation sequencing which stimulated the 
genetic screening of patients by academic and commercial centers.1,2 While in the 90’s diagnosis 
was solely based on phenotypical features like retinal fundus imaging and classic visual acuity 
tests, the advances in genetic testing as of today allows earlier diagnosis and prognosis of 
inherited retinal diseases, and importantly, enables phenotype-genotype linking.1–3 The 
identification of these genes further led to the discovery of a collection of naturally occurring 
animal models of retinal disease. In addition, thanks to the progress made in producing targeted 
mutations and gene knockouts, a wide variety of engineered animal models of diverse species 
has been added to this collection.3,4  
 
Figure 7.1 │ Mapped and identified retinal disease genes from 1980-2017. Taken from 5 
 
The increasing insight into inherited retinal disease and its causative mutations together with the 
growing number of available in vivo disease models provided a solid foundation for the 
progression of retinal gene therapy with recombinant viruses as key players. Here, adeno-
associated viral vectors (AAV) are by far the most successful and therefore most applied ones for 
retinal gene transfer.3 Our ability of engineering their capsids has further improved their 
therapeutic power by tuning of their cellular specificity, onset of gene expression and 
extracellular interactions.6 In view of the pre-clinical success of AAV vectors (especially type 2), 
the majority of clinical trials involve subretinal injection of these vectors for gene augmentation 
strategies. Two target genes connected to loss-of-function mutations predominate the clinical 
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trials, i.e. CHM which causes choroideremia and RPE65, which is linked to Leber Congenital 
Amaurosis (LCA). In context of the latter disease, Spark therapeutics’ AAV2 vector Voretigene 
Neparvovec was recently recommended for approval by the U.S. Food and Drug Administration 
(FDA).7 As the first gene therapy to reach this stage in the U.S. this signifies a great leap forward 
for treatment of retinal dystrophies. A full overview of completed and ongoing clinical trials can 
be found here3,8. 
As discussed in Chapter 1 and 5, nanomedicines have several advantages over viral vectors, yet, 
in contrast to the successes achieved with viral vectors, non-viral ones are until now lagging 
behind when it comes to efficacy of retinal gene transfer. However, while no nanomedicines 
have reached the clinical stage thus far, some interesting pre-clinical results have been reported 
on. An example of an elegantly designed nanoparticle (NP) was given by Rajala et al. who 
synthesized lipid-protamine-DNA NPs that were further functionalized with a cell-penetrating 
peptide and a nuclear localization signaling peptide. This combination proved to be effective 
since subretinal injection of these particles in RPE65 knockout mice led to a substantial 
improvement in ERG response as well as photoreceptor integrity.9 Another example of a 
successful lipid-based carrier is the solid lipid nanoparticles (SLN) as described by Apaolaza et 
al.10 SLN’s are composed of a solid lipid core surrounded by a surfactant and can be 
functionalized with smart ligands such as hyaluronic acid (HA). Interestingly, the retina’s of Rhs1-
deficient mice bearing symptoms of X-linked juvenile retinoschisis showed improved structural 
integrity after IVT injection of HA-functionalized SLN’s.10 The group of Muna Naash has been 
working on so-called compacted DNA particles, where DNA is folded into DNase-resistant 
nanostructures by applying PEG-substituted polylysine. These particles have shown beneficial 
results in several disease models, including mice knocked out for RPE65, RHO (RP) and ABCA4 
(Stargardt’s disease).11–14 These studies demonstrate that it is worthwhile to proceed our 
research into the potential of nanomedicines for retinal gene therapy even though their efficacy 
until now does not match that of viral vectors. Nevertheless, there are some challenges to be 
met for nano to truly advance in the field of retinal gene therapy as will be discussed later in this 
chapter. 
Despite the fact that the progress in retinal gene therapy over the last 20 years is immense, 
there are still issues to be tackled and challenging goals to aim for. A fundamental aim at the 
moment is the attempt to increase the number of disease targets.8 Current clinical trials are 
predominantly limited to gene augmentation strategies that aim to compensate for loss-of-
function mutations.3 However, this gene augmentation strategy may not provide relief for 
patients suffering from inherited retinal diseases based on gain-of-function mutations.8,15 To 
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treat these cases, other gene-specific therapeutic strategies are being researched of which the 
most eminent one is gene editing technology (e.g. CRISPR/Cas9). As mentioned in Chapter 1, this 
approach involves gene-specific adjustment of the genome and comes with the advantage that 
the therapeutic effect is expected to be lifelong.16 As an example of this approach, Bakondi et al. 
were able to prevent retinal degeneration and improve visual function in rats suffering from 
autosomal dominant RP by selectively ablating the RHO gene using the CRISPR/Cas9 gene editing 
technology.17 A concern that for now limits the clinical translation of CRISPR/Cas9 is potential 
off-target cleaving which could induce unintended mutations.18 However, seeing the worldwide 
excitement about gene editing and effort dedicated to it, we are convinced the strategy will be 
further fine-tuned in order to prevent off-target effects. The complexity of inherited retinal 
disease and the great number of genes involved furthermore highlights the need for mutation-
independent approaches which are able of treating a retinal disease irrespective of the mutation, 
if any. As already briefly touched upon in Chapter 1, optogenetics is an example of such an 
approach. Many studies in small laboratory animals have demonstrated its feasibility, and one 
phase I/II clinical trial has been registered so far. The first outcomes of this dose-escalation study 
were encouraging since no inflammation or ocular adverse effects were observed in the low 
dose cohort of patients diagnosed with advanced retinitis pigmentosa.18a The primary obstacle 
preventing optogenetics to become clinically successful is likely the fact that the intensity of light 
required to trigger the neuronal cells lies above the safety threshold. This obstacle is directly 
connected to the inherent light sensitivity of the opsins expressed in the target neuronal cells 
together with the high level of opsin expression needed. Remarkably, Chaffiol et al. very recently 
confirmed the feasibility of optogenetics in cynomolgus macaques, and more importantly, 
managed to acquire light responses with light intensities below the safety threshold for retinal 
illumination. To this end, they made use of an ultra light-sensitive version of channelrhodopsin19 
combined with an optimized promotor able of inducing high expression in RGCs, their target cell 
type.20 We are convinced that these promising preclinical outcomes and the fine-tuning of gene 
expression lying at the root of this success will pave the way for the clinical development of 
optogenetics. Another mutation-independent approach is neuroprotection, of which we have 
already discussed the concept and recent progress in Chapter 4. Another restricting factor for 
AAV-mediated gene augmentation therapy that should be overcome is their limited cargo 
capacity which is not sufficient for some diseases caused by large genes (e.g. ABCA4 in Stargardt 
disease). Several options are therefore investigated including lentiviral vectors (which have 
almost twice as much capacity compared to AAV), dual vector systems and of course, 
nanomedicines.8 
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Since the efficacy of retinal gene therapy is highly dependent on the delivery of therapeutic 
genes to the target site, future research should definitely focus on enhancing the delivery of 
gene carriers to the retina. As extensively discussed in Chapter 2, many physiological barriers 
hinder the efficient delivery into the retina and hence their induced transgene expression. Here, 
the density of the retina clearly poses a problem since subretinal injection rarely induces strong 
expression in inner retinal layers while IVT injection has trouble delivering carriers to the outer 
layers. Considering the advantages IVT injection has over subretinal administration, many 
research groups put effort in improving the delivery of their non-viral and viral carriers after IVT 
injection by adjusting the surface characteristics of the carriers.21 Next to optimizing the delivery 
based on these delivery routes, other administration routes have emerged that remain relatively 
unexplored and deserve more attention in the future such as periocular and suprachoroidal 
administration (cfr. Chapter 2). In addition, progress in surgical delivery such as robot-assisted 
surgery could enhance the efficiency as well as the safety of retinal gene delivery.22 
Finally, future research should continue to look into alternatives for retinal gene therapy, which 
could aid to restore or improve vision of patients suffering from inherited as well as acquired 
retinal degeneration. An alternative strategy that is explored at the moment is the use of stem 
cells, which amongst other sources can be embryo-derived or induced from patient derived 
cells.23 These cells can be manipulated to differentiate into retinal cell types like photoreceptor 
cells or RPE cells, after which they can be transplanted into the retinal tissue. Diseases currently 
investigated for this type of therapy include RP, AMD and Stargardt’s macular dystrophy.23 Some 
clinical trials, which primarily focus on evaluating safety, have been completed showing 
promising results.24 Next to these advanced biological strategies also technological progress can 
help patients suffering from vision loss. An example of a technology-based device is the Argus II 
retinal prosthesis. Here, a camera in the patient’s glasses captures the surroundings, transforms 
this signal and sends it to an array of electrodes implanted in the patient’s eye. Next, this array 
electrically stimulates the remaining retinal cells which can next signal this information to the 
brain.25 While this Argus II offers limited improvement of visual acuity, other prosthesis systems 
are being tested preclinically that are expected to ameliorate vision to a greater extent.26,27 
Nanomedicine and nanotoxicology 
In view of the many advantageous properties NPs possess (cfr. Chapter 5), the scientific 
community was strongly convinced that nanomedicine would completely transform the 
diagnosis and treatment of a variety of diseases. So far, the potential of nanomedicines has 
mainly been studied for the treatment of cancer. It was indeed rumored that nano would 
outperform the efficacy and safety of the currently available anti-cancer therapies. However, 
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despite the overwhelming amount of preclinical data and proof-of-concept studies, the 
translation of NPs toward the clinic has been disappointing. While nano is still expected to have 
an impact on the medicinal field, the enthusiasm of the public about its potential is slightly 
tempered in light of the absence of clinical success. Many of the NPs are halted in Phase 3 trials 
since they fail to improve treatment compared to the standard therapies. Remarkably, this is not 
that surprising considering the analysis made by Wilhelm et al.: careful scrutiny of the available 
literature on intravenous delivery of NPs to tumors revealed that merely 0,7% of the injected 
dose truly reached the tumour (Figure 7.2).28 Moreover, the authors state that the median 
delivery efficiency did not improve over 10 years. 
 
Figure 7.2 │ Nanoparticle delivery efficiency (expressed as percentage of injected dose) to solid tumor 




Nevertheless, some NPs have received FDA-approval or are being evaluated in clinical trials at 
the moment; an overview of the NP systems that have reached these stages can be found in 
Figure 7.3.29 The majority of approved nanomedicines are liposomes encapsulating cytotoxic 
agents such as Doxorubicin (Myocet™) and Daunorubicin (DaunoXome™).30 Interestingly, the 
clinical benefit of most approved anti-cancer nanomedicines has been improved safety rather 
than enhanced efficacy.30,31 The overall future goal of nanomedicine in context of anti-cancer 
therapy is therefore rather straightforward: make it live up to its promises. Also for other 
applications, such as retinal gene therapy, nanoparticles still face many hurdles on the road to 
the clinic. Some drastic changes in nanoparticle development and evaluation will therefore likely 
be needed to turn nanomedicine into a success story. Surely, we are convinced that a few 
fundamental issues lie at the root of the lack of clinical translation, which we will discuss later in 
this chapter.  
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Figure 7.3 │ Schematic overview of nanoparticle types that have been approved or are in clinical trials. 




In the past 20 years a myriad of NPs have been toxicologically evaluated in a multitude of cell 
types and models which has led to the discovery of a few commonly observed toxicological 
mechanisms that many NPs share (cfr. overview in Chapter 5). Initially, nanotoxicology advanced 
slowly due to the absence of appropriate toxicological assays for evaluation of NPs, although it 
became soon clear that by changing the physicochemistry of a NP its elicited cellular effects 
could vary – as we have confirmed in Chapter 6. This insight led to the development of NP 
characterization tools which proved to be fundamental for the progression of the field. This 
characterization initially primarily focused on basic NP parameters like size and surface charge. 
Then, the discovery came that the protein corona, a layer of proteins that surrounds the NP 
when it is exposed to biological fluids, truly defines the biological identity of a NP and therefore 
dictates the interactions with its environment.32 Up to today, this concept has encouraged the 
field to continue their efforts to come up with novel characterization methods to analyze the 
composition and morphology of this complex protein layer and its influence on NP 
physicochemistry.33 In addition, rather than one clear toxicity mechanism, it was found that NPs 
can provoke cellular changes via various pathways. In response to this phenomenon the field 
evolved its methodology from rather basic cytotoxicity assays to a more multiparametric 
approach.34 The field has generally matured greatly over the last decade, with overall a high 
number of available tools to assess NPs and their interactions in vitro and in vivo. With the 
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increasing number of complex NP being developed for biomedical applications significant effort 
is now dedicated to developing high-throughput and high-content systems.35  
2. ISSUES & CHALLENGES LIMITING OUR PROGRESS IN NANO 
The fact that nano is a booming field is likely an understatement since the number of 
publications has increased dramatically over the years. Nevertheless, despite the exploding 
number of studies, the nano field does not progress at the expected pace. In this section we will 
discuss two considerable issues applied to nanotoxicology and non-viral retinal gene therapy that 
we believe need to be challenged in order to make nano prosperous. 
Inefficient enthusiasm 
Along with the interest in nanotechnology, nanotoxicology became a hot topic as proven by the 
7-fold raise in number of publications discussing toxicity of NPs in a decade (from 1250 in 2007 
to 8700 in 2017, according to Web Of Science). Since in context of retinal diseases 
nanomedicines have more limited applications and are relatively unexplored, the issues related 
to ‘inefficient enthusiasm’ as discussed below are primarily connected to nanotoxicology.  
The enthusiasm elicited by the discovery of the special properties of NPs encouraged many 
researchers to jump into the nano field which led to an explosion of publications. Especially in 
nanotoxicology, a seemingly endless variety of NPs have been evaluated in an equally large 
collection of cell types. Due to the novelty of the field and limited experience with NPs, the 
initial studies, often published in high impact journals, lacked sufficient characterization and/or 
uptake data which led to questionable outcomes. Moreover, many of the results directly 
contradict each other: nearly each type of NP (IONP, AuNP, CNT,…) has led to positive and 
negative biological responses based on a myriad of underlying mechanisms. This stimulating 
enthusiasm indeed generates a massive amount of data, however, at the same time it works 
counterproductive since this makes it hard to filter out the most relevant studies. Literature 
reviews such as Chapter 2 and Chapter 5 can assist in this, yet the diversity of NPs and their 
coatings as well as cell types studied make it problematic to draw broad conclusions. Truthfully, 
the relevance of many publications is limited to the publication itself since the results cannot be 
extrapolated to other cell types or even NPs of the same type. This is not only owing to 
inefficient study design, but also due to the inherent difficulty of studying and synthesizing NPs: 
altering one aspect of a NP (e.g. size) inevitably leads to changes in many other features of the 
NP which in their turn affect its interaction with the biological environment. Next to the variation 
in NPs and biological models, also the immense diversity of methods applied to examine NP-
induced effects hamper the reliability and extrapolation of toxicological data. Up to now, there 
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are no official standardized toxicity protocols specifically set up for NPs, although the need for it 
is well-established worldwide. Some promising steps forward in this regard are taken by the U.S-
based National Institute of Standards and Technology (NIST) who have set up reproducible and 
validated protocols for physicochemistry measurements that should allow more direct 
comparisons between laboratories.36 They furthermore manufactured several reference NPs 
(e.g. Au and Ag NPs) with the aim to improve the reliability of nanotoxicological assessments.32,37 
A last issue that hinders us to predict the in vivo toxicity elicited by NP exposure is the contrast in 
dose and exposure time between toxicity studies and real life. Indeed, besides the matter that 
the dose metric (surface charge/particles per volume/mass per volume/…) remains to be 
decided on, the majority of in vitro studies are based on short-term exposure to unrealistically 
high NP doses while real life NP exposure is expected to be low dosages for a longer term. 
Dosimetry complications are also inherently associated to the concept nano: NPs can 
agglomerate, aggregate and dissolve, making it hard to predict to which concentrations of 
particles or its ions a cell is exposed.38,39  
The above-mentioned nano concerns are also present in the field of retinal gene therapy, 
although to a lesser extent. Seeing the field is less broad and the number of available retinal cell 
types is limited (in great contrast with nanotoxicology), studies are usually performed on a 
relevant cell type (e.g. RPE cells). On the other hand, nearly all in vitro studies on nanomedicines 
are performed on the widely distributed epithelial ARPE-19 cell even when the final application is 
IVT injection where it would be more preferable to focus on inner layer cell types (e.g. Müller 
cells).40,41 In addition, the leap from in vitro to in vivo is more quickly undertaken than in 
nanotoxicology which implies that doses are faster updated to in vivo settings. The key 
parameter to define after administration of gene carriers in vivo is the retinal gene expression 
(often GFP) for which a couple of standard methods are available that are widely applied in the 
field. Nevertheless, it remains challenging to define conclusions when going over the various 
studies because of the variety of NPs that have been tested on different species.  
While a few issues written above are inherently connected to the concept of nano, we are 
convinced some issues can be resolved by drafting a project design while having the final 
application in mind at every stage of the project. In this way, not only the project but also the 
respective NP will be rationally designed. By clearly specifying the target tissue some 
fundamental choices can be made, including: 1) most relevant experimental models (e.g. cell 
type), 2) characterization experiments (e.g. in vitreous/ in blood), 3) selection of dosages at 
relevant human exposure levels. In addition, it might be useful to take a few steps back and 
perform systematic studies on simple NPs that only vary in 1 physicochemical feature. This 
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would allow us to link NP physicochemistry to cellular effects in a more straightforward manner. 
Furthermore, the creation of elegantly structured databases could help to define more general 
trends in nanotoxicology and retinal drug delivery. Per publication included in the database all 
data could be catalogued such as detailed physicochemical information of each NP as well as the 
cellular effects and cell models investigated. In fact, quite recently the ‘eNanoMapper’ has been 
created, a database funded by the European commission that is meant to enhance the utilization 
of data and in this way support effective European nanotechnology research.42 The database 
indeed enhances data sharing and provides a basis for advanced analysis like computational 
modeling. In the same category, we believe literature reviews can be helpful since they can 
provide an overview of existing studies and more importantly, attempt to create order in the 
chaos. Finally, study outcomes are largely defined by the models investigated throughout the 
experiments. The limitations and challenges regarding the applied experimental models will be 
extensively debated later in this chapter. 
The many studies focusing on the influence of NPs on autophagy summarized in our literature 
review (Chapter 5) is a perfect example of the concerns mentioned above. Besides some 
guidelines which are updated every few years,43 there are no standardized assays or minimal 
requirements implemented that define how to examine the effect of NPs on autophagy. Many 
researchers hence falsely conclude a certain NP induces or inhibits autophagy. On the other 
hand, while we specifically looked for studies that do aim to link effects on autophagy to specific 
physicochemical traits of NPs (e.g. positively & negatively charged materials), uptake data is 
often absent which impedes us to attribute intracellular effects to particle physicochemistry. 
Aware of the arguments above and with the intention to give a good example we performed a 
systematic study aimed to look into the interaction of QDs with autophagy as reliable as we 
could master in Chapter 6. To this end, we looked into the aggregation status of the two QDs 
who only differ in surface coating in water, PBS and full cell culture medium. We furthermore 
attempted to cancel out the differences in endocytosis when interpreting autophagic effects by 
measuring the uptake of both QDs and examining their intracellular effects at similar intracellular 
dosages. Finally, we applied multiple methods to investigate the changes in lysosomal and 
autophagosomal status, ensuring unbiased results. Our study is however not flawless since we 
established our assessment of intracellular effects on dosages determined by in vitro cytotoxicity 
assays rather than expected in vivo doses, and like many nanotoxicologists looked into short-
term exposure. Also, while HeLa cells can be practical in view of the amount of data available in 
literature, this is therapeutically not the most relevant cell type. 
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Similar to Chapter 5, the literature review presented in Chapter 2 sought to look for links 
between NP physicochemistry and NP behavior but in context of retinal drug delivery. Again, this 
proved not to be very straightforward, especially since the studies discussed were performed in 
different species and it is well-established that ocular barrier properties are highly species-
dependent. In Chapter 3 we aimed to contribute to elucidating the ILM barrier properties by 
performing a systematic study in our newly developed vitreoretinal explant by examining the 
behavior of simple polystyrene beads with different sizes. This was a purposeful choice since we 
wanted to focus on the potential links between physicochemistry and NP behavior rather than 
finding a therapeutic carrier in a trial-and-error manner. Still, while we had the intention to 
purely look into size-related effects, the surface charge of the beads changed along with the size. 
It is therefore possible that the varying penetration of the beads into the retina was also 
influenced by the surface charge.  
Seeing Chapter 4 is a preliminary study that, rather than optimizing a NP design, looked for 
intracellular effects of a commonly applied design, the chapter is limited to essential 
experiments and thus does not take the above-mentioned guidelines into account. For example, 
the extrapolation of cellular observations made in a 2D Müller monoculture to Müller cell 
response in retinal tissue is debatable. Characterization and compexation of the lipoplexes 
should furthermore be performed in presence of vitreous to estimate the NP physicochemistry 
and stability when administered by IVT injection. Also, while the experiments in that study are 
restricted to 24 hours, longer exposure times should be evaluated to look into Müller cell 
responses.  
Missing models that matter 
The minimal ability to extrapolate in vitro results to in vivo or clinical observations is an 
important topic of debate in both research fields discussed in this thesis. A notable example 
hereof in nanotoxicology regards QDs: while numerous publications have indicated severe 
cytotoxicity induced by a variety of QDs in vitro, a pilot study where QDs were intravenously 
injected in primates revealed no significant acute toxicity.44 Similarly, many NPs for retinal 
drug/gene delivery are optimized in 2D cell monocultures until favorable results are obtained, 
yet next fail to deliver when relevant in vivo models come into play. The key issues in 
nanotoxicology and retinal drug delivery regarding models are thus very similar although they 
manifest themselves in a slightly different manner. In light of the ocular model-related content 
of Chapter 2 and Chapter 3 we will primarily focus this section on retinal delivery of NPs. 
When performing experiments on 2D cell monocultures it is of importance to realize that these 
models bear little resemblance to the complexity of the clinical situation30 which is a direct 
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consequence of several well-established shortcomings, including: lack of intercellular 
communication, lack of a 3D environment, lack of heterogeneity, absence of extracellular 
barriers and the presence of cell-type dependent effects.45 These weaknesses more than often 
result in biased information since in case of nanotoxicology these shortcomings generally result 
in an overestimation of NP toxicity while in retinal drug delivery it leads to an overestimation of 
the therapeutic potential of NPs. In nanotoxicology, there is a substantial number of cell types 
available depending on the expected NP exposure route which translates into the fact that these 
type of studies dwell for a long time in the in vitro stage. This is in great contrast to retinal NP 
delivery where the restricted number of available retinal cell types pushes ocular researchers to 
switch more quickly to in vivo experiments. These studies are primarily performed in mice, 
which, as thoroughly discussed in Chapter 2, is not an ideal species for projects aiming to design 
an effective NP.  
 
Figure 7.4 │ Diagram of the vicious circle characteristic of non-viral retinal delivery research.  
 
As illustrated in Figure 7.4, the current in vitro – in vivo paradigm widely applied in studies 
researching non-viral retinal delivery after IVT injection has created a vicious circle with as 
adverse outcomes misinformation and inefficiency. In this paradigm, a novel NP is designed, 
usually based on the available literature on ‘successful’ nanomedicines. Then, the NP is further 
optimized in vitro to obtain high expression levels with limited toxicity. This optimized NP is next 
tested in vivo in mice which usually results in limited though encouraging results that are then 
published. However, the bulk of these projects cease here since the following drug delivery 
studies in larger animals fail, presumably due to the more realistic physiological barriers present 
in these species. Regrettably, these unfavorable results are not reported on which overall results 
in a collection of publications describing highly promiseful non-viral carriers that, in the end, do 
not deliver (i.e. misinformation). While this biased representation of the delivery potential of 
specific NPs misleads other researchers aiming to design an effective NP, we are furthermore 
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convinced that studying unrealistic drug delivery barriers prior to representative ones is rather 
inefficient. We therefore suggest to shift the large animal phase to an earlier stage in NP 
development, though applying an ex vivo approach rather than an in vivo one. 
This problematic workflow and associated concerns can be traced back to one fundamental 
issue, i.e. the lack of accessible representative models that imitate the complexity of clinical 
reality. This matter was also brought forward by Hare et al. in their critical perspective where 
they stated that the application and development of relevant animal models is one of the key 
areas to focus on in order to get clinical translation of nanomedicines.30 Using these models we 
could tune NP properties in function of their interaction with biological barriers rather than 
empirically testing various NPs.30 In vivo experiments in non-human primates or large animals are 
the most ideal pre-clinical models, however, these studies require the approval of ethical 
committees and are very costly. Hence, they are only available for later stages of NP 
development and evaluation and will therefore not break the vicious circle explained above. 
However, as discussed in detail in Chapter 2 we are strongly convinced that some ex vivo 
experimental models can be at least as valuable as in vivo ones while having the advantage of 
being more readily available to researchers.46 In line with this view we have presented a novel 
large animal ex vivo model ourselves in Chapter 3. In addition, while research focusing on 
therapeutic applications is perhaps more challenging and obtains funding more easily, genuine 
fundamental research remains pivotal for the field to advance. It is sometimes necessary to take 
a few steps back in order to move forward in an effective way. In case of retinal gene therapy it 
would for example be valuable to characterize the barrier properties in commonly applied 
laboratory animals (see further). Finally, it goes without saying that multidisciplinary 
collaborations, where expertise in NP formulation and drug delivery models of all sorts can be 
combined, could speed up the quest for the ideal NP that is able of reaching the retina after IVT 
injection. 
3. RETINAL GENE DELIVERY BY NANOMEDICINES AFTER 
INTRAVITREAL INJECTION: HOW DO WE GET THERE? 
Design of successful nanoparticles 
Due to the challenges described above only a few nanomedicines have shown true pre-clinical 
potential for the treatment of retinal diseases. Based on the reflections made throughout this 
chapter we therefore propose a general research strategy that might support the community to 
advance in the design of an effective non-viral carrier able of overcoming the different barriers 
present in the eye (Figure 7.5).  
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Figure 7.5 │ Proposed workflow for research in retinal delivery of nanoparticles.  
 
As a first step in this workflow, we feel it might be necessary to go back to the basics and put 
significant effort into fundamental research. This effort should be primarily focused on detailed 
characterization of the biological barriers present in the eye. As an example, it would be valuable 
to map the thickness, composition and morphology of the ILM in multiple species like pig and 
cow and compare this to the human state. Similar basic studies have been performed before on 
e.g. the vitreous composition of different species, yet these studies all date from the 80’s. While 
it is obvious that human tissue is preferred, the demand greatly exceeds its availability. By 
accurately defining the properties and especially the potential differences among species, the 
correct animal model for each drug delivery barrier could be decided on. Furthermore, this could 
aid us in the development of representative drug delivery models that can be applied to study 
NP-barrier interactions. Our research group has already attempted to contribute to this concept 
by the development of two drug delivery models, one to check the interaction of NPs with the 
vitreous,47 and the other one to examine the behavior of NPs in the vitreoretinal interface (cfr. 
Chapter 3). Applying models ranging from in vitro to in vivo, systematic studies into the 
interaction of diverse NP types with varying physicochemistry with the distinct extracellular and 
intracellular barriers could be performed. The observations made in these studies could then be 
collected in a structured database which is available to all researchers. A leading example of such 
a database is the Cancer Nanomedicine Repository,48 which was created in response to a critical 
publication highlighting the current challenges in cancer nanomedicine.28 By implementing the 
knowledge derived from a similarly structured database, optimal NPs for retinal delivery could 
be designed which next should be tested in in vivo models e.g. Non-human primates. If the 
results are beneficial, i.e. increased delivery efficiency is observed, these NPs could proceed 
further into clinical trials. However, if the optimal NP systems as designed based on our 
proposed workflow would not be adequately successful, we could look into advanced strategies 
to enhance the delivery of NPs into the retina.  
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Advanced strategies to enhance retinal delivery 
Since the ILM represents the primary extracellular barrier to overcome for non-viral and viral 
particles after IVT injection (cfr. Chapter 3), the strategies discussed here focus on physical 
approaches to aid particles in overcoming this hurdle. A first strategy which is under 
investigation at the moment is the use of ultrasound. Ultrasound, routinely applied for 
diagnostic imaging, has gained a lot of attention in the drug delivery field over the last decade. In 
the ocular field it has been researched to enhance delivery across multiple barriers including the 
cornea,49,50 the sclera51 and the retina52. Generally, ultrasound-enhanced delivery across the VR 
interface could be achieved by two concepts: 1) physical destruction of the ILM elicited by the 
burst of ultrasound-responsive microbubbles,53,54 and 2) use of the acoustic force that 
accompanies ultrasound to physically ‘push’ particles in the direction of the retina.55,56 The 
concept of both strategies in context of IVT injection has been validated by proof-of-concept 
studies. IVT injection of a mixture of microbubbles with AAV vectors indeed elicited enhanced 
transgene expression upon ultrasound treatment in rats.53 On the other hand, human serum 
albumin NPs showed higher diffusivity and permeation in a bovine retinal explant when exposed 
to ultrasound. 55 These observations indicate there is potential for ultrasound in retinal therapy, 
yet apart from these proof-of-concept studies the concept remains largely unexplored. Further 
fine-tuning of the method and future research into its safety and its therapeutic power in large in 
vivo models is crucial to define the true potential of this approach. 
A currently unexplored approach in the eye is the concept of applying photoporation to 
puncture the ILM locally, in this way creating passageways for NPs to enter the retina. This could 
be achieved by applying gold nanoparticles (AuNPs) at the surface of the ILM, followed by 
irradiation with a short pulse of laser light. Upon absorption of the laser pulse the AuNPs heat 
up, resulting in evaporation of the water surrounding the AuNP surface, thus creating explosive 
vapour nanobubbles (VNB) that disrupt the ILM (Figure 7.6). Due to the extremely short lifetime 
of VNBs and the insulating effect of vapor, diffusion of heat from the AuNPs to the environment 
is negligible. Instead, the laser energy used to irradiate the AuNPs is completely converted into 
mechanical energy of the expanding and collapsing VNB.57 Therefore, VNBs and the resulting 
high-pressure shock waves are ideally suited to cause local disruptions of their surroundings, 
without causing thermal damage to cells or tissues in the retina. Conveniently, the size of the 
VNB (and thus the extent of local damage) can be tuned (~0.1-10 µm) by adjusting the AuNP 
(size, shape) as well as the laser parameters (energy, illumination time). A particular benefit is 
that AuNPs have an extremely large light absorption cross-section, so that strong focusing of the 
laser beam is not needed. The combination of a broad laser beam (hundreds of micrometers) 
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with the fact that only one laser pulse is needed to generate VNB, a large area can be treated in 
a short amount of time.  
 
Figure 7.6 │ Schematic drawing the photoporation approach to disrupt the ILM. AuNPs are delivered to 
the ILM after which they are illuminated with a short but powerful laser pulse. By absorption of the 
laserlight vapour nanobubbles (VNBs) form around the AuNP surface after which the VNBs collapse. This 
mechanical effect results in disruption of the ILM. M: Müller cell; G: ganglion cell. 
 
Photoporation has already been investigated in vitro to enhance intracellular delivery of 
macromolecules as well as in vivo to eradicate microtumours.57–59 In the retina, on the other 
hand, photoporation has not yet been investigated. It is obvious that while this is theoretically an 
innovative and attractive approach to overcome the ILM, the concept raises a lot of questions 
that need to be addressed, including the fate of the AuNPs following treatment, the toxicity of 
AuNPs in the eye and overall feasibility of the concept. 
4. CONCLUSIONS 
Many innovative therapeutic concepts invented to restore or preserve vision could be regarded 
as science-fiction 20 years ago, yet have now been at least proven to work preclinically (e.g. 
optogenetics or photovoltaic prostheses). Surely, the field of vision research is advancing fast,  
with the first retinal gene therapy treatment approved by the FDA only very recently. On the 
other hand, despite the immense worldwide interest in applying nanoparticles as drug delivery 
vehicles, the progress in this area is slightly disappointing. To rectify this, the community will 
have to rethink their current methodologies and set modest intermediate goals. As repeatedly 
emphasized throughout this thesis, we trust that the combination of systematic fundamental 
studies together with the development of more representative models will be essential to 
accomplish this reorganization and above all, to turn nano into a success story. 
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Thanks to worldwide research nanotechnology is one of the key drivers of the current scientific 
advancements in the 21st century. The field has expanded astonishingly over the last decade, 
where it is estimated that nearly 10 % of all publications indexed in Web of Science in 2016 
involved nanotechnology. Nonetheless, despite this extensive research the translation of these 
widely investigated nanoparticles (NPs) toward the clinic is rather limited. For organic particles 
such as liposomes and polymeric particles this is mainly owing to their lack of efficacy evoked by 
the many intra-and extracellular barriers they encounter. The translation of inorganic particles is 
primarily restricted by safety concerns, since many of them, including Quantum Dots (QDs), are 
made up of heavy metals that are known to be toxic. As confirmed in this thesis, it is established 
that the physicochemical features define how the cell ‘sees’ the particle and thus dictates the 
NP’s efficacy and toxicity – what you see is what you get!  
While this perception is fully acknowledged by the nanotechnology community it remains 
challenging to connect certain physicochemical properties to specific biological effects, making it 
hard to predict the therapeutic power or potential toxicity of a NP. This is primarily due to faulty 
project design, the lack of representative models and the inherent complexities associated to 
working in the nano-range. The difficulty to link NP physicochemistry to desired or unwanted 
effects is an issue that affects nearly every research field that aims to take advantage of the 
unique and powerful properties of NPs, yet in this thesis we aimed to aid in overcoming this 
issue in context of retinal gene delivery (Part I, Chapter 1-4) and autophagy (Part II, Chapter 5 
and 6).  
In Chapter 1 we provided an overview of the most prevalent acquired diseases and most well-
documented inherited retinal diseases that could be treated with retinal gene therapy. We 
furthermore described the morphology and functions of the Müller cell, the target cell type for 
our non-viral approach.  
Based on the overview of publications linking physicochemical properties of therapeutics and 
their carriers presented in Chapter 2, we concluded that the ideal physiochemical characteristics 
of a therapeutic (carrier) highly depends on the barrier it needs to overcome and therefore also 
on the preferred administration route. We further found that nearly each barrier undergoes 
changes in function of age and disease, an important notion when evaluating the potential of 
carriers to cross delivery barriers. We found many useful in vitro and ex vivo approaches to study 
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drug delivery barriers in the posterior segment of the eye, though argue that there is still a great 
need for more straightforward and representative models. 
Convinced of the latter argument, we presented the so-called ‘vitreoretinal explant’ in Chapter 
3,  an novel ex vivo model especially developed to look into the interaction of nanomedicines 
with the vitreoretinal (VR) interface. This interface comprises the vitreous and the inner limiting 
membrane (ILM), both well-recognized drug delivery barriers. We confirmed the viability of this 
explant model and validated its value by means of polystyrene beads. Since 40 nm beads more 
efficiently crossed the VR interface than 100 or 200 nm particles we concluded that the entry of 
NPs into the retina is size-dependent. Moreover, we found that removing the vitreous, as 
commonly done for culture of conventional explants, led to an overestimation of NP uptake, and 
concluded that the principal barrier to overcome for retinal entry is unquestionably the ILM. This 
VR explant is currently the most representative ex vivo model available that is alive for a 
sufficiently long time to study NP uptake in the retina.  
In Chapter 4 we applied an elementary set-up to examine if Müller cells, which we regard as an 
ideal target for neuroprotective strategies, are able of efficiently processing lipoplexes and 
expressing their pDNA or mRNA cargo. Here, we found that mRNA lipoplexes outperformed the 
DNA lipoplexes in transfection of healthy Müller cells since both the number of transfected cells 
as well as the level of GFP expression was higher for mRNA lipoplexes. In Müller cells that were 
exposed to hyperglycemia, oxidative stress or hypoxia no changes in mRNA-induced expression 
was observed when compared to healthy Müller cells. On the other hand, we did find that Müller 
cells treated with oxidative stress or hypoxia were more sensitive to lipoplex-induced toxicity 
while hyperglycemia had a protective effect. Although preliminary, this study indicates that, 
despite a stressful environment, Müller cells are capable of taking up lipoplexes and expressing 
their nucleic acid cargo. 
Chapter 5 presented an overview of the most relevant reports on NP-mediated autophagy 
alterations and intended to investigate the interplay between NP physicochemistry and 
autophagic changes. Hence, several NP properties were put forth as probable influencing factors 
of NP-induced autophagy disruption or upregulation such as size, charge and chemical 
composition. However, owing to the shortcomings of some studies and the contradicting claims 
made in literature it was virtually impossible to draw general conclusions. We thus judged that 
systematic studies which include sufficient characterization data could greatly support us to truly 
elucidate the impact of NP physicochemistry on NP-associated autophagy changes.  
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In view of this understanding we performed a study in Chapter 6 with as goal to carefully define 
the influence of QD coating on lysosomal health and autophagy. Our study showed that the 
cellular effects induced by QDS on HeLa cells were strongly dictated by the surface coat (i.e. MPA 
or PEG) of the otherwise identical particles. MPA-coated QDs proved to be highly compatible as a 
result of lysosomal activation and ROS reduction, two cellular responses that help the cell to 
cope with NP-induced stress. In contrast, PEG-coated QDs were substantially more toxic owing to 
a rise in ROS production and lysosomal impairment. This impairment next resulted in autophagy 
dysfunction which likely added to their toxic effects. Taken together, our study showed that 
coating QDs with MPA is a better strategy than PEGylation for imaging applications.  
In Chapter 7, we summarized the advances in retinal gene therapy and nanotoxicology and 
discussed potential challenges that hinder NPs to advance further into clinical stages. We 
brought forward several guidelines that we believe could aid the nano field to progress and 
reconstructed them into a general approach that could aid researchers in overcoming the NP 
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Nanotechnologie is dankzij wereldwijd onderzoek geëvolueerd tot één van de belangrijkste 
drijfkrachten van de huidige wetenschappelijke vooruitgangen in de 21ste eeuw. Het veld is 
verbazingwekkend uitgebreid in het afgelopen decennium, waarbij naar schatting bijna 10% van 
alle publicaties die in Web of Science zijn geïndexeerd in 2016 nanotechnologie betrof. 
Niettegenstaande dit diepgaand onderzoek is de vertaling van nanopartikels (NP's) naar de 
kliniek eerder beperkt. In het geval van organische NPs zoals liposomen en polymere partikels 
komt dit voornamelijk door hun gebrek aan efficaciteit wat veroorzaakt wordt door de vele intra- 
en extracellulaire barrières die ze tegenkomen. De translatie van anorganische deeltjes wordt 
voornamelijk beperkt door veiligheidsbelangen gezien veel van deze partikels, waaronder 
Quantum Dots (QD’s) zijn samengesteld uit zware metalen waarvan geweten is dat ze toxisch 
zijn. Zoals bevestigd in deze thesis, is reeds vastgesteld dat het de fysicochemische kenmerken 
zijn die bepalen hoe een cel een NP ‘ziet’ en dus zo de werkzaamheid en toxiciteit van het NP 
dicteert – what you see is what you get! 
Hoewel deze perceptie volledig wordt erkend door de nanotechnologie gemeenschap, blijft het 
een uitdaging om specifieke fysicochemische eigenschappen te koppelen aan bepaalde 
biologische effecten. Hierdoor wordt het dan ook moeilijk om het therapeutisch vermogen of 
potentiële toxiciteit van een NP te voorspellen. Dit is voornamelijk te wijten aan gebrekkig 
project design, het ontbreken van representatieve modellen en de inherente complexiteiten die 
samengaan met het werken met NPs. De moeilijkheid om NP fysicochemie te koppelen aan 
gewenste of ongewenste effecten is een probleem dat bijna elk onderzoeksveld beïnvloedt dat 
als doel heeft voordeel te halen uit de unieke en krachtige eigenschappen van NPs. In deze thesis 
hebben we ons echter gefocust op het helpen oplossen van deze problemen in context van 
retinale genaflevering (Deel I, hoofdstuk 1-4) en autofagie (Deel II, hoofdstuk 5 en 6). 
In Hoofdstuk 1 hebben we een overzicht gegeven van de meest voorkomende verworven ziekten 
alsook de best gedocumenteerde erfelijke retinale aandoeningen die kunnen worden behandeld 
met retinale gentherapie. We beschreven verder de morfologie en de vele functies van de Müller 
cel, het doelceltype voor onze niet-virale aflevering van genen. 
In hoofdstuk 2 gaven we een overzicht van publicaties die de fysicochemische eigenschappen 
van therapeutica en hun dragers bespreken. Hieruit concludeerden we dat de ideale 
fysiochemische kenmerken van een therapeutische (drager) sterk afhangen van de barrière die 
het NP moet overwinnen en dus ook van de gewenste toedieningsroute. We ontdekten verder 
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dat bijna elke barrière veranderingen ondergaat in functie van leeftijd en ziekte, wat een 
belangrijke invloed kan hebben op het evalueren van het potentieel van dragers om deze 
barrières te overbruggen. We hebben veel nuttige in vitro en ex vivo methodes en modellen 
gevonden om barrières voor medicijnafgifte in het achterste segment van het oog te bestuderen, 
hoewel er volgens ons nog steeds veel behoefte is aan meer eenvoudige en representatieve 
modellen. 
Overtuigd van dit laatste argument presenteerden we in hoofdstuk 3 de zogenaamde 
'vitreoretinale explant', een nieuw ex vivo model dat speciaal is ontwikkeld om de interactie van 
nanogeneesmiddelen met de vitreoretinale (VR) interface te onderzoeken. Deze interface omvat 
het vitreum en de inner limiting membrane (ILM), beide erkende hindernissen voor de aflevering 
van geneesmiddelen. We bevestigden de levensvatbaarheid van dit nieuw model en valideerden 
de waarde ervan met behulp van polystyrene partikels. Gezien 40 nm partikels efficiënter de VR 
interface doorkruisten dan 100 of 200 nm NPs, konden we concluderen dat de afgifte van NPs in 
de retina afhankelijk is van de grootte van NPs. We ontdekten bovendien dat het verwijderen 
van het vitreum, zoals vaak wordt gedaan voor de kweek van conventionele explants, leidde tot 
een overschatting van de NP-opname en concludeerden verder dat de voornaamste barrière die 
overwonnen moet worden voor om de retina te bereiken onbetwistbaar het ILM is. Deze VR 
explant is momenteel het meest representatieve ex vivo model op de markt dat voldoende lang 
in leven kan gehouden worden om de opname van NPs in de retina te bestuderen. 
In hoofdstuk 4 hebben we een elementaire set-up toegepast om te onderzoeken of Müller 
cellen, die we beschouwen als een ideaal doelwit voor neuroprotectieve strategieën, in staat zijn 
om lipoplexen efficiënt te verwerken en hun pDNA- of mRNA-lading tot expressie te brengen. 
We ondervonden dat mRNA-lipoplexen beter presteerden dan de DNA-lipoplexen bij transfectie 
van gezonde Müller-cellen, omdat zowel het aantal getransfecteerde cellen als het niveau van 
GFP-expressie hoger was voor mRNA-lipoplexen. In Müller cellen die werden blootgesteld aan 
hyperglycemie, oxidatieve stress of hypoxie werden geen veranderingen in mRNA-geïnduceerde 
expressie waargenomen in vergelijking met gezonde Müller cellen. Aan de andere kant vonden 
we dat Müller cellen behandeld met oxidatieve stress of hypoxie gevoeliger waren voor de door 
lipoplexen geïnduceerde toxiciteit, dit terwijl hyperglycemie een beschermend effect had. 
Hoewel ongetwijfeld meer onderzoek nodig is, geeft deze studie aan dat, ondanks een 
stressvolle omgeving, Müller cellen in staat zijn om lipoplexen op te nemen en hun 
nucleïnezuurlading tot expressie te brengen. 
Hoofdstuk 5 gaf een overzicht van de meest relevante publicaties handelend over NP-
gemedieerde veranderingen in autofagie dit met het oog op het onderzoeken van de interacties 
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tussen NP fysicochemie en veranderingen in autofagie. We hebben inderdaad verschillende NP-
eigenschappen naar voren kunnen brengen die hoogstwaarschijnlijk de mate of manier van NP 
geïnduceerde verstoring van autofagie beïnvloeden, waaronder grootte, lading en chemische 
samenstelling. Vanwege de tekortkomingen van sommige studies en de tegenstrijdige 
beweringen in de literatuur was het echter vrijwel onmogelijk om algemene conclusies te 
trekken. We hebben daarom geoordeeld dat systematische studies die voldoende 
karakteriseringsgegevens bevatten ons enorm zouden kunnen ondersteunen om de impact van 
NP fysicochemie op NP-geassocieerde autofagiewijzigingen te verduidelijken. 
Op basis van deze argumentatie hebben we in hoofdstuk 6 een onderzoek uitgevoerd met als 
doel de invloed van QD coating op lysosomale integriteit en autofagie zorgvuldig the definiëren. 
Onze studie toonde aan dat de cellulaire effecten geïnduceerd door QDs op HeLa cellen sterk 
werden gedicteerd door de coating (zijnde MPA of PEG) van de overigens identieke deeltjes. 
MPA-gecoate QDs bleken zeer compatibel te zijn als gevolg van lysosomale activering en reductie 
van ROS, twee cellulaire responsen die de cel helpen om te gaan met NP-geïnduceerde stress. 
Daarentegen waren PEG-gecoate QDs aanzienlijk meer toxisch als gevolg van een toename in 
ROS productie en lysosomale stoornissen. Deze stoornissen resulteerden vervolgens in 
afwijkingen in autofagie die hoogstwaarschijnlijk bijdroegen aan de geobserveerde toxische 
effecten. Samengevat heeft ons onderzoek aangetoond dat voor biomedische toepassingen het 
coaten van QDs met MPA een betere strategie is dan met PEG. 
In Hoofdstuk 7 hebben we de vooruitgang in retinale gentherapie en nanotoxicologie 
samengevat en mogelijke uitdagingen besproken die NPs verhinderen om verder in de klinische 
stadia te geraken. We hebben verschillende richtlijnen naar voren gebracht waarvan we denken 
dat ze het nano-veld kunnen helpen om vooruitgang te boeken, en hebben deze tot een 
algemene benadering omgevormd die onderzoekers zou kunnen helpen bij het overwinnen van 
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